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ABSTRACT 
 
Sarahmona M. Przybyla: Examining Correlates of Serostatus Disclosure and Sexual 
Transmission Risk Behaviors among People Living with HIV in North Carolina 
 
(Under the direction of Carol Golin) 
 
Prevention programs targeting people living with HIV/AIDS (PLWHA) are critical in 
reducing the spread of the virus.  Prevention efforts include promotion of risk reduction 
behaviors as well as disclosure of one’s serostatus to sex partners.  A substantial body of 
literature on HIV serostatus disclosure exists.  However, most studies have focused solely on 
gay or bisexual men or among urban populations.  A better understanding of the mechanisms 
through which PLWHA disclose their serostatus and practice safer sex behaviors is necessary 
to inform the development of interventions to facilitate disclosure and to meet the needs of a 
diverse population of PLWHA to help reduce HIV transmission.   
The data for these secondary analyses come from SAFETALK, a motivational 
interviewing-based, safer sex intervention for HIV-positive patients in North Carolina 
(n=490). Predictors of interest were informed by behavioral theory and previous research on 
serostatus disclosure and sexual transmission risk behaviors.  Descriptive statistics and 
logistic regression were used to assess study aims.  Serostatus disclosure and transmission 
risk behaviors were assessed at baseline.  Overall, 78.9% of respondents disclosed to sexual 
partners.  Multinomial logistic regression found that participants who had casual partners, 
unknown serostatus partners, and experienced stigma related to their HIV were more likely to 
withhold disclosure to partners.  Only 16% of the sample reported engaging in unprotected 
 iv  
vaginal or anal sex with an at-risk partner.  Overall, serostatus disclosure was associated with 
transmission risk behavior as those who disclosed their status were less likely to engage in 
unprotected sex with an at-risk partner than those who withheld disclosure.   
Clarifying the relationship between serostatus disclosure and transmission risk 
behavior remains a critical public health priority as researchers need to better understand the 
strategies people employ to decide whether or not to disclose and how the dyad ultimately 
decides to engage in protected or unprotected sexual activity.  While the majority of the 
sample did not engage in transmission risk behaviors, the fact that unprotected sex with at-
risk partners was found provides a rationale for continuing Prevention with Positives 
programs in HIV clinical care settings where PLWHA can discuss their experiences with 
disclosure and risk behavior with their health care providers. 
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CHAPTER ONE: INTRODUCTION 
 
 
1.1 PROBLEM STATEMENT 
Prevention programs targeting people living with HIV/AIDS (PLWHA) are critical in 
reducing the spread of the virus.  Prevention efforts include promotion of risk reduction 
behaviors, such as correct and consistent condom use as well as disclosure of one’s serostatus to 
sex partners (CDC, 2003a).  Because the majority of PLWHA are sexually active (Marks, Burris, 
& Peterman, 1999; Stein et al., 1998) and approximately one-third engage in high-risk sexual 
behaviors including unprotected sex or multiple sexual partners (Ciccarone et al., 2003; S.C 
Kalichman, 2000; S. C. Kalichman & Nachimson, 1999; Marks & Crepaz, 2001; McGowan et 
al., 2004; Stein et al., 1998) prevention efforts among PLWHA are needed.  Furthermore, studies 
have shown that between 30-46% of sexually transmitted HIV infections are transmitted by 
people who know they are infected with the virus (Janssen & Valdiserri, 2004; Marks, Crepaz, & 
Janssen, 2006).  Thus effective prevention interventions for PLWHA are needed.  A recent meta-
analytic review of a dozen prevention studies with HIV-positive individuals published between 
1988 and 2004 determined that behavioral interventions led to decreased acquisition of sexually 
transmitted infections and a 43% reduction in unprotected sex among PLWHA (N Crepaz et al., 
2006).   
One important aspect of reducing HIV transmission is seropositive individuals’ informing 
their sexual partners of their HIV status, as recommended by 1988 U.S. Public Health Service 
guidelines.  Serostatus disclosure allows the partner of an index case to make an informed choice 
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about initiating, or in some cases re-initiating, sexual contact and practicing safer sex.  It also 
creates an opportunity for both people to negotiate and discuss options with regards to safer sex.  
Yet, studies indicate that serostatus disclosure does not occur in a substantial minority of sexual 
partnerships (Niccolai, King, D'Entremont, & Pritchett, 2006).  Overall rates of serostatus 
disclosure to sexual partners vary between studies due, in part, to the use of different outcome 
measures (Duru et al., 2006).  Proportions of HIV-positive persons who disclosed their serostatus 
to sex partners in these studies ranged from 50% to 95%.  A substantial body of literature on 
HIV serostatus disclosure exists; however, most studies have focused solely on men who have 
sex with men or among urban populations.  A better understanding of the mechanisms through 
which PLWHA disclose their serostatus as well as practice safer sex behaviors is necessary to 
inform the development of interventions to facilitate such disclosure and to meet the needs of a 
diverse population of HIV-positive individuals to help reduce the spread of the virus.   
 
1.2 STUDY AIMS 
The aims of the proposed study are: 
1) To describe and examine the correlates of serostatus disclosure to sexual partners 
among HIV-positive patients in care at three clinics in North Carolina  
2) To assess the relationship between serostatus disclosure and sexual transmission 
risk behaviors among HIV-positive patients in care at three clinics in North 
Carolina and to evaluate the role of moderating variables in this relationship 
 
These two aims are addressed through secondary data analysis of the SAFETALK 
study, a longitudinal study of HIV-positive individuals in North Carolina.  SAFETALK is a 
3 
randomized controlled trial that takes place in three infectious disease clinics in North 
Carolina where approximately 2,400 male and female patients are receiving care.  The parent 
study sought to examine the association between changes in participants’ motivations, 
intentions, and self-efficacy regarding safer sex practices and their self-reported sexual 
behaviors.   
This research study is imperative for many reasons.  First, it responds to the CDC’s 
Advancing HIV Prevention initiative that has the goal of increasing safer sex behaviors 
among PLWHA.  Second, the scope of the HIV/AIDS epidemic in the South is different from 
that within the United States as a whole.  As a region, the Southeast has the highest reported 
incidence of HIV in the nation.  In addition, the annual rate of new HIV infections has 
increased among minority groups compared to their White counterparts in the United States 
as a whole, but particularly in the Southeastern U.S. (NC-DHHS, 2006).  The region also has 
the greatest proportion of HIV cases from small metropolitan areas and non-metropolitan 
areas (CDC, 2007).  Recent research suggests that health and economic disparities contribute 
to the higher HIV incidence among ethnic minorities and women seen in the Southeast 
(Adimora & Schoenbach, 2005; Adimora et al., 2006).  Similar to other Southern states, 
North Carolina’s HIV epidemic is more rural and more heterosexually transmitted in nature.  
The state has the second highest number of AIDS cases in the nation from non-metropolitan 
areas.  In addition, the number of people living with HIV in North Carolina has increased 
22% between 2002 and 2006 (NC-DHHS, 2007).  Third, the proposed research will help us 
identify the factors that are associated with serostatus disclosure among PLWHA and how 
such disclosure influences a reduction in transmission risk behaviors in order to help develop 
more effective behavioral interventions. 
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1.3 ORGANIZATION OF THE DISSERTATION 
The dissertation will have six chapters.  Chapter Two provides the background and 
significance of the HIV epidemic in the United States, presents the scope of the epidemic in 
North Carolina, and describes the rationale for HIV prevention programming for PLWHA 
(known as Prevention with Positives).  It also reviews studies assessing correlates of HIV 
serostatus disclosure, as well as the association between such disclosure and transmission 
risk behaviors among PLWHA.  Chapter Three describes the study’s conceptual model, 
presents the research questions, and sets forth the hypotheses to be tested. Chapter Four 
details the study methodology, including study design, sample population, variable 
definitions, and data analysis plan. Chapter Five presents the results of the analyses. Finally, 
Chapter Six summarizes and synthesize the key findings to make recommendations for future 
HIV prevention research and practice. 
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CHAPTER TWO: LITERATURE REVIEW 
 
In this chapter, I will: (1) describe the scope of the HIV epidemic in the United States, 
the Southeast and in North Carolina; (2) discuss a rationale for HIV Prevention with 
Positives (PwP) research; (3) present a review of the literature that has evaluated serostatus 
disclosure and factors that influence it, including partner characteristics, stigma, transmission 
risk beliefs, viral load detectability, subjective norms, and urbanicity; and (4) present a 
review of the studies that have assessed the association between serostatus disclosure and 
transmission risk behaviors, including a discussion of how partner characteristics may 
moderate the relationship between serostatus disclosure and transmission risk behaviors.  I 
conclude the chapter with a summary of the shortcomings of previous research of these 
questions.  I argue that further research is needed to understand better the factors that 
influence whether or not PLWHA will disclose their serostatus to sexual partners.  Also 
needed are studies that shed light on the relationship between disclosure and transmission 
risk behaviors among PLWHA.  
  
2.1 HIV/AIDS IS AN EPIDEMIC IN THE UNITED STATES 
The first few cases of acquired immune deficiency syndrome (AIDS) were identified in the 
United States in 1981.  Since that time scientists have come to understand that human 
immunodeficiency virus (HIV) is the virus that causes AIDS and have made remarkable 
progress in understanding its modes of transmission and how to prevent its spread.  Advances 
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in the detection, diagnosis, and treatment of HIV have also considerably improved the 
mortality and quality of life of persons living with HIV/AIDS (PLWHA) with a significant 
decline in AIDS-related deaths over time (Karon, Fleming, Steketee, & De Cock, 2001). 
As a result of advances in HIV treatment, the U.S. has experienced considerable 
growth in the number of people living with HIV.  At the end of 2006, an estimated 1,106,400 
persons were living with HIV infection in the United States (CDC, 2008).   
The 2007 HIV/AIDS Surveillance Report shows that there has been a 15% increase in HIV 
diagnoses in the United States from 2004 to 2007 (CDC, 2009).  It is important to note that 
this increase may be due to a variety of factors including changes in state reporting 
regulations, rises in testing rates, changes in state reporting regulations, or an actual increase 
in incidence.   
The Centers for Disease Control and Prevention (CDC) estimated that in 2006 
approximately 56,300 people were newly infected with HIV (Hall, 2008).  In August 2008, 
CDC published the first national HIV incidence estimates using new technology and revised 
methodology that more directly measure the number of new HIV infections.  The analyses 
showed the new estimate of 56,300 HIV infections was substantially higher than the previous 
estimate of approximately 40,000 new infections annually.  However, it should be noted that 
this revised incidence estimate does not represent an actual increase in the numbers of HIV 
infections, but rather reflects a more accurate way of measuring new infections given new 
technology and methodology.  
Given this incidence rate coupled with decreases in AIDS-related deaths, the number 
of HIV cases is expected to rise in the future (Wolitski, Janssen, Onorato, Purcell, & Crepaz, 
2005).  As more people are living with HIV, it has become increasingly important to educate 
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and provide them with the skills needed to reduce their risk of transmitting HIV to others.  
Given that the annual number of people newly acquiring HIV has not decreased over the last 
decade, we need more effective approaches to reducing HIV transmission than those 
currently implemented. 
One way to gain a better understanding of the state of the domestic HIV epidemic, 
that is, who is being more affected by the epidemic currently, is to compare HIV incidence 
and prevalence among different sub-groups, such as groups based upon people’s age, 
race/ethnicity, and mode of virus acquisition.  Of the estimated number of HIV/AIDS cases 
in 2005, Table 1 shows the distribution of person’s age at time of diagnosis (CDC, 2009).
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In addition to age, the CDC also monitors HIV/AIDS cases among five racial and 
ethnic groups: White, Black (African American), Hispanic, Asian/Pacific Islander, and 
American Indian/Alaska Native.  There is a stark racial disparity in HIV diagnoses in the 
U.S.; while African Americans comprise only 12.4% of the population (US, Census Bureau 
2006), this racial group represented 48.9% of HIV diagnoses in 2005 (CDC, 2009).  The 
CDC also monitors cumulative HIV cases by gender.  While women account for a substantial 
minority of HIV cases in the United States (approximately 25%), this percentage has risen 
over the last two decades.  In addition, HIV rates and the risk factors for infection differ for 
women of various races or ethnicities, which are important to consider for prevention 
programs to reduce transmission.  For example, even though the annual estimated rate of 
HIV diagnosis for Black women decreased from 82.7 per 100,000 population in 2001 to 60.2 
per 100,000 population in 2005, it remained 20 times the rate for White women (CDC, 2009; 
McDavid, Li, & Lee, 2006).  In addition, HIV rates for Black women are higher than the 
rates for all racial groups of men with the exception of Black men (CDC, 2006, 2009; 
Whitmore, Satcher, & Hu, 2005).   
Table 1: U.S. HIV/AIDS Incident Cases by Age Category, 2005 
Age Category HIV/AIDS Cases Percent 
Under 13 168 <1 
Ages 13-19 1,256 3.3 
Ages 20-29 8,457 22.7 
Ages 30-39 11,246 30.1 
Ages 40-49 10,450 28.0 
Ages 50-59 4,325 11.6 
Ages 60 and older 1,428 3.8 
Please note: These numbers do not represent reported case count but rather point estimates, 
which result from adjustments of reported case counts. The case counts have been adjusted 
for reporting delays and for redistribution of cases in persons initially reported without an 
identified risk factor, but not for incomplete reporting. 
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To understand how to reduce HIV transmission, it is important to understand how it is 
spread.  There are six commonly recognized modes of transmission of HIV/AIDS, including: 
male-to-male sexual contact, injection drug use, male-to-male sexual contact and injection 
drug use, heterosexual contact, mother-to-child (perinatal) transmission, and other (includes 
blood transfusions and unknown cause).  Table 2 below illustrates the distribution of the 
estimated number of diagnoses of HIV/AIDS in 2005 by gender and transmission category.  
Of HIV/AIDS cases diagnosed among males, two-thirds were attributed to male-to-male 
sexual contact and 15% were attributed to high-risk heterosexual contact1.  Additionally, 
13% of cases in males were attributed to injection drug use and 5% attributed to a 
combination of both male-to-male sexual contact and injection drug use.  The majority (80%) 
of the HIV/AIDS diagnoses among females was attributed to high-risk heterosexual contact, 
and 19% were attributed to injection drug use.  Thus, sexual behavior is related to HIV 
transmission in the vast majority of new infections in the United States.  
Table 2: U.S. HIV Cases by Transmission Category and Gender, 2005 
Transmission Category Adult and Adolescent Male 
Adult and 
Adolescent 
Female 
Total 
Number % Number % Number  % 
Male-to-male sexual contact 18,296 67 -- -- 18,296 49 
Injection drug use (IDU) 3,441 13 1,851 19 5,292 14 
MSM sexual contact and IDU 1,324 5 -- -- 1,324 4 
High-risk heterosexual 
contact* 4,255 15 7,734 80 11,989 32 
Other** 139 1 124 1 263 <1 
*Heterosexual contact with a person known to have, or to be at high risk for, HIV infection. 
** Includes hemophilia, blood transfusion, perinatal, and risk not reported or not identified. 
 
 
 
 
                                                 
1
 High-risk heterosexual contact means sexual activity with a person known to have, or to be at high risk for, HIV 
infection. 
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2.2 SCOPE OF THE HIV/AIDS EPIDEMIC IN THE SOUTHEAST 
AND IN NORTH CAROLINA  
 
As a region, the Southeast had the greatest proportional increases in HIV/AIDS 
incidence since 1990 (Whetten-Goldstein & Nguyen, 2002).  From 2000 to 2003, there was a 
5.2% increase of newly reported AIDS cases nationally, compared to a 36% increase in the 
Deep South (Alabama, Georgia, Louisiana, Mississippi, North Carolina, and South Carolina) 
(Whetten & Reif, 2006).  The annual incidence rate has increased among minority groups 
compared to their White counterparts in the U.S. as a whole, but particularly in the Southeast 
(NC-DHHS, 2006).  The region also has the greatest proportion of HIV cases from small 
metropolitan areas and non-metropolitan areas (CDC, 2007).  Recent research suggests that 
health and economic disparities contribute to the higher HIV incidence among ethnic 
minorities and women seen in the Southeast (Adimora & Schoenbach, 2005; Adimora et al., 
2006).  Similar to other Southern states, North Carolina’s HIV epidemic is more rural, and 
more heterosexually transmitted in nature.  The state has the second highest number of AIDS 
cases from non-metropolitan areas.  In addition, the number of people living with HIV in the 
state has increased 22% between 2002 and 2006 (NC-DHHS, 2007).   
Through December 2007, the public health surveillance system in the state of North 
Carolina has reported 32,583 cumulative HIV cases.  In 2007, the reported number of new 
cases of HIV in the state was 2,356 ((DHHS, 2008)).  Furthermore, CDC records the 
estimated prevalence rates of individuals living with HIV in 2005;  their most recent report 
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indicates that North Carolina is one of only nine states2 with a prevalence rate of >150 per 
100,00 population (CDC, 2009). 
Table 3 below illustrates the age and gender breakdown for HIV cases in North 
Carolina in 2006.  While the 30-39 and 40-49 age groups represent the highest percentages of 
cases for both genders, roughly one in five cases occurred among younger individuals (aged 
20-29 years) (NC-DHHS, 2007).  These state figures are relatively consistent with national 
percentages of HIV cases by age and gender.     
Table 3: North Carolina HIV Cases by Age and Gender, 2006 
Age Group Male Female Total 
Number % Number % Number  % 
0-12 1 <1 6 1 7 <1 
13-19 55 4 27 5 82 4 
20-29 355 24 94 17 449 22 
30-39 417 28 153 28 570 28 
40-49 423 29 165 30 588 29 
50 and over 229 16 97 18 326 16 
Total 1,480 100 542 100 2,022 100 
 
A significant racial disparity exists in infection rates among North Carolinians.  For 
example, the rate of infection for non-Hispanic Blacks (71.0 per 100,000) is more than eight 
times greater than for non-Hispanic Whites (8.1 per 100,000).  These rates are similar to 
those found in the U.S. population as a whole with rates of HIV cases among Blacks at 71.3 
per 100,000 and 8.8 per 100,000 for Whites (CDC, 2009).  In 2006, the highest rate of 
infection was among non-Hispanic Black males at 103.3 per 100,000 which is more than 
seven times the rate for their non-Hispanic White counterparts (13.9 per 100,000).   
This racial disparity also exists among women, where non-Hispanic Black females 
had an infection rate of 42.2 per 100,000 compared to 2.5 per 100,000 among non-Hispanic 
                                                 
2
 The nine states with prevalence rates of >150 per 100,000 population are: New York, New Jersey, Nevada, 
Colorado, Mississippi, Louisiana, Florida, North Carolina, and South Carolina. 
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White females (NC-DHHS, 2007).  A 2005 Morbidity and Mortality Weekly Report focusing 
specifically on African American women in North Carolina found that the most commonly 
reported reasons for engaging in behaviors that place them at risk for HIV infection were: 1) 
financial dependence on male partners, 2) feeling invincible, 3) low self-esteem coupled with 
a need to feel loved by a male figure, and 4) alcohol and drug use (CDC, 2005).  Table 4 
below illustrates the HIV cases in the state by race/ethnicity and gender for 2006. 
Table 4: North Carolina HIV Cases by Race/Ethnicity and Gender, 2006 
Race/Ethnicity Male Female Total 
Number % Number % Number  % 
Non-Hispanic White 406 27 77 14 483 24 
Non-Hispanic Black 919 62 422 78 1,341 66 
American Indian/Alaska Native 12 <1 0 0 12 <1 
Asian/Pacific Islander 14 <1 4 <1 18 <1 
Hispanic 127 9 38 7 165 8 
Unknown 2 <1 1 <1 3 <1 
Total 1,480 100 542 100 2,022 100 
 
 As evidenced in Table 5, of HIV incidence among adults and adolescents in 2006, the 
main transmission risk category among North Carolinians was men who have sex with men 
(51%), however heterosexual transmission risk occurred nearly as often (40%) whereas 
injecting drug use was rarely a cause (6%).  Among males only, MSM (69%) and MSM/IDU 
(2%) together accounted for 71% of new HIV cases in 2006.  Among females, 86% of new 
HIV cases result from heterosexual contact (NC-DHHS, 2007). 
Table 5: North Carolina Incident HIV Cases by Transmission Category and Gender, 2006 
Transmission Category Male Female Total 
Number % Number % Number  % 
MSM 1,109 69 -- -- 1,019 51 
IDU 66 4 59 11 125 6 
MSM/IDU 28 2 -- -- 28 1 
Blood products/hemophilia 13 1 14 3 27 1 
Heterosexual 353 24 463 86 816 40 
Total 1,479 100 536 100 2,015 100 
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2.3. RATIONALE FOR PREVENTION WITH POSITIVES (PwP) 
The CDC estimates that approximately one-quarter of people living with HIV in the 
United States are unaware of their infection (Glynn & Rhodes, 2005).  While the number of 
new HIV infections each year that result from unsafe encounters with people who know they 
are infected is difficult to calculate with certainty, the CDC estimates that about 30-46% of 
all new sexually transmitted HIV infections are transmitted from someone who is aware of 
their serostatus (Janssen & Valdiserri, 2004; Marks et al., 2006). 
Studies have found that approximately 70% of PLWHA continue to engage in sexual 
activity after diagnosis (N. Crepaz & Marks, 2002; Marks et al., 1999).  While many either 
reduce or eliminate risk behavior after diagnosis (Weinhardt, Carey, Johnson, & Bickham, 
1999; Wolitski, MacGowan, Higgins, & Jorgensen, 1997), this risk reduction is not certain 
for all individuals under all circumstances.  Furthermore, people who  reduce transmission 
risk behaviors immediately after diagnosis may not maintain safer practices over time (N. 
Crepaz & Marks, 2002; McGowan et al., 2004).  Several research studies have found needle 
sharing and unprotected sexual behavior among PLWHA (Ciccarone et al., 2003; N Crepaz 
& G Marks, 2003; DeRosa & Marks, 1998; S. C. Kalichman, Rompa, Luke, & Austin, 2002; 
Kok, 1999; Marks et al., 1999; Marks & Crepaz, 2001; McGowan et al., 2004; Niccolai, 
Dorst, Myers, & Kissinger, 1999; Stein et al., 1998).  While rates of unprotected sexual 
behaviors reported in studies vary as a result of differences in research methodologies, recall 
periods, and risk behavior definition, one of the most commonly cited articles that reviewed 
several studies found that approximately 30% of PLWHA have unprotected intercourse (S.C 
Kalichman, 2000).   
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2.3.1 Historical Overview of PwP 
Historically, most HIV prevention programs in the U.S. have focused on addressing 
the needs of those at risk for contracting HIV, such as specific high-risk subgroups and the 
general population.  The chronological trajectory of PwP programs is interesting to note.  It 
began with no PwP programs in existence and then moved to a few programs that ultimately 
failed to demonstrate effectiveness.  By the late 1990s, a paradigm shift in HIV prevention 
was beginning to occur in which the lack of interventions for PLWHA was recognized by the 
CDC, and several calls for PwP programs in clinical settings followed in subsequent years.  
This historical trajectory is described in greater detail below. 
Although there were calls for prevention programs for HIV-positive persons during 
the early years of the epidemic, no data demonstrated efficacious programs for PLWHA.  
The initial prevention programs for PLWHA that had been carried out had attempted to adopt 
programs that had been successful among people who were HIV-negative; not surprisingly, 
these programs were not effective for PLWHA.   Since the aims and strategies of prevention 
were often markedly different for HIV-negative people compared with those for HIV-
positive people, these programs were not directly applicable.  With few exceptions, the 
primary prevention programs that existed for PLWHA entailed a single post-test counseling 
session when individuals received their diagnosis and briefly discussed safer sex practices 
and partner notification (Wolitski et al., 2005). 
The need for targeted prevention programming for PLWHA did not become widely 
recognized or accepted until the broad dissemination of highly active antiretroviral therapy 
(HAART) in the mid-1990s led to increased longevity for people living with HIV.  In 1997, 
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some of the strongest support for the need for Prevention with Positives (PWP) programs 
came from a National Institutes of Health panel which concluded: 
“Programs must be developed to help individuals already infected with 
HIV to avoid risky sexual and substance behavior.  This National priority 
will become more pressing as new biological treatments prolong life.  
Thus, prevention programs for HIV-positive people must have outcomes 
that can be maintained over long periods of time, in order to slow the 
spread of infection.” (page 26) (National Institutes of Health (U.S.). 
Continuing Medical Education., 1997, p. 28).  
 
 
In 2000, the Institute of Medicine released No Time to Lose: Getting the Most from 
HIV Prevention which reported that the populations in greatest need of prevention efforts had 
changed since the early years of the epidemic; specifically the report noted that growing 
proportion of HIV cases were among women, racial minority groups, and rural and smaller 
urban areas (Ruiz & Institute of Medicine (U.S.). Committee on HIV Prevention Strategies in 
the United States., 2001).  With this change in the demographic distribution of HIV, the 
report offered specific strategies for HIV prevention including: 1) developing an accurate 
surveillance system of new HIV infections to predict better the epidemic’s trajectory; 2) 
allocating prevention resources guided by principles of cost-effectiveness; 3) developing and 
implementing prevention services for PLWHA that are integrated into the clinical care 
setting; 4) translating findings from prevention research into action at the community level; 
5) investing in the development of new tools and technologies to expand prevention efforts; 
and 6) aiming to overcome social and political barriers that impede HIV prevention efforts. 
The CDC initiated the Serostatus Approach to Fighting the HIV Epidemic (SAFE) in 
2001.  This new approach defined a framework for improving the health of PLWHA and 
preventing transmission to other individuals.  SAFE sought to achieve an increase in five 
factors: 1) the number of HIV-infected persons who know their serostatus; 2) the use of 
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health care and preventive services among PLWHA; 3) high-quality care and treatment for 
people diagnosed with HIV; 4) adherence to HIV therapy among persons diagnosed with 
HIV; and 5) the number of persons diagnosed with HIV who adopt and maintain behaviors 
that reduce the risk of HIV and STI transmission (Janssen et al., 2001).  
Two years late in 2003, the CDC announced the Advancing HIV Prevention (AHP) 
initiative to complement the SAFE approach.  AHP formally adopted PwP as one of three 
core elements of a comprehensive approach to HIV prevention (2003b). Those three 
elements included: 1) HIV counseling, testing, and referral; 2) prevention for persons at high 
risk for HIV; and 3) prevention with persons living with HIV.  AHP also included the 
availability of substantial public health resources to design and implement large-scale 
programs including one specific approach to prevent new infections by working with 
PLWHA and their partners (Seth C. Kalichman, 2005) and to integrate HIV prevention into 
the medical care of PLWHA.  
In 2003, the CDC also released new guidelines for health care providers to 
incorporate HIV prevention into the care of their patients including recommendations for: 1) 
screening for HIV transmission risk behaviors and STIs, 2) providing brief behavioral risk-
reduction interventions in the clinical setting and referring selected patients for additional 
prevention services, and 3) facilitating partner notification and counseling (CDC, 2003b).    
There are potential auxiliary benefits to successful PwP initiatives in addition to 
prevention of new cases of HIV infection.  A reduction in unprotected sexual activity 
protects PLWHA from contracting other sexually transmitted infections as well as from HIV 
reinfection, both of which can adversely impact their health (Blackard, Cohen, & Mayer, 
2002; Filippini et al., 2001; O'Brien et al., 2003).  In addition, programs for PLWHA can 
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provide access to medical services and improve adherence to medication regimens (Janssen 
et al., 2001).  PwP initiatives often also include mental health, social service, and related 
ancillary programs to improve the general health and well-being of PLWHA, offering 
assistance with daily needs, such as transportation, meals, housing, and financial support 
(Conviser & Pounds, 2002). 
 
2.4 HIV SEROSTATUS DISCLOSURE  
A critical element of reducing HIV transmission risk is serostatus disclosure, that is, 
the informing by seropositive individuals of their serostatus to their sexual partners, in 
congruence with U.S. Public Health Service guidelines.  HIV self-disclosure is commonly 
defined as the act of informing another person of one’s own HIV serologic status.  The 
general term “disclosure” in the context of HIV prevention has been primarily used for 
people who are HIV seropositive.  Numerous factors influence one’s decisions regarding 
when, how, and to whom to disclose.   
 Two reasons that public health officials have focused on serostatus disclosure to 
sexual partners as a critical element of PwP programs are that: 1) it may lead to safer sexual 
practices and 2) it may reduce the risk of re-infection with a resistant strain of HIV if both 
partners are HIV-positive.  It can also decrease the risk of acquiring another STI if the 
discussion facilitates safer sex practices.  In addition, disclosure may have greater public 
health benefit because it allows partners of HIV-positive individuals to make informed 
choices before initiating, or in some cases re-initiating, sexual contact.  It also provides 
information to individuals that may motivate them to practice safer sex.  Furthermore, 
disclosure creates an opportunity for both parties to negotiate and discuss options and 
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preferences for safer sex.  When HIV-positive individuals do not disclose to their sexual 
partners, the partners may underestimate their own risk and may subsequently engage in less 
self-protective behaviors (Ciccarone et al., 2003; Derlega, Winstead, Oldfield, & Barbee, 
2003; Zea, Reisen, Poppen, & Diaz, 2003).  The lack of perceived personal benefit that 
PLWHA derive from disclosing may hinder them from disclosing.  This raises the question 
of the extent to which HIV-infected persons disclose to sexual partners. 
There are personal, social, and legal pressures to disclose one’s HIV serostatus to sex 
partners.  For example, 23 states currently have laws that make it a criminal offense for HIV-
positive persons to engage in various types of sexual activity without serostatus disclosure to 
prospective sexual partners (Galletly & Pinkerton, 2006).  In many states, health care 
professionals are also required to report to appropriate authorities instances when HIV-
positive individuals have unprotected sex without informing partners of their infection 
(Lambda Legal Defense Fund, 2002). 
Despite these incentives to disclose, other social pressures, such as stigma may serve 
as a barrier to disclosure.  Several studies have assessed the proportion of PLWHA in a 
sample who have disclosed to partners but results vary, and the U.S. studies have been 
conducted primarily among gay or bisexual HIV-positive men.  Proportions reported of HIV-
positive persons who disclosed to sex partners in these studies ranged from 34% to 98% 
(Batterham, Rice, & Rotheram-Borus, 2005; D'Angelo et al., 2001; DeRosa & Marks, 1998; 
Hays et al., 1993; S. C. Kalichman et al., 2002; R. Klitzman et al., 2007; Marks et al., 1999; 
Marks & Crepaz, 2001; Niccolai et al., 1999; Patel et al., 2006; Prestage et al., 2001; Stein et 
al., 1998).   
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There is far more research in the international literature than the U.S. literature 
regarding serostatus disclosure among women.   Most published studies were conducted in 
sub-Saharan Africa.  Research from two studies of HIV-positive women in Kenya found 
disclosure rates ranging from 27% (time since diagnosis not reported) (Temmerman et al., 
1990) to 37% within 1 year of diagnosis (Temmerman, Ndinya-Achola, Ambani, & Piot, 
1995). Another study of women in Tanzania found that 17% disclosed their status to their 
partner (Kilewo et al., 2001). In a study of Tanzanian women, researchers found that a 
disclosure prevalence that varied based on time since diagnosis where 22% of HIV-positive 
women disclosed to a partner ranged within 2 months of diagnosis compared to 40% 
disclosing after a 4 year-period (Antelman et al., 2001).  In a more recent study among 
women receiving HIV testing at a clinic in Dar es Salaam, Tanzania 64% of those who tested 
positive disclosed their HIV status to their sexual partners (Maman et al., 2003).  Similarly, a 
study among women in Mali and Burkina Faso found a disclosure rate of 79.9% to sexual 
partners (Ndiaye et al., 2009).  Of note, many of the barriers to disclosure discussed in the 
U.S. literature are also found in the international literature among women.  For example, 
stigma, discrimination, level of intimacy in the sexual partnership, and fear are often cited as 
negative outcomes that may serve as barriers to disclosure of one’s status to sexual partners 
(Daftary, Padayatchi, & Padilla, 2007; A. Norman, Chopra, & Kadiyala, 2007). 
Table 6 on the following pages is a summary of studies that have assessed the extent 
of serostatus disclosure among PLWHA.  Results from these studies illustrate that serostatus 
disclosure is not absolute, as partner serostatus and relationship type plays a role in 
disclosure decisions.
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TABLE 6: STUDIES ASSESSING DISCLOSURE AMONG PLWHA 
CITATION SAMPLE SIZE AND 
DESCRIPTION 
PARTICIPANT 
DESCRIPTION 
PRIMARY 
OUTCOME RESULTS 
Simon Rosser 
et al, 2008 
675 HIV-positive 
MSM  
45% AA 
25% White 
23% Hispanic 
Disclosure to 
secondary sexual 
partners 
Disclosure to some secondary partners: 31% 
Disclosure to no secondary partners: 30% 
 
Klitzman et al, 
2007 
1,828 HIV+ MSM at 
medical clinics and 
community agencies 
in LA, NY, 
Milwaukee, San 
Francisco 
38% White 
18% Hispanic 
80% Homosexual 
18% Bisexual 
Disclosure to sexual 
partners 
Disclosure to all partners: 46% 
Disclosure to main partner: 88%  
Disclosure to all casual partners: 42% 
Disclosure associated with relationship type and  perceived 
partner status 
Mohammed 
and Kissinger, 
2006 
273 HIV+ adults 
seeking HIV care in 
rural Louisiana 
58% AA 
68% Male 
Mean age: 30 
Disclosure to partners 
3 mos. after diagnosis 
and 3 mos. prior to 
interview 
Disclosure to past partners: 57% 
Disclosure to current partner: 81% 
African Americans and those with >1 partner less likely to 
disclose to current partners. 
Raj et al, 2006 124 HIV+ adults in 
HIV Alcohol 
Longitudinal Cohort 
study  
49% AA 
79% Male  
Age range: 25-61 
Disclosure to sexual 
partners in past 6 
mos. 
Disclosure to partner: 68% 
Odds of nondisclosure higher for those with multiple partners 
Batterham et 
al, 2005 
604 HIV+  
adolescents at clinics 
in LA, NY, Miami, 
San Francisco 
Pre-HAART cohort:  
72% Male 
 
 
Post-HAART 
cohort:                
70% Male 
Disclosure to sexual 
partners in past 3 
mos. 
Odds of disclosure higher among MSM and those who have 
had a longer time since diagnosis.   Odds of disclosure lower if 
partners were casual or were known to be HIV-negative. 
Parsons et al., 
2005 
858 gay and bisexual 
males in 
Seropositive Urban 
Men’s Study  
25% AA 
15% Hispanic 
50% White 
Disclosure to casual 
sexual partners in the 
past 3 mos. 
Disclosure to all casual partners: 29% 
Disclosure to some casual partners: 38% 
Disclosure to no casual partners: 33% 
Poppen et al, 
2005 
219 HIV+ males in 
large-scale study 
from clinics in 
Washington, DC, 
NY, Boston 
Age range: 23-62 Disclosure to most 
recent sexual partner 
Disclosure to HIV+ partners: 83% 
Disclosure to HIV- partners: 78% 
Disclosure to HIV? partners: 20% 
Disclosure to main partner: 81% 
Disclosure to casual partner: 34% 
Crepaz and 
Marks, 2003 
105 HIV+ male 
patients at public 
64% AA 
20% White 
Disclosure to most 
recent sexual partner 
Disclosure to at-risk partner: 53% 
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outpatient clinic in 
LA 
16% Latino 
Age range: 26-58 
O’Brien et al, 
2003 
269 HIV+ adults at 
outpatient clinic in 
New Orleans 
84% AA 
12% White 
52% Male 
Age range:18-74 
Disclosure to various 
types of people 
Disclosure to main partner: 74% 
Disclosure to casual partner: 25%  
D’Angelo et 
al, 2001 
317 HIV+ 
adolescents in 15-
site REACH study 
72% White 
14% Hispanic 
70% Female 
Disclosure to sexual 
partners 
Disclosure to any partner: 47.5% 
Disclosure more likely to HIV+ partners (vs. HIV- or HIV?) 
and to main (vs. casual partners) 
Petrak et al, 
2001 
95 HIV+ adults at 
outpatient clinics in 
London 
76% White 
83% Male 
 
Disclosure to 
significant other 
Disclosure to current partner: 91% 
 
Kalichman 
and 
Nachimson, 
1999 
266 HIV+ adults at 
social service 
agencies and 
providers in Atlanta 
67% AA 
29% White 
76% Male 
 
Disclosure to sexual 
partners 
Disclosure to most recent partner: 78% of men and 79% of 
women.  Non-disclosure was associated with lower self-
efficacy for disclosure.   
Niccolai et al, 
1999 
147 HIV+ adults 
reporting to public 
STD clinic in New 
Orleans 
52% Male  
88% AA 
44% under age 30 
Disclosure to most 
recent partner 
Disclosure to last partner: 76%  
Being in a monogamous relationship predicted disclosure.   
DeRosa and 
Marks, 1998 
255 HIV+ male 
patients at 2 
outpatient clinics in 
LA 
43% Hispanic    
40% White         
62% Homosexual 
29% Bisexual 
Disclosure  to sexual 
partners in past 2 
mos. 
Disclosure to HIV+ partner: 93% 
Disclosure to HIV- partner: 57%  
Disclosure to HIV? partner: 23% 
Stein et al, 
1998 
129 HIV+ adults at 
two hospitals in 
Boston and 
Providence  
46% AA  
23% Hispanic  
69% Male 
Disclosure to sexual 
partners in past 6 
mos. 
Disclosure to all partners: 60%  
Of the 40% non-disclosers, 50% did not disclose to their one 
and only partner. 
Wolitski et al, 
1998 
701 HIV+ and HIV- 
men in Dallas, 
Denver, Seattle, and 
Long Beach 
90% White 
6% Hispanic 
Age range: 18-71 
Disclosure to various 
types of people 
Disclosure to main sex partner: 89% 
Mason et al, 
1997 
369 HIV+ men at 
outpatient clinics in 
LA 
72% White 
28% AA 
Mean age: 38 
Disclosure to various 
types of people 
Disclosure to intimate lover: 89% of AA and 97% of Whites 
Mansergh et 
al, 1995 
684  HIV+ patients 
at 2 HIV outpatient 
clinics in LA 
42% Hispanic 
40% White 
Median age: 36 
Disclosure to various 
types of people 
Men recently diagnosed were more likely to have informed 
intimate lovers and friends than family members.  Disclosure 
was lower among asymptomatic than symptomatic men. 
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Simoni et al, 
1995 
65 HIV+ female 
patients at 2 
outpatient clinics  in 
LA 
63% Hispanic  
20% AA 
Age range: 18-69  
Disclosure to various 
types of people 
Disclosure to lover/partner: 87% 
Spanish-speaking Latinas were less likely to disclose than 
English-speaking Latinas, African Americans, and Whites.  
Stempel et al, 
1995 
93 HIV+ patients at 
hospital in San 
Francisco 
Not available Disclosure within 
year of diagnosis 
Disclosure to main partners: 82% 
Hays et al, 
1993 
163 HIV+ males in 
AIDS Behavioral 
Research Project 
96% White 
Age range: 24-68  
Disclosure to various 
types of people  
Disclosure to partner: 98% 
Schnell et al, 
1992 
249 HIV+ males in 
AIDS Community 
Project 
86% White 
10% Hispanic 
Median age: 32 
Disclosure to sexual 
partners 
Disclosure to main partner: 89%  
Marks et al, 
1991 
138 HIV+ male 
patients at public 
clinic in LA 
75% Hispanic 
15% White 
Disclosure since 
diagnosis 
Disclosure to one or more partners: 48%    
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2.4.1 Factors Motivating PLWHA to Conceal or Disclose their Serostatus  
Nondisclosure of one’s HIV status can be regarded as either passive (“passive 
omission”) or active (“active deception”) (Stein et al., 1998).  Disincentives to revealing 
one’s status exist and may motivate people to avoid disclosing their serostatus (Ciccarone et 
al., 2003).  Some commonly cited reasons for nondisclosure include the fear of 
discrimination, (Petrak, Doyle, Smith, Skinner, & Hedge, 2001) fear of physical violence 
from a partner, (Gielen, O'Campo, Faden, & Eke, 1997) fear of rejection, stigmatization, or 
fear that confidentiality will be broken (Hays et al., 1993; Moneyham et al., 1996) and the 
desire to maintain secrecy and to protect others from emotional distress (J. Simoni et al., 
1995).   
On the other hand, some people are motivated to disclose because, keeping one’s HIV 
status a secret from others can have detrimental effects on one’s physical and emotional well-
being.  For many PLWHA, disclosure can lead to gaining a variety of physical, social, and 
emotional resources (J.M. Serovich, 2001).  Disclosure can lead to greater emotional support 
in helping PLWHA to cope with their illness as well as obtaining assistance in managing 
their illness, such as child care assistance or transportation to doctor appointments (Black & 
Miles, 2002).  Furthermore, some studies have found that the sense of personal responsibility 
to protect one’s partner is a motivator to disclose one’s status (J. M. Serovich & K. E. 
Mosack, 2003; J. Simoni et al., 1995; Wolitski, Bailey, O'Leary, Gomez, & Parsons, 2003).   
 
2.4.2 Theoretical Frameworks for Understanding HIV Disclosure 
Unfortunately, few theoretical frameworks exist that specifically seek to explain HIV 
disclosure by PLWHA.  However, Mason and colleagues contend that the theory of reasoned 
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action can be used to understand and explain much of the disclosure research ((Mason, 
Marks, Simoni, Ruiz, & Richardson, 1995).  The theory of reasoned action (TRA) assumes 
that individuals are rational actors and make rational choices, with motivational factors 
serving as determinants of their likelihood of performing a given behavior.  TRA states that 
behaviors are best predicted by intentions which stem partly from an individual’s 
motivations.   
More recently, two disclosure theories have been postulated: the disease progression 
theory and the competing consequence theory (J.M. Serovich, 2001).  Disease progression 
theory proposes that PLWHA disclose their status as their HIV progresses to full-blown 
AIDS because they are no longer able to keep their illness a secret (Aronstein & Thompson, 
1998; Seth C. Kalichman, 1995).  Previous research supports this theory demonstrating that 
there is an association between increasing symptom severity, physical deterioration, and 
hospitalization and an increased likelihood of disclosure (Hays et al., 1993; Marks et al., 
1992; Mason et al., 1995).  However, research on disease progression and disclosure 
specifically to sexual partners have not demonstrated this relationship (Mansergh, Marks, & 
Simoni, 1995; Perry et al., 1994).  It is also possible that the relationship between disease 
progression and disclosure may be less clear with the increased availability and use of 
HAART, as many of the aforementioned studies were conducted before HAART was 
available.  As many PLWHA are living longer, healthier, more productive lives since the 
advent of HAART, the disease progression theory may be less plausible than it was in the 
early years of the epidemic. 
On the other hand, consequence theory argues that the association between disease 
progression and serostatus disclosure is moderated by the consequences an individual expects 
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as a result of disclosure (J. M. Serovich, 2001).  In other words, stresses accumulate as one’s 
HIV progresses, resulting in the need for an individual to evaluate the negative and positive 
consequences of disclosure.  This theory builds from social exchange theory, which 
postulates that individuals tend to avoid costly relationships and prefer to seek rewarding 
ones (Thibaut & Kelley, 1959).  The consequences theory also expands upon the disease 
progression theory in that it recognizes that disclosure is motivated by more than overt 
symptoms, such as one’s physical appearance, as disclosers take into consideration the 
expected reactions of those to whom they disclose.  As noted earlier, the negative 
consequences associated with HIV serostatus disclosure are considerable and can include 
feelings of anxiety and threats to personal well-being (J.M. Serovich, 2001).   
Support for the consequence theory in the literature is growing.  For example, 
Derlega and colleagues found that the process of reducing risks and increasing benefits of 
serostatus disclosure resulted in the selectivity of to whom to disclose (1998).  Others have 
also found support for the consequence theory with findings that suggest an individual 
assesses the rewards and costs associated with disclosure before actual disclosure takes place 
(Emlet, 2006; J.M. Serovich, 2001).   
However, what remains unclear is the process that individuals undergo to determine 
and evaluate such rewards and costs (Robert Klitzman & Bayer, 2003).  Serovich argues that 
better research into understanding disclosure patterns specifically to sexual partners is needed 
because they are a unique sub-group of individuals to whom disclosure occurs.  These 
disclosure patterns, and the rewards and costs associated with them, may be quite different 
from disclosure to family members, friends, or health care professionals.  In particular, 
Serovich states that feeling of an obligation or duty to inform may be more predictive of 
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disclosure to sexual partners that to other subgroups.  Other relationship variables, such as 
strength and duration of a relationship or power differentials between partners, might be 
important to consider when applying the consequences theory to understanding disclosure 
patterns.  In addition, given that serostatus disclosure to sexual partners is not carried out for 
all HIV-positive persons in all instances, understanding important factors that serve as 
barriers or disincentives to disclosure and the role the disclosure may play in facilitating safer 
sex are important for better understanding how to reduce transmission among PLWHA.   
 
2.5 OVERVIEW OF STIGMA  
There are many factors that contribute to the health and health-related behaviors of 
HIV-positive individuals.  One such factor is stigma.  Recent research demonstrates that 
HIV-related stigma may have an impact on various health behaviors, such as medication 
adherence (Fortenberry, 2002; Stall, 1996; Worthington, 2003) and disclosure (Clark, 2003; 
Derlega, 2002; Laryea, 1993; Lester, 2002).     
Social anthropologist Erving Goffman defines a stigmatized individual as one who is 
seen as possessing an undesirable trait or characteristic that is viewed negatively or deemed 
to be flawed by societal standards.  As an outcome, stigma takes place when the negative 
social meanings applied to the discrediting trait become connected to the individual.  As a 
result of this link, an individual’s social identity changes, leading to a less than full 
acceptance of the person in social interactions (Goffman, 1963). 
In Goffman’s view, the person’s experience of stigma is influenced by the nature of 
the stigmatizing attribute.  For example, if the trait is not directly apparent to others, the 
individual is considered “discredible” rather than immediately discredited.  This reality 
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contributes to an individual’s ability to conceal the attribute from others to be able to “pass” 
as “normal” (Goffman, 1963).  However, even those individuals who effectively hide their 
stigma trait may still experience their own internalized perception of being imperfect or 
flawed.  According to Goffman, both the awareness of how one violates social norms by 
possessing the trait as well as the negative reactions that stigmatized individuals either expect 
or have experienced first-hand in the past play a role in negative self-evaluation, anxiety, 
social withdrawal, and loss of self-esteem.  However, a stigmatizing trait does not 
automatically induce a stigmatizing reaction in every situation.  The inability to accurately 
predict a person’s reaction contributes to the anxiety produced for the stigmatized individual.  
Some people completely reject the notion of shame and difficulty associated with accepting 
their stigmatizing trait or condition (Goffman, 1963).  Rather, while acknowledging that they 
possess the attribute, they reject the social meaning assigned to the trait and to themselves as 
a possessor of that trait.  Such individuals may become leaders in educational efforts or in 
community activism, which may include self-disclosure of one’s attribute (Berger, Ferrans, 
& Lashley, 2001). 
Research on stigma has been applied to a variety of health conditions, ranging from 
cancer (Fife & Wright, 2000) to mental illness (Link, Phelan, Bresnahan, Stueve, & 
Pescosolido, 1999).  Health-associated stigma can result from a noticeable physical condition 
or limitation, such as a limb amputation, or from a concealable condition, such as 
asymptomatic HIV infection (Berger et al., 2001).  Stigma has been found to be associated 
with a variety of psychological concerns including feelings of shame, guilt, fear, and anger 
(M. Bennett, 1990; Laryea & Gien, 1993).  Stigmatized individuals are also susceptible to 
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feelings of self-hatred, often resulting from internalization of society’s negative views of 
them (Herek, 1990; Novick, 1997). 
 
2.5.1 HIV Stigma  
Herek contends that HIV possesses four characteristics that explain its high 
stigmatization (1999).  First, HIV is a disease that is perceived to be the responsibility of the 
individual affected, since the primary methods of transmission are behaviors considered to be 
controllable and avoidable.  Second, HIV is perceived as a condition that is generally fatal, 
despite medication advances such as the effectiveness of HAART that are transforming HIV 
into a chronic rather than lethal disease.  Third, those health conditions that are contagious 
are more likely to carry greater stigma than those conditions that are not communicable.  
Finally, health conditions that are visually noticeable, such as the advanced stages of 
HIV/AIDS, are more stigmatized than those conditions that are concealable.    
Berger, Ferrans, and Lashley describe a model of HIV stigma that accounts for the 
seropositive individual’s perception of stigma (2001) rather than the general public’s views 
of PLWHA.  They argue that because HIV may not have overt or noticeable symptoms or 
physical characteristics, an HIV-positive person can “pass” as normal.  However, the 
individual may perceive him/herself negatively.  This perception of stigma has two contexts: 
first, an internalized stigma component—the individual’s own perception of being infected 
with HIV and an externalized component—individual’s perception of society’s view of the 
HIV-positive individual.   
Much of the empirical research on HIV-related stigma has tended to focus on the 
attitudes and beliefs of those who are perceived to stigmatize others (Parker & Aggleton, 
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2003).  For example, recent population-based telephone surveys in the United States have 
found that nearly 25% of those surveyed believed that people with AIDS “have gotten what 
they deserve,” 22% believe that people with AIDS don’t care if they infect others, and one-
third reported that they would actively avoid interacting with an HIV-positive individual 
(Herek, Capitanio, & Widaman, 2002).  It has been suggested that HIV stigma derives from 
the dislike of marginalized communities initially infected with HIV such as injection drug 
users and homosexuals (Herek & Glunt, 1988) as well as the connection to lifestyles and 
behaviors that are culturally taboo, such as homosexuality, sexual promiscuity, and illegal 
drug use (Hayes, Vaughan, Medeiros, & Dubuque, 2002; Herek et al., 2002; Herek & Glunt, 
1988; Pryor, Reeder, Yeadon, & Hesson-McLnnis, 2004).  For example, research has found 
that PLWHA who contracted the disease through sex with multiple partners or through 
sharing needles were viewed more negatively than those infected through sex with only one 
partner.  PLWHA who contracted the virus through sex, gay and bisexual men are also 
viewed more negatively than heterosexual men and women (Herek and Capitanio, 1998).  In 
addition, misinformation and fear of PLWHA also contributes to the persistence of HIV 
stigma in the general public (Vanable, Carey, Blair, & Littlewood, 2006).  More recent 
qualitative research has suggested that the layering of stigma among PLWHA with gender, 
race, and sexual orientation stigmas presents a methodological challenge when attempting to 
understand stigma as well as develop effective interventions to lessen its effects 
(Sandelowski, Barroso, & Voils, 2009). 
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2.5.2 Research about the Association between HIV Stigma and Disclosure  
The role of stigma is an important consideration when examining reasons for non-
disclosure.  Previous research has found that stigma has a negative impact on a number of 
factors in the lives of PLWHA including when, how, and to whom to disclose (Derlega, 
Winstead, Greene, Serovich, & Elwood, 2002; Lie & Biswalo, 1996; van der Straten, 
Vernon, Knight, Gomez, & Padian, 1998).  Findings in the literature have shown that 
disclosure is consistently associated with stigma perceptions (Clark, Lindner, Armistead, & 
Austin, 2003; Derlega et al., 2002; Simbayi et al., 2006; Smith, Rossetto, & Peterson, 2008).  
Stigmatization may have an influence on disclosure decisions due in large part to 
preconceived ideas about PLWHA.  For example, research has found that those who feel 
shameful about their HIV status are more likely withhold disclosure to casual sex partners 
(Serovich, 2003).  In addition, nondisclosure can be viewed as an act of “protective silence” 
whereby limiting disclosure can control the possibility of facing stigma (Emlet, 2006).   
As illustrated by Serovich’s consequences theory of disclosure, research studies have 
found that the disclosure decision-making process results from people weighing the pros and 
cons associated with serostatus disclosure (Armistead, Tannenbaum, Forehand, Morse, & 
Morse, 2001; Black & Miles, 2002; J.M. Serovich, 2001).  Stigma may deter PLWHA from 
disclosing their serostatus to others, including sexual partners, for fear of rejection, hostility, 
discrimination, (Chesney and Smith, 1999) fear of relationship dissolution or disruption 
(Mohammed & Kissinger, 2006) and fear of physical violence by their partner (Zierler et al., 
2000).  For example, one study found 50% of PLWHA who disclosed their status 
experienced rejection (Laryea & Gien, 1993) while another study found non-disclosure to be 
associated with fear of rejection and self-blame (Derlega et al, 2002).  A more recent study 
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found that higher levels of stigma were associated with decreased levels of disclosure as well 
as psychosocial functioning (Clark et al., 2003).  In addition, self-disclosure decreases the 
ability to control secondhand disclosure by others, which may lead to stigmatizing 
consequences (Ostrom, Serovich, Lim, & Mason, 2006).  Regardless of one’s previous 
experiences with and others’ reaction to serostatus disclosure, many PLWHA fear they risk a 
stigmatizing response with each prospective disclosure.    
A commonly cited result of stigma which makes it particularly challenging for HIV 
serostatus disclosure is the perceived loss of social support from partners, friends, and family 
members (S. C. Kalichman & Simbayi, 2003).  Though no one community is immune to HIV 
transmission, it is still viewed as a disease that primarily affects marginalized populations 
and is associated with undesirable behaviors, such as injection drug use, prostitution, or 
promiscuity (Herdt, 2001).  Black and Miles argue that few illnesses in modern times carry 
the level of stigma and resulting social isolation as seen among HIV-positive individuals 
(2002).  Conceptualization of the epidemic as a process of disease and illness over time with 
consideration for those sub-populations that have been most impacted, one can begin to 
comprehend how stigma and discrimination have shaped rates of HIV infection as well as 
impacts the likelihood of serostatus disclosure (Herdt, 2001).  
 
 
2.6 TRANSMISSION RISK PERCEPTIONS 
 
The widespread use of HAART in the United States since 1996 has dramatically 
reduced the morbidity and mortality associated with HIV infection (CDC, 2002).  The goal of 
HAART treatment is to lower the HIV viral load to levels that are deemed undetectable (<50 
copies/mL), as research has shown that high viral load levels impair an individual’s immune 
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system and can lead to the opportunistic infections characteristic of an AIDS diagnosis.  
Many HIV-positive persons have been able to achieve lower viral loads due to HAART use 
and strict adherence to their treatment regimens (Carpenter, 1997; Friedland, 1999; 
Montaner, 1998).  
While there are clear clinical benefits of HAART availability and use, there may be 
some unintended negative effects of HAART use on the sexual behaviors of PLWHA.  
Research studies suggest that optimism about the effectiveness of HAART may be 
contributing to relaxed attitudes toward safer sex practices and increased sexual risk-taking 
by some PLWHA (Fleming & Wasserheit, 1999; Kelly, Hoffman, Rompa, & Gray, 1998; 
Kravcik et al., 1998; Van de Ven, Kippax, Knox, Prestage, & Crawford, 1999).  In addition, 
serostatus disclosure patterns may have shifted recently in ways that have not yet been fully 
examined due to HAART availability and use (Klitzman et al., 2004).  
Despite an abundance of literature investigating disclosure after the widespread 
availability of HAART, few studies have specifically examined HAART-associated 
perceptions among PLWHA or risk perceptions with undetectable viral loads as they relate 
specifically to serostatus disclosure.  While some studies on disclosure include clinical or 
medical indicators (such as CD4 count) as variables of interest, the role of HAART-related 
beliefs has received much less focus in the disclosure literature.  The few published studies 
discuss disclosure and actual HAART adherence, not disclosure and HAART-related beliefs 
among PLWHA (R. L. Klitzman et al., 2004).  Furthermore, the research studies on 
transmission risk beliefs with HAART and risk perceptions given different viral loads have 
used unprotected sexual activity as the primary outcome variable, not serostatus disclosure 
(Crepax, Hart & Marks, 2004; Kalichman et al., 2006).  Crepaz and colleagues argue that it is 
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important to investigate whether beliefs about HAART and its use are associated with sexual 
risk taking behaviors (2004).  Yet, only one qualitative study to date has examined the 
relationship between serostatus disclosure and HAART beliefs (Klitzman et al., 2004).  This 
study found that the desire to remain healthy and take one’s medications may conflict with a 
desire to maintain privacy about one’s HIV status, where disclosure can both facilitate and 
impede medication adherence.   
Traditional health behavior theories tend to focus on constructs that emphasize an 
individual’s attitudes, beliefs, motivations, and behaviors in an effort to predict or explain 
events or situations, often conceptualized as a way to keep oneself healthy and avoid disease 
or illness.  Since the HIV transmission risk beliefs discussed above pertain to reducing or 
eliminating an individual’s chances of exposing another individual to HIV, it is difficult to 
link directly theoretical constructs to these concepts.  Despite the limitations of applying 
traditional health behavior theoretical constructs to these transmission risk beliefs, further 
research is needed into understanding the role of HAART-related beliefs and risk perceptions 
based on undetectable viral loads with serostatus disclosure among PLWHA, particularly 
since HAART is offering PLWHA to live longer, healthier lives.  More specifically, 
additional studies examining these relationships are warranted that include a diverse sample 
of PLWHA, as beliefs may not be uniform across different sub-populations, such as MSM, 
women, and heterosexual men.  
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2.7 SUBJECTIVE NORMS 
Subjective norms are defined as the beliefs about whether most people approve or 
disapprove of a given behavior (Glanz, Rimer, & Lewis, 2002).  They represent a construct 
of the Theory of Planned Behavior (TPB) (Ajzen, 1991) and are determined by the perceived 
social pressure to perform a given behavior. The TPB has received significant support from 
research on the adoption of many health-related behaviors, including safer sex behavior 
(Albarracín, Fishbein, Johnson, & Muellerleile, 2001; Rye, Fisher, & Fisher, 2001; Sheeran, 
Abraham, & Orbell, 1999).  TPB has been applied to a study on understanding the provision 
of HIV prevention information by health care providers to their patients (Montano, Kasprzyk, 
von Haeften, & Fishbein, 1998) and predictors of condom use among Black, Hispanic, and 
White heterosexual women at risk for HIV and STIs (Von Haeften & Kenski, 2001).   
However, there has been a lack of research examining the influence of subjective 
norms on the disclosure practices of HIV-positive individuals.  How different referent groups 
(friends, family members, and sexual partners) feel about the need for HIV-positive persons 
to 1) disclose their status and 2) engage in safer sex behavior may influence the actual 
behaviors of HIV-positive persons.  This is an area that has been under-researched yet may 
shed some light into better understanding the influence of social forces on risk behavior. 
 
2.8 URBANICITY 
The demography of the HIV epidemic in the United States has changed over the last 
25 years.  While most cases were initially found among gay white men in urban areas (Kelly 
& Murphy, 1992) cases more recently are found in minority populations, heterosexual men, 
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women, and those living in non-urban areas (Chu & Selwyn, 2008; Karon et al., 2001).  
Similar to other Southern states, North Carolina’s HIV epidemic is more rural and more 
heterosexually transmitted in nature.  The state has the second highest number of AIDS cases 
in the nation from non-metropolitan areas.  Approximately one-quarter of the state’s HIV 
cases come from rural areas (DHHS, 2008).  HIV-positive individuals who reside in rural 
areas are often less educated, lack health insurance, and are more likely to be unemployed 
compared to those living in urban areas (Gaskins, 2006).  Furthermore, rural areas are more 
likely to have conservative cultural norms that may contribute to stigmatization for PLWHA 
and influence disclosure decisions (McKinney, 2002; Nguyen & Whetten, 2003; Tiemann, 
2006; Whetten-Goldstein, Nguyen, & Heald, 2001).  A recent study among HIV-positive 
patients in New England found that the size of the community where a person resides was 
associated with the level of disclosure stigma experienced (Gonzalez, Miller, Solomon, 
Bunn, & Cassidy, 2008).  Specifically, the authors found that rural women were more likely 
to report disclosure concerns than women residing in metropolitan and micropolitan areas. 
Similarly, rural women reported more disclosure concerns than rural men.  In addition, men 
residing in micropolitan communities were more likely to report disclosure concerns than 
men in rural areas. 
Given these findings, it is important to examine the level of urbanicity as a correlate 
of serostatus disclosure.  Rural urban community area (RUCA) codes classify U.S. census 
tracts using measures of population density, urbanization, and daily commuting.  The most 
recent RUCA codes are based on data from the 2000 census. The codes are categorized as 
whole numbers (1-10) and delineate metropolitan, micropolitan, small town, and rural 
commuting areas based on the size and direction of the primary (largest) commuting flows. 
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2.9 RELATIONSHIP BETWEEN SEROSTATUS DISCLOSURE AND 
TRANSMISSION RISK BEHAVIORS 
 
Underlying efforts to encourage serostatus disclosure is the assumption that 
disclosure will increase the safety of later sexual behaviors with informed partners.  
According to Norman and colleagues, “it is reasonable to assume that a couple’s diligence in 
using condoms consistently and correctly would be enhanced by one partner’s disclosure of 
positive serostatus (L. R. Norman, Kennedy, & Parish, 1998).  Many have speculated that 
there is a relationship between serostatus disclosure to sexual partners and transmission risk 
behaviors.  However, the relationship between HIV disclosure and sexual risk behavior is 
complex, and there has been inconsistency in research findings about this relationship.   
A variety of ethical concerns are raised when discussing sexual contact in the absence 
of disclosure of one’s serostatus.  One of the largest ethical concerns is the denial of an 
opportunity for an at-risk partner to make an informed decision about acceptable levels of 
risk behaviors (Bayer, 1996; R. Bennett, Draper, & Frith, 2000).  As a result of this concern, 
many public health officials have contended that disclosure and protected sex are necessities 
with all sexual partners in all cases, (Marks & Crepaz, 2001) particularly since 23 states have 
laws that make it a criminal offense for HIV-positive persons to engage in various types of 
sexual activity without, in most cases, serostatus disclosure to prospective sexual partners 
(Galletly & Pinkerton, 2006).   
Studies suggest that disclosure may promote safer sex practices, such as safer sex 
negotiation and condom use, with serodiscordant partners (Hays et al., 1993; Marks, 
Richardson, & Maldonado, 1991; Prestage et al., 2001; Schnell et al., 1992; Semple, 
Patterson, & Grant, 2000).  Disclosure has been found to be associated with reduced sexual 
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risk behavior (S. C. Kalichman & Nachimson, 1999; Niccolai et al., 1999) and having fewer 
sexual partners (Marks et al., 1991) although the direction of a potential causal relationship is 
unknown.  Perceived partner serostatus may influence these patterns.  For example, 
unprotected sex may be more likely in seroconcordant couples who have disclosed (Marks et 
al., 1994). Marks and Crepaz found that while 40% of PLWHA did not inform all sexual 
partners of their status, they were more likely than disclosers to use condoms regularly 
(Marks & Crepaz, 2001).   
Just because individuals do disclose their status to sexual partners does not ensure 
that they will subsequently abstain from any unsafe sexual practices.  Disclosure does not 
necessarily indicate that sexual partners will use this information to protect themselves from 
infection (J.M. Serovich & K.E. Mosack, 2003).  Research supports this notion as several 
studies have found no association between disclosure and transmission risk behaviors (Hart, 
Wolitski, Purcell, Parsons, & Gomez, 2005; S. C. Kalichman et al., 2002; Marks & Crepaz, 
2001; Stein et al., 1998; Wolitski, Rietmeijer, Goldbaum, & Wilson, 1998).  In an effort to 
better characterize the relationship between disclosure and transmission risk behavior, Marks 
and Crepaz’s 2001 study found that HIV-positive men fell into one of four categories 
regarding the relationship between disclosure and sexual practices: 
1) 40% engaged in informed protection (safer sex with disclosure)  
2) 35% engaged in uninformed protection (safer sex without disclosure) 
3) 12% engaged in informed exposure (unsafe sex with disclosure)  
4) 13% engaged in uninformed exposure (unsafe sex without disclosure).    
Conversely, it should not be assumed that nondisclosure will automatically lead to 
unprotected sexual activity as some individuals may feel that safer sex obviates the need for 
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disclosure.  For example, HIV-positive individuals may consciously choose not to disclose as 
a way to protect their privacy and escape the possible negative consequences of disclosure, 
such as stigma.  Yet, these individuals will engage in protected sexual activity despite 
nondisclosure, perhaps as a result of personal responsibility to protect their partner (Seth C. 
Kalichman, 2005).  However, practicing safer sex without disclosure is not an ideal behavior, 
as safer sex may not be practiced on a consistent basis with these partners.   
Varied findings from the aforementioned studies suggest that future researchers 
should not assume that disclosure will lead to safer sex behaviors.  Methodological 
limitations in many of these studies, such as a failure to assess the specific timing of 
disclosure in relation to sexual activity, lack of assessment of the serostatus of partners, and 
inconsistency in definitions of safer sex, prohibit the ability to make definitive interpretations 
about the relationship between serostatus disclosure and safer sex.  In addition, the lack of a 
strong correlation in many studies between disclosure and safer sex may be due to the high 
frequency of uninformed protection (safer sex without disclosure) and informed exposure 
(unsafe sex with disclosure) likely to exist for many PLWHA.  In terms of uninformed 
exposure (unsafe sex without disclosure), instances of this behavior are relatively small.  
However, even a small number of such cases can contribute to new cases of HIV infection 
(Marks & Crepaz, 2001; Simoni & Pantalone, 2005). Table 7 describes studies that have 
assessed the relationship between serostatus disclosure and transmission risk behaviors.  
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Table 7: Studies Assessing Serostatus Disclosure and Transmission Risk Behaviors 
Citation Sample Description 
Disclosure to Sexual 
Partners 
Transmission Risk 
Behaviors 
Association between Disclosure  
and Transmission Risk Behavior 
Simon 
Rosser et al 
(2008) 
675 HIV+ 
men in 6 
cities 
Secondary partners: 
30% disclosed to none 
31% disclosed to some 
39% disclosed to all 
66% of those with 
serodiscordant partners 
had unprotected sex 
Those who disclosed to none of their partners had 
significantly greater odds of unprotected anal sex with a 
serodiscordant partner 
Duru et al 
(2006) 
875 HIV+ 
adults in HIV 
Cost and 
Services 
Utilization 
Study 
MSM: 40% disclosed to every 
partner 
MSW: 66% disclosed to every 
partner 
Women: 73% disclosed to every 
partner 
Not directly reported Knowledge of partner serostatus associated with sex without 
disclosure. 
 
Women less likely to have sex without disclosure than men 
Crepaz and 
Marks 
(2003) 
105 HIV+ 
male patients 
at clinic in 
LA 
53% disclosed to HIV-negative 
or HIV? partner 
28% engaged in 
unprotected anal or 
vaginal sex with at-risk 
partner 
Disclosure was not related to safer sex  
Ciccarone 
et al 
(2003) 
1,421 HIV+ 
adults in HIV 
Cost and 
Services 
Utilization 
Study 
Not reported Sex w/o disclosure: 
42% of MSM 
19% of MSW 
17% of women 
13% of serodiscordant partnerships involved unprotected 
anal or vaginal sex without disclosure 
Kalichman 
et al  
(2002) 
269 HIV+ 
men and 114 
HIV+ women 
in Milwaukee 
78% of those with a regular 
partner disclosed  
54% of those with non-regular 
partner disclosed 
71% of those who  had 
sex did so with 
serodiscordant partners 
% of protected sex with regular or non-regular serodiscordant 
partners (68-77%) was similar regardless of whether 
disclosure had occurred 
Marks and 
Crepaz 
(2001) 
206 HIV+ 
men at clinic 
in LA 
52% disclosed to HIV-negative 
or HIV? partner 
25% engaged in 
unprotected anal or 
vaginal intercourse 
Safe sex more prevalent among disclosers (78%) than non-
disclosers (73%) 
Sturdevant 
et al  
(2001) 
153 HIV+ 
and HIV- 
adolescent 
girls 
Among HIV+ girls, disclosure 
related to perception partner was 
HIV+ 
59% of HIV+ youth 
reported unprotected 
sex in past 3 mos. 
Among HIV+ girls, without disclosure (vs. with disclosure) 
less condom use was reported 
Kalichman 
and 
Nachimson 
(1999) 
266 HIV+ 
adults from 
clinics near 
Atlanta 
59% had disclosed to at least 1 
partner in the last 6 mos. 
78% of men and 79% of women 
had disclosed to last partner 
Not directly reported Among men, disclosers reported higher rates of condom use 
(especially during anal sex) than non-disclosers 
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Niccolai et 
al  
(1999) 
147 HIV+ 
adults at 
clinic in New 
Orleans 
76% disclosed (passively or 
actively) to last partner 
76% reported 
consistent condom use, 
85% reported condom 
use at last sexual 
intercourse 
Those with consistent condom use were 2.7 times more likely 
to disclose than those with inconsistent condom use.   
Stein et al 
(1998) 
203 HIV+ 
adults in 
Boston and 
Providence 
60% disclosed to all partners 43% reported 
consistent condom use 
Consistent disclosers, inconsistent disclosers, and non-
disclosers reported similar condom use rates.  
De Rosa 
and Marks 
(1998) 
255 HIV+ 
men at 2 
clinics in LA 
93% disclosed to HIV+ partners 
57%  disclosed to HIV- partners 
23% disclosed to HIV? partners 
26% of informed 
partners and 16% of 
uninformed partners 
had protected sex  
Among HIV- partners, exclusively protected sexual activity 
occurred with a significantly greater percentage of informed 
than uninformed partners 
Wolitski    
et al  
(1998) 
701 MSM in 
4 cities  
89% disclosed to primary 
partner 
34% disclosed to non-primary 
partner 
16% reported 
inconsistent condom 
use with an uninformed 
non-primary partner 
With primary partners, HIV+ disclosers and non-disclosers 
did not differ in sexual practices or condom use.  With non-
primary partners, disclosers more likely than non-disclosers 
to report consistent condom use for insertive anal sex 
Sobel et al 
(1996) 
200 HIV+ 
adults in NY 
77% disclosed 41% reported 
inconsistent or no 
condom use 
No difference in proportion of consistent condom users vs. 
inconsistent/non-users who disclosed 
Geary et al 
(1996) 
167 HIV+ 
males with 
hemophilia 
42% disclosed to most recent 
partner 
64% of disclosers and 
66% of non-disclosers 
reported consistent 
condom use  
No significant association between disclosure and condom 
use 
Marks et al 
(1994) 
609 HIV+ 
men at 2 
outpatient 
clinics in LA 
86% disclosed to HIV+ partners 
46% to HIV- partners 
18% to HIV? partners 
9% engaged in 
unprotected insertive 
sex in past 2 mos. 
HIV+ respondents had unprotected insertive anal sex with 
18% of HIV- partners who were informed and with 23% of 
HIV- partners who were not informed 
Marks, 
Richardson, 
and 
Maldonado 
(1991) 
138 HIV+ 
men at clinic 
in LA 
48% of sexually active men 
disclosed to all partners, 
disclosure more common to 
HIV+ than HIV- partners 
17% engaged in 
unprotected insertive 
anal sex with HIV- 
partners without 
disclosure 
Disclosure to HIV+ partners occurred with unprotected 
contact, whereas disclosure to HIV- partners occurred with 
protected contact 
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2.9.1 Partner Characteristics  
Partner characteristics, such as type of relationship (main/regular versus casual/non-
regular) and serostatus of the partner (positive, negative or unknown) may also play a role in 
the relationship between serostatus disclosure and sexual transmission risk behaviors.  
Studies have found that HIV-positive persons are more likely to engage in unprotected sex 
with main versus casual partners and with HIV-positive partners versus uninfected partners 
(N. Crepaz & Marks, 2002; S.C Kalichman, 2000; S. C. Kalichman et al., 2002; Lightfoot, 
Song, Rotheram-Borus, & Newman, 2005).  In addition, serostatus disclosure has been found 
to be associated with partner serostatus and relationship type.  One study found that 
disclosure was more likely to occur to sex partners who were HIV-positive (90%) than to 
those partners who were HIV-negative (50%) or to those whose HIV serostatus was 
unknown (25%) (DeRosa & Marks, 1998).   In a 16-study review, HIV-positive men were 
more likely to disclose to main sex partners than casual or non-steady partners (Sullivan, 
2005).  However, other studies have not found an association between type of relationship 
and serostatus of the partner with transmission risk behaviors (Milam et al, 2006).  
Unfortunately, many of these studies were conducted only with MSM, often in large, urban 
areas of the United States.  Future research is needed to better understand the relationship 
between serostatus disclosure and transmission risk behaviors among heterosexual men and 
women.   
 
2.10 SUMMARY 
The methodological shortcomings of many previous studies on predictors of 
serostatus disclosure and on the relationship between disclosure and transmission risk 
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behavior suggest that further investigation is warranted.  In addition, few studies have 
examined thoroughly the study aims with a heterogeneous population of PLWHA in the 
Southeast.  More research also is needed on the extent to which transmission risk beliefs, 
stigma experienced by PLWHA, and subjective norms are correlated with serostatus 
disclosure.  Furthermore, additional study on the role of partner characteristics as moderators 
of the relationship between disclosure and transmission risk behavior is necessary to better 
develop and implement prevention programming for PLWHA.  To address these issues, the 
study presented here will investigate these areas of interest with a sample of HIV-positive 
patients at three clinics in North Carolina.   
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CHAPTER THREE: RESEARCH QUESTIONS, 
HYPOTHESES, AND CONCEPTUAL MODEL 
 
 
Based on the review of the literature in Chapter Two, theoretical perspectives and 
empirical findings from the HIV prevention field inform the conceptual model for the 
proposed study.  In this chapter, I present my specific aims and their associated research 
questions and hypotheses.  I also present my conceptual model and illustrate the relationships 
between study variables of interest as set out in the research questions and hypotheses. 
 
3.1 RESEARCH QUESTIONS AND HYPOTHESES 
The broad goal of the proposed dissertation research is to assess the factors that are 
associated with HIV serostatus disclosure to sexual partners and HIV transmission risk 
behaviors among participants in a randomized controlled trial of patients attending three HIV 
clinics in North Carolina.  The first aim is analytical and includes hypotheses about the extent 
to which predictor variables are associated with the dependent variable (serostatus 
disclosure), controlling for socio-demographic and HIV-related factors. The second aim is 
analytical and includes hypotheses about the potential moderating variables that may 
influence the relationship between serostatus disclosure and HIV transmission risk behaviors. 
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3.1.1  Aim 1 
To describe and examine the correlates of serostatus disclosure to sexual partners among 
HIV-positive patients in care at three clinics in North Carolina  
 
RQ 1.1. What is the prevalence of serostatus disclosure to sexual partners among HIV-
positive patients?  Does it vary by risk group, indicating participant gender-partner gender 
combination?  
 
RQ 1.2. To what extent is serostatus disclosure associated with 1) partner relationship type 
(main versus casual partner) and 2) partner serostatus type (HIV-positive, HIV-negative, 
unknown serostatus)?  
H 1.2.1: HIV-positive persons are more likely to disclose their serostatus to other 
HIV-positive persons than to HIV-negative or unknown serostatus persons. 
H 1.2.2: HIV-positive persons are more likely to disclose their serostatus to main 
partners than casual partners. 
 
RQ 1.3. What is the prevalence of disclosure stigma (defined as the experiences of or 
perceived consequences of other people knowing one’s HIV status) among HIV-positive 
patients?  Does it vary by risk group? 
 
RQ 1.4. To what extent is serostatus disclosure associated with disclosure stigma among 
HIV-positive patients? 
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 H 1.4.1: Disclosure stigma is negatively associated with serostatus disclosure such 
that people with high levels of disclosure stigma are less likely to disclose than those 
with low levels of disclosure stigma. 
 
RQ 1.5. To what extent do the following three factors predict serostatus disclosure by HIV-
positive patients: 1) beliefs in the seriousness of transmission risk in the presence of highly 
active antiretroviral therapy (HAART) medications; 2) transmission risk perception based on 
viral load; and 3) viral load detectability? 
H 1.5.1: HIV-positive patients who believe the risk of transmitting the virus is less 
serious with the availability of new anti-HIV medications are less likely to disclose 
than those who believe that the risk of transmitting the virus is more serious.  
H 1.5.2: HIV-positive patients who believe transmission risk is low given an 
undetectable viral load are less likely to disclose than those who believe that 
transmission risk is less serious. 
H 1.5.3: HIV-positive patients who report undetectable viral load test results are less 
likely to disclose than those who report detectable viral load test results. 
 
RQ 1.6. To what extent do subjective norms predict serostatus disclosure by HIV-positive 
patients? 
H 1.6.1:  HIV-positive patients who agree that that their friends, family members, and 
sexual partners think that HIV-positive individuals should disclose to sexual partners 
are more likely to disclose than those who disagree.   
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RQ 1.7. To what extent is serostatus disclosure associated with urbanicity among HIV-
positive patients? 
 H 1.7.1: Urbanicity is positively associated with serostatus disclosure such that 
people who reside in more urban areas are more likely to disclose than those who 
reside in less urban areas.  
 
RQ 1.8. What combination of the above factors best explain the variability in HIV-positive 
patients’ serostatus disclosure to sexual partners? 
 
3.1.2 Aim 2 
To assess the role of moderating variables in the relationship between disclosure and sexual 
risk transmission behaviors among HIV-positive patients in care at three clinics in North 
Carolina  
 
RQ 2.1. What proportion of participants report transmission risk behaviors? (defined as 
unprotected acts of vaginal or anal sex with an at-risk partner, meaning HIV-negative or 
unknown serostatus partner) 
 
RQ 2.2. What is the association between serostatus disclosure and sexual risk transmission 
behaviors? 
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RQ 2.3. Does the relationship between disclosure and sexual risk transmission behaviors 
differ by partner characteristics that belong to (1) relationship type and (2) partner serostatus 
type?  
H 2.3.1:  The association between serostatus disclosure and safer sex behaviors is 
moderated by relationship type, such that persons who disclose to main partners are less 
likely to practice safer sex behaviors than persons who disclose to casual partners. 
H 2.3.2:  The association between serostatus disclosure and safer sex behaviors is 
moderated by partner serostatus type, such that persons who withhold disclosure to HIV-
negative partners are more likely to practice safer sex behaviors than persons who 
withhold disclosure to unknown serostatus partners.  
 
 
3.2 CONCEPTUAL MODEL 
 
3.2.1 Model Description 
The conceptual model (Figure 1) illustrates the relationships among predictor and 
outcome variables as described in my aims and research questions.  Disclosure stigma, 
transmission risk beliefs, subjective norms, urbanicity, and partner characteristics are 
hypothesized to independently predict serostatus disclosure to sexual partners.  The proposed 
conceptual model hypothesizes that the relationship between serostatus disclosure and 
transmission risk behavior is moderated by partner characteristics (relationship type and 
serostatus type).  Note that boxes shaded in blue represent Aim #1, the box in pink represents 
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partner characteristic variables in Aims #1 and #2, the box in yellow represents Aims #1 and 
#2, and the box in green represents Aim #2. 
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Figure 1: Conceptual Model 
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CHAPTER FOUR: METHODS 
 
The proposed research is a secondary analysis of data from a three-clinic study of 
HIV-positive patients in North Carolina on which I served as a research assistant beginning 
in August 2005.  In this chapter, I describe the: (1) data source, including a description of the 
SAFETALK study sites, (2) study sample, including eligibility criteria, recruitment, and 
enrollment procedures of the SAFETALK study, (3) construction and operationalization of 
study variables; and (4) analytic strategies by study aim.   
 
 
4.1 DATA SOURCE 
The data for the proposed study has been collected from baseline data for the 
SAFETALK study.  SAFETALK is a two-armed, randomized controlled trial of a 
motivational interviewing-based safer sex intervention among 490 HIV-positive patients at 
three clinics in North Carolina.  Data collection began in July 2006 at one site, September 
2006 at the second site, and March 2008 at the third site.   
The enrollment target of 490 participants was reached in July 2008.  Participants who 
were randomized to the motivational interviewing arm of the study were scheduled to receive 
four counseling sessions approximately one month apart with a clinic-based SAFETALK 
counselor.   Each session had a corresponding CD and booklet to help participants prepare
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for their counseling appointments.  Participants randomized to the control arm of the study 
received four heart healthy counseling sessions approximately one month apart with a 
counselor in the clinic.  They also received written materials and four corresponding CDs 
that included information about healthy eating habits, recipes, and other nutritional 
information.     
The primary data source for the proposed study is audio computer-assisted self-
interviews (ACASI).  At the baseline study visit, participants completed a 45-60 minute 
ACASI-administered survey with follow-up surveys at approximately 4, 8, and 12 months 
after baseline.    
While a longitudinal analysis is possible for the proposed study, I chose to conduct a 
cross-sectional design for several reasons.  First, the structure of the ACASI instrument did 
not allow me to assess if the serostatus disclosure and transmission risk behavior patterns 
over time represent behavior that occurs with the same sexual partners at each time point.  
Thus, it was possible that a participant can report a particular number of disclosed and 
undisclosed partners at baseline and a different number on subsequent data collection time 
points.  Given the nature of the ACASI questions, it was impossible to determine if the 
sexual partner(s) reported across surveys are all the same, all different, or a mix of both.  For 
example, if a participant reported no sex with undisclosed partners at baseline and then 
reported some unprotected sexual activity with undisclosed partners at follow-up 1, this 
would represent movement in the “wrong” direction regardless of the newness of the partner, 
since unprotected sexual activity is occurring at follow-up where it was not occurring at 
baseline.   Another possible scenario is a participant could report no sex with an undisclosed 
partner at baseline, with whom they have ended that relationship by follow-up 1.  Then at 
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follow-up 1, they reported a new disclosed partner with whom they are having protected 
sexual activity.  This would represent movement in the “right” direction.  However, the 
ACASI data collected in the SAFETALK study did not allow me to determine whether 
people disclosed to after baseline assessment are partners that participants hadn’t disclosed to 
at baseline.  Nor was I able to assess if partners with whom protected sex is reported at 
follow-up are the same partners with whom unprotected sex was reported at baseline.  The 
same problem occurs when assessing partner type (main versus casual).  Even participants 
who report one main partner at baseline, 4 months, and 8 months may have three completely 
different partners at each time, which we have no way of assessing with the SAFETALK 
dataset. 
 
4.1.1 Description of Study Sites 
The research occurred at three HIV clinics in North Carolina that collectively see 
more than 2,400 HIV-infected patients annually.  The first site is the University of North 
Carolina at Chapel Hill Infectious Diseases Clinic located in UNC Hospitals.  There are 27 
medical providers at the clinic, including 14 attending physicians, 9 fellow trainees, two 
nurse practitioners, and two physician’s assistants.  At the time of data collection the clinic 
had over 1,600 active patients and saw approximately 420 patients per month, 400 of whom 
are continuing patients and 20 of whom are new patients.  The demographics of the clinic are 
as follows: 62% African American, 4% Hispanic, 2% Native American, and 33% female.  
The median age is 38 years.  Most are low-income (65% earn less than $10,000/year) 
individuals.  Approximately 60% contracted HIV through heterosexual contact (75% of 
women and 45% of men) and 21% through MSM sexual activity.  Nearly 70% have active 
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substance abuse or mental illness, however, intravenous drug use is rare.  In an ongoing 
prospective chart audit by the ID clinic, 75% of patients are receiving antiretroviral therapy 
(ART) and of those, 52% are viremic.    
The second site is the Wake County HIV Clinic located in the County Health 
Department in Raleigh, North Carolina.  The clinic has 9 medical providers, including 5 
physicians, 3 nurse practitioners, and one physician’s assistant.  It serves more than 600 
patients and 200 additional HIV clients through its affiliated “Under One Roof” case 
management agency.  Similar to the patient demographics at UNC, approximately 71% of 
Wake County HIV clinic patients are African American, 36% are female, 23% are MSM, and 
1% bisexual.  Nearly 75% of patients are sexually active and 50% are viremic.  Nearly all 
(92%) are on ART.   Statistics are not available for income level, substance abuse, mental 
illness among this clinic population. 
The third site is Lincoln Community Health Center Early Intervention Clinic located 
in Durham, North Carolina. The clinic has 5 medical providers, including four physicians and 
one nurse practitioner.  The clinic served more than 330 patients in 2008.  Each month, 
approximately 215 of patients are seen for continuing care and 4-6 individuals are new 
patients to the clinic.  More than 87% of the clinic patients are African American, and 46% 
are between the ages of 25-44 years.  More than three-quarters (83.6%) of patients are equal 
to or below the federal poverty level.  Approximately 51% contracted HIV through 
heterosexual contact, 30% through MSM sexual activity, and 14% through intravenous drug 
use.  Statistics are not available for patients who have active substance abuse, mental illness, 
or are receiving ART. 
 
 54
4.2 STUDY SAMPLE 
4.2.1 Sample Selection 
Figure 2 below illustrates the sample selection process for SAFETALK participants.  
Enrollment began in July 2006 at the first site, September 2006 at the second site, and March 
2008 at the third site. 
 
Figure 2: Sample Selection 
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4.2.2 Study Eligibility Criteria 
Participants are eligible for the SAFETALK study if they are: 
a) HIV infected; 
b) 18 years of age and over; 
c) English-speaking; 
d) Have given prior consent to the clinic screener to be contacted regarding participation 
in research studies (only at UNC). 
 
Exclusion criteria for participants are designed to eliminate individuals who are unable to 
participate in the study.  A potential participant is excluded if he/she: 
a) Has cognitive inability to provide consent; 
b) Is too sick to travel to make frequent clinic visits; 
c) Is currently participating in the STAR study (prevention with positives program at 
UNC ID clinic where HIV-positive patients enrolled in the program can be 
randomized to the motivational interviewing experimental arm); 
d) Has received motivational interviewing counseling in the past 6 months as part of the 
STAR study; 
e) Is coming to the clinic for his/her first visit; 
f) Is intending to leave the clinic within the next 12 months;  
g) Is a female patient at the Lincoln Community Health Center site (See 4.2.3 
Recruitment and Enrollment). 
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For my study, a potential participant is also excluded if he/she: 
a) Is a female who reports sexual activity with a female (WSW); 
b) Is transgender; 
c) Is not sexually active in the previous three months. 
  
4.2.3 Recruitment and Enrollment 
Participant recruitment strategies differed somewhat at each of the three clinic sites 
due to differences in clinic infrastructure.  At UNC, patients were screened for eligibility in 
two steps.  First, a clinic screener identified potentially eligible participants who met the 
following criteria: 1) HIV infected, 2) not first visit to clinic, 3) have provided consent to be 
contacted for studies, 4) English speaking, and 5) age 18 or older by chart review of 
scheduled patients.  While the prescreened patients identified as potentially eligible for the 
study are at the UNC ID clinic for an appointment (either before or after the provider visit), a 
research assistant approached them to assess their interest in hearing about the study using a 
standardized recruitment script (See Appendix 1).  Patients who did not have time to 
participate that day were approached at a later date if they give permission for the study team 
to re-approach them.  
At the Wake County HIV clinic, where no clinic screener or prior consent to 
approach patients for research are available, medical providers and nurses gave patients who 
were potentially eligible for the study an informational study flier with a space to indicate 
interest in the study.  Patients who completed the form either spoke to study staff that day or 
were contacted by phone to schedule an appointment to learn more about the study.  
 57
At the Lincoln Community Health Center Early Intervention Clinic, general study 
fliers were available on the front desk of the clinic.  In addition, providers were asked to give 
fliers to every male patient on the two days a week that study staff members were available at 
the clinic. Substance abuse counselors and social workers also had fliers in their offices and 
occasionally referred interested patients.  Female patients were not approached regarding the 
SAFETALK study as there is another study specifically for HIV-positive women at this 
clinic.   
For those patients interested in learning more about the study, the research assistant 
explained the study in detail to potential participants.  For those participants who expressed 
interest, the research assistant assessed their eligibility in a private room. The research 
assistant asked the additional exclusion criteria questions described above and administering 
a brief screener to verify patient sexual activity (oral, vaginal, or anal sex) in the past 12 
months.  For patients who were eligible and interested, the RA further informed them of the 
study and obtained their consent after assessing their understanding of the study procedures.  
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4.3 MEASURES 
In an iterative process, we developed the ACASI instrument by adapting previously 
validated measures for most constructs. For those constructs where no acceptable validated 
measures were available, we developed and refined new items. We then conducted cognitive 
interviews of the instrument to assess its understandability and meaning for participants.   
 
4.3.1 Description of the Study Instrument 
The ACASI instrument is divided into 12 sub-sections (see Appendix 1): 
 
1. HIV History and Current Medical Status 
2. Beliefs and Attitudes toward Safer Sex and Nutrition 
3. Motivations and Intentions to Avoid Unsafe Sex 
4. Stress and Coping 
5. HIV Stigma 
6. Discrimination 
7. Sexual Behavior Self-Efficacy 
8. Sexual Risk Assessment 
9. Health Habits involving Substance Use and Physical Activity 
10. Emotional Well-Being 
11. Subjective Norms 
12. Demographics 
 
4.3.2 Pre-testing of ACASI instrument: Cognitive Interviews 
 Five HIV-positive participants who had previously given permission to be contacted 
for future studies were recruited from the UNC ID clinic in March 2006 to complete 
cognitive interviews of the ACASI instrument.  These interviews were conducted to assess 
potential participants’ comprehension of the survey instrument items and comprehension of 
the response options.  I conducted four of the interviews and one was completed by the 
study’s project manager.  The cognitive interviews were completed with two women and 
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three men.  Two were African American and three were White, non-Hispanic.  Their ages 
ranged from 34-49 (mean age 42.4 years). 
Individuals were asked to complete the baseline questionnaire with a SAFETALK 
research assistant using the “think aloud” technique.  This process involves the research 
assistant reading each question aloud from the questionnaire and asking participants to think 
aloud and verbalize the considerations that come to mind for them as they formulate their 
responses.  This procedure is designed to assess the cognitive processes that happen as 
respondents answer items, and is a means to obtain insight into the way each survey item is 
comprehended by the respondent and the strategies they use to come up with responses 
(Visser, Krosnick, & Lavrakas, 2000).  The research assistant also asks the participant 
specific questions about the items to elicit feedback about their wording and content.  
Answers to these questions assist in understanding whether the items were clear and elicit 
respondents’ interpretations of what an item was designed to assess.  All five participants 
agreed to have their session audiotaped.  Two participants completed the entire survey and 
were compensated $45.  Three participants were asked to complete a sub-section of the 
questionnaire and received $20.   
The results of the cognitive interviews were used to refine the survey instrument.   
Changes to the instrument included a clarification of time frames for several items and listing 
the most socially desirable response last in the list of response options.  We also added 
“Refuse to Answer” and “Not applicable” as response options for certain items, where 
appropriate.  For transition from one survey instrument section to the next, we re-worded the 
lead-in sentences to allow for a stronger transition and to better introduce the types of 
questions to expect in the proceeding section.  Based on the results of the cognitive 
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interviews, we also underlined key phrases for emphasis and clarity.  To reduce participant 
burden, we eliminated some items, specifically regarding HIV stigma.   
 
 
4.3.3 Independent Variables of Interest 
Participant-Level Variables 
Disclosure Stigma (Questionnaire page 20-22) 
Disclosure stigma is measured with a multi-item scale originally developed and 
validated by Berger, Ferrans, and Lashley (2001).  There are seven items in our abbreviated 
subscale that measure disclosure stigma from the original 12 items.  These items measure 
disclosure stigma relating to keeping one’s status a secret or worrying that others who knew 
one’s HIV status would tell others, where disclosure stigma is defined as the experiences of 
or perceived consequences of other people knowing one’s HIV status.  I chose to use an 
abbreviated sub-scale consisting of the top seven items which had factor loadings between 
.65 and .73.  We also modified the wording of the original four-point response options from 
strongly disagree, disagree, agree, and strongly agree to 1 = agree a lot, 2 = agree a little, 3 = 
disagree a lot, and 4 = disagree a little.  Scores ranged from 7 to 28 with higher values 
indicating higher disclosure stigma. 
 
Subjective Norms about Disclosure (Questionnaire page 52-53) 
I measured subjective norms regarding serostatus disclosure using an item that asked 
three times, one for each of three different referent groups (friends, close family members, 
and sex partners), “How much do you agree or disagree that: Most of your [reference group] 
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think that people living with HIV should always tell their sex partner their HIV status before 
having vaginal or anal sex with them.”  Responses were scored on a four-point scale as 2 = 
agree a lot, 1 = agree a little, -1 = disagree a little, and -2 = disagree a lot.  I then summed the 
three subjective norm scores and multiplied it by the respondent’s answer to an item which 
asks, In general, how important or unimportant is it to you what other people think you 
should do?  These responses are 1 = not at all important, 2 = somewhat important, 3 = very 
important, and 4 = extremely important.   
 
Transmission Risk Beliefs (Questionnaire page 5-6) 
I assessed transmission risk beliefs using two items.  The first asked participants, on a 
5-point scale, to rate their perception of the seriousness of HIV transmission risk given the 
availability of new HIV medications.  Responses were coded on a five-point scale with 1= 
much less serious than it used to be, 2 = a little less serious than it used to be, 3 = about as 
serious as it used to be, 4 = a little more serious than it used to be, and 5 = much more serious 
than it used to be.  The second item asked about the chances of HIV transmission given the 
respondent’s current viral load.  Responses were scored on a four-point scale, 1= high, 2 = 
medium, 3 = low, and 4 =no chance. 
 
Urbanicity (Not assessed directly in Questionnaire) 
 I assessed level of urbanicity using rural urban community area (RUCA) codes.  
These codes classify U.S. census tracts using measures of population density, urbanization, 
and daily commuting.  Based on the size and direction of the primary (largest) commuting 
flows, the 33 codes are categorized on a scale from 1-10 where smaller numbers delineate 
metropolitan and micropolitan areas and larger numbers indicate small town and rural areas.   
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The RUCA codes are intended to be aggregated for use.  I obtained a list of participants’ zip 
codes (without the release of any personal identifying information) from the SAFETALK 
project manager and linked them to RUCA codes to determine level of urbanicity for each 
study participant.  Due to low frequencies in several RUCA codes, I chose to aggregate them 
into two groups: rural and urban with a dichotomous variable where 0 == rural and 1 = 
urban.  
 
 
Viral Load Detectability (Questionnaire page 3) 
 I assessed viral load detectability using one ACASI item which asks of those 
participants who reported having a viral load test in the past six months, “At that time, were 
you undetectable?”  Responses were coded on a three=point scale where 0 = undetectable, 1 
= unaware, and 2 = detectable.  Participants were classified as unaware of their viral load 
detectability if a) they did not report having a viral load test in the past six months, b) they 
don’t know if they had a viral load test in the past six months, and c) they had a viral load test 
in the last six months but they don’t know the test result.  
 
Partner-Level Variables 
Partner Relationship Type  
Partner relationship type was determined in two manners based on the number of 
reported sexual partners.  First, participants who reported only one sexual partner were 
asked, “Were you in a primary relationship with this sex partner?  By primary we mean 
someone you have lived with or seen a lot, and to whom you have felt a special emotional 
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commitment.”  Responses of “yes” (1) were categorized as a main partner and responses of 
“no” (0) were categories as a casual partner.   
Second, participants who reported more than one sexual partner were asked, “Were 
you in a primary relationship with at least one female sex partner during the last 3 months? 
This would be someone you have lived with or seen a lot, and to whom you have felt a 
special emotional commitment.”  Those who answered yes were then asked, “How many 
primary partners have you had in the last 3 months?”  Those who answered “1” were 
categorized as having one main partner (1).  Those who answered “more than one” were 
asked a subsequent question, “How many primary partners have you had in the last 3 
months?” and were able to write in a response.   
I created a thee-category variable for partner relationship type to collapse all 
participants regardless of number of partners where 0 indicates casual partners only, 1 
indicates a mixture of both casual and primary partners, and 2 indicates primary partners 
only.   The primary partner category serves as the reference group. 
 
Partner Serostatus Type   
Partner serostatus type was determined in two manners based on the number of 
reported sexual partners.  First, participants who reported only one sexual partner were asked, 
“What was this partner's HIV status?” with response options of 0 = positive, 1 = negative, 
and 88 = not sure.  Second, participants who reported more than one sexual partner were 
asked how many partners they had in the past three months. They were then asked about the 
HIV statuses of these partners with three subsequent questions:  1)“How many of your 
[Response to M1a=total number of partners] sex partners were HIV-positive?”  2) “How 
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many of your [Response to M1a=total number of partners] sex partners were HIV-
negative?” and 3)“How many of your [Response to M1a=total number of partners] sex 
partners were you unsure of?”3    
I first created a categorical variable for partner status type to collapse all participants 
regardless of number of partners to compare: 1) HIV-positive partners relative to HIV-
negative and unknown status partners, 2) HIV-negative partners relative to unknown status 
partners and HIV-positive partners, and 3) unknown status partners relative to HIV-positive 
partners and HIV-negative partners.  I then created a four-category variable for partner status 
type to collapse all participants regardless of number of partners where 0 indicates only 
negative partners, 1 indicates only unknown serostatus partners, 2 indicates a combination of 
negative, unknown, and positive partners, and 3 indicates only positive partners.  The HIV-
positive partner category serves as the reference group. 
 
4.3.4 Dependent Variables 
HIV Serostatus Disclosure (Questionnaire page 29-43)  
HIV serostatus disclosure was assessed by the ACASI responses to questions 
regarding whether or not a study participant actively told any sexual partner(s) from the last 
three months that he/she is HIV-positive.  This variable was assessed by a multi-item index 
that measures the proportion of sexual partners to whom respondents have disclosed their 
HIV status.  All response formats were open-ended so study participants fill in a numerical 
value to avoid subtle influences that may result from a closed format.  Given the bimodal 
distribution of the data, I created a three-level variable indicating disclosure to none (0%), 
                                                 
3
 ACASI item M1a refers to MSW.  Items M15a refer to MSM, and W1a refers to WSM. 
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some (1-99%), or all (100%) sexual partners.  I counted an item as missing if the response for 
the number of partner(s) disclosed to was “don’t know” or “refused to answer.”   
I assessed serostatus disclosure based on a proportion whereby the numerator 
represented the number of partners disclosed to and the denominator represented the total 
number of partners.  For analysis, I defined this proportion categorically as disclosure to 
none, some, or all partners.   
I also categorized participants into risk groups based on their gender and the gender 
of their sexual partner(s) to create the following groups: MSW, MSM, and WSM.   Men were 
placed in the MSW category if they only had sexual contact with women in the last three 
months.  Men were placed in the MSM category if they only had sexual contact with men in 
the last three months.  When men indicated they had had sexual contact with both men and 
women in the previous three months (n=5), they were categorized as MSM and information 
about their female sexual contact, and subsequently dropped from the analysis.  All women 
were included in one group of women who have sex with men (WSM).   
Table 8 below presents a schematic of the proposed levels of disclosure of HIV status 
to sexual partners.  I looked at the aforementioned categories of partners disclosed to among 
MSW, MSM, and WSM.  This table illustrates all potential pairings of participant gender 
with sexual partner gender as well as the HIV serostatus of partners that were assessed.  
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Table 8: Disclosure by Gender of Participant, Gender of Sexual Partner, 
and Serostatus of Partner 
Gender of 
participant 
and sexual 
partner 
HIV Status of Sexual Partners 
Total HIV-positive HIV-negative HIV status 
unknown 
Men with 
women 
(MSW) 
HIV+ female 
partners disclosed to 
HIV- female 
partners disclosed to 
HIV? female 
partners disclosed to 
Total female 
partners 
disclosed to 
Men with men 
(MSM) 
HIV+ male partners 
disclosed to 
HIV- male partners 
disclosed to 
HIV? male partners 
disclosed to 
Total male 
partners 
disclosed to 
Women with 
men 
(WSM) 
HIV+ male partners 
disclosed to 
HIV- male partners 
disclosed to 
HIV? male partners 
disclosed to 
Total male 
partners 
disclosed to 
Total HIV+ sexual partners disclosed to 
HIV- sexual partners 
disclosed to 
HIV? sexual partners 
disclosed to 
Sexual partners 
disclosed to 
 
Transmission Risk Behaviors (Questionnaire page 28-46) 
Participants were asked about the frequency of their sexual behavior over the past 
three months, the frequency of condom use, and the serostatus of their partner(s).  All 
response options were open-ended, requiring numerical values for responses to be entered by 
the participant. 
I looked at reported vaginal and anal sexual activity in the past three months with 
different types of partners (main versus casual) and serostatus of an at-risk partner (HIV-
positive or HIV-negative/unknown serostatus.  We asked participants how many times they 
had vaginal and anal sex with their HIV-positive, HIV-negative, and unknown serostatus 
partners.  We then asked how many times a condom was used for these reported sex acts.  
For the MSM subgroup, we asked about frequency of insertive and receptive anal sex 
separately and frequency of condom use for each type of act separately.   
Transmission risk behavior was dichotomized into “protected” (100% condom use) 
and “unprotected” (condom use less than 100%) as only consistent condom use is associated 
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with reduced HIV transmission risk (Rotheram-Borus, Swendeman, & Chovnick, 2009; 
Weller & Davis, 2002).  HIV transmission risk behavior (TRB) is defined as any unprotected 
acts of vaginal and anal sex with HIV-negative or unknown serostatus partners.  Since the 
SAFETALK study did not assess partner-by-partner data for serostatus disclosure and sexual 
transmission risk behaviors, it is not possible to examine the relationship between serostatus 
disclosure and transmission risk behavior for those individuals who report more than one 
sexual partner in the previous three months.  As such, the sample for Aim 2 includes those 
participants who report one partner.   
 
4.3.5 Control Variables 
Potential control variables include the following variables obtained at baseline: 
gender, age, race/ethnicity, employment status, health insurance, relationship status, 
educational attainment, time between date of HIV diagnosis and date of baseline ACASI, 
alcohol use in the past three months, substance use (marijuana, crack, or cocaine) in the past 
three months, and previous enrollment in the STAR study.  Previous studies have found that 
these covariates, with the exception of STAR enrollment, are associated with both serostatus 
disclosure and transmission risk behavior among HIV-positive individuals.   Table 9 presents 
the control variables.  The full ACASI Instrument is presented in the Appendix 1. 
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Table 9: Control Variables 
Variable # of items Original ACASI Item Scale 
Recoded Variable in 
Analysis 
Gender 1 
BS8Q1 Are you: (select one) 
1 = Male 
2 = Female 
3 = Transgender (male to female) 
4 = Transgender (female to male) 
Nominal 
Recoded into two 
groups: 
0 = Male 
1 = Female 
 
Age 1 BS12Q1 How old are you?  ___ Continuous No change 
Race/Ethnicity 1 
BS12Q2 What is your primary race 
or ethnic identification?  
1 = Black/African American 
2 = Hispanic/Latino 
3 = White, not of Hispanic origin 
4 = Asian/Pacific Islander 
5 = American Indian/Alaska Native 
6 = Another race/ethnicity 
7 = Mixed race 
Nominal 
Collapsed into three 
groups: 
1 = Black 
2 = White 
3 = Other 
Employment 
status 2 
BS12Q3a At this time, are you: 
1 = Working full-time 
2= Working part-time 
3 = Not working 
Nominal 
Collapsed into two 
groups: 
0 = Unemployed 
1 = Employed 
Health insurance 1 
BS12Q4 What kind of health 
insurance do you have now?  
__ Medicaid 
__ Medicare 
__ Veteran’s Administration 
__ Private insurance or HMO 
__ None 
__ Other 
Nominal 
Collapsed into two 
groups: 
0 = No health insurance 
1 = Health insurance 
Relationship 
status 1 
BS12Q6 How would you describe 
your relationship status at this point 
in time? 
1 = Single, not living with a partner 
2 = Single, living with a partner 
3 = Married 
4 = Separated 
5 = Divorced 
6 = Widowed 
7 = Other: __________________ 
Nominal 
Collapsed into two 
groups: 
0 = single not living 
with a partner, 
separated, divorced, or 
widowed 
1 = married or single 
living with a partner 
Sexual identity 1 
BS12Q7 Do you now identify as: 
(Choose one) 
1 = Straight/heterosexual 
2 = Gay/Homosexual 
3 = Bisexual 
4 = Other 
5 = Not sure 
Nominal 
Collapsed into two 
groups: 
1 = Heterosexual 
0 = Homosexual, 
bisexual, other, not sure 
Educational 
attainment 1 
BS12Q8 What is the highest level of 
education you have completed? 
(Choose one) 
1 = No formal education 
2 = Did not graduate high school 
3 = High school graduate or GED 
Ordinal 
 
Collapsed into four 
groups: 
0 = No formal 
education or did not 
graduate from high 
school 
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4 = Some college/AA 
degree/technical school training 
5 = College graduate (BA/BS) 
6 = Some graduate school 
7 = Master’s degree 
8 = Doctorate/medical degree/law 
degree 
1 = High school 
graduate or GED 
2 = Some college/AA 
degree 
3 = College degree or 
more 
Time between 
HIV diagnosis 
and date of 
baseline ACASI 
1 
BS1Q2 What month and year did 
you first learn that you were HIV-
positive?  
 
__ __ / __ __ __ __ (mm / yyyy) 
Interval 
1 = < 1 year 
2 = 1-5 years 
3 = 5-10 years 
4 = 10-15 years 
5 = 15-20 years 
6 = >20 years 
Alcohol use 2 
BS9Q1 Pick the answer that best tells 
how often you drank alcohol in the 
last 3 months.  By alcohol, we mean 
wine, beer, or any kind of liquor.  In 
the last 3 months, did you drink 
alcohol:  
1 = Every day 
2 = 2 to 6 times a week 
3 = Once a week 
4 = 1 to 3 times a month 
5 = Less than once a month 
6 = Never 
Categorical 
Recoded into two 
groups: 
0 = No use 
1 = Any use 
Substance use 
 
1 
BS9Q4 Please check the box next to 
all those drugs that you sniffed, 
snorted, smoked, swallowed or 
injected in the last 3 months.  (Select 
all that apply) 
__ Marijuana 
__ Crack, freebase cocaine, or rock 
cocaine 
__ Powder cocaine  
 
*Note that these are the only drugs 
with greater than 5% use. 
Categorical No change   
Previous 
enrollment in the 
STAR study 
NA 
0 = not a STAR participant, or STAR 
participant but not randomized to MI 
arm, or STAR participant 
randomized to the MI arm but no MI 
sessions completed. 
1 = STAR participation in the MI 
arm and at least one MI session 
completed.  
Categorical See column to the left 
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4.4 DATA ANALYSIS 
4.4.1 Data Preparation 
Missing Data:  Every effort was made by the SAFETALK team to obtain complete data on 
all study participants.  For each variable of interest in the proposed study, missing values 
were identified and distributions and patterns of these missing values were evaluated 
carefully.  Participants who refused to answer questions regarding disclosure or sexual 
behavior or were otherwise missing information on whether or not they disclosed were 
classified as missing.  I chose not to employ any imputation methods for stand-alone items or 
items as part of scales that were missing.  Missing values were less than 5% for every 
variable of interest with the exception of one control variable (relationship status had 5.6% 
missing values).   
 
Data Editing and Cleaning: Study staff noticed several baseline ACASIs in which data 
appeared to have been entered incorrectly, possibly due to participants’ clicking the wrong 
button on the computer or clicking a button too many times.  These would include 
participants who reported an unusually large number of sexual partners (e.g., 333) in the past 
three months.  We received IRB approval to speak with these participants to double-check 
answers that appear to be erroneous.  When there were key-in errors identified, ACASI 
responses were corrected by re-asking the participant the relevant questions that were 
associated with the erroneous initial responses.  These updated responses were added to my 
revised dataset.   
 
 71
Data Screening: I conducted my data analyses using Stata 10.0.  To screen the data, I 
examined the dataset for reasonableness using univariate descriptive statistics to produce 
frequencies, distributions, measures of central tendency, and measures of dispersion for all 
variables of interest.  The existence of outliers was examined.  When such cases were found, 
separate analyses were performed including and excluding those outliers.  I also analyzed 
scales to assess their psychometric properties (DeVellis, 2003).  I assessed internal 
consistency estimates of reliability for scales (reporting Cronbach’s alpha) and item-by-tem 
analysis was conducted to consider any items that should be dropped from the scales.   
Overall scale scores were calculated by averaging item responses.  I chose to not impute any 
missing responses.  Scale items had, on average, fewer than 5% missing values.   
 
Assessing for Multicollinearity:  Multicollinearity occurs when independent variables are 
highly correlated with one other, making it difficult to assess the independent importance of 
an individual predictor variable as each accounts for similar variance in the dependent 
variable.  When two variables are highly correlated, they are basically measuring the same 
phenomenon.  When multicollinearity between variables is present, p-values can be 
misleading and the regression coefficients’ confidence intervals will be very wide.  This can 
lead to incorrect conclusions about the relationships between independent and dependent 
variables of interest.  Since my research questions seek to estimate the contributions of 
individual correlates of serostatus disclosure (see Aim 1 below), I assessed for 
multicollinearity by producing a Pearson correlation matrix in Stata to examine the bivariate 
correlations between my independent variables.  The analysis failed to detect a high level of 
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association among any of the predictor variables.  Therefore, no variables were deleted from 
the model as a result of high multicollinearity.   
Stata output also displays collinearity diagnostics, including tolerance and Variance 
Inflation Factor (VIF) values for each predictor variable.  Tolerance indicates the percent of 
variance in the predictor that cannot be accounted for by the other predictors.  As such, very 
small values indicate that a predictor is redundant, and values that are less than .10 merit 
further investigation. If the VIF calculated as 1 divided by tolerance, is greater than 10 there 
are cause for concerns about multicollinearity.  Based on these criteria, no variables 
demonstrated high correlation.  Thus, all were included in subsequent analyses. 
 
  
4.4.2 Analysis for Aim 1 
To describe and examine the correlates of serostatus disclosure to sexual partners among 
HIV-positive patients  
The dependent variable for Aim 1 was serostatus disclosure to sexual partners.  My 
conceptual model includes eight correlates listed below.  Note that the first two variables 
listed below relate to characteristics of the partner of the participant and the remaining six 
variables pertain to the participant case directly. 
1) Partner relationship type (main versus casual) 
2) Partner serostatus (HIV-positive, HIV-negative, unknown serostatus) 
3) Disclosure stigma 
4) Beliefs in the seriousness of transmission risk in the presence of HAART  
5) Beliefs in transmission risk based on viral load 
6) Subjective norms regarding serostatus disclosure 
7) Urbanicity 
8) Viral Load Detectability 
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To address Aim 1, I examined bivariate relationships between serostatus disclosure to 
sex partners as the dependent variable and each of the independent variables of interest.  
Those independent variables that were significantly associated with serostatus disclosure at 
an alpha of 0.20, the standard threshold for achieving a parsimonious model, were retained 
for the subsequent multivariate analysis.  I then entered all independent variables into a 
logistic regression model simultaneously based on my conceptual model.   
I used multinomial logistic regression to determine the independent associations 
between serostatus disclosure and the proposed independent variables and to determine the 
best combination of variables that predict serostatus disclosure.  I used a p-value of .05 as the 
criterion for statistical significance of factors in the final regression models.  In order to be 
able to compare each of the categories of disclosure (to none, some, or all partners) I ran two 
separate multinomial logistic regression models.  In the first model, disclosure to all partners 
was entered as the base category for a comparison with disclosure to no partners.  The second 
model was performed with disclosure to all partners serving as the base category for a 
comparison with disclosure to some partners.   Adjusted odds ratios and 95% confidence 
intervals are presented in the final model for the variables. 
Multinomial logistic regression is a commonly used technique for determining the 
probability of a dichotomous outcome variable, given a set of independent variables that may 
be continuous, discrete, dichotomous, or a mixture of types.  Logistic regression allows for 
flexibility compared to other techniques as the correlates do not have to be linearly related, 
normally distributed, or of equal variance in each group (Tabachnick & Fidell, 2001).   
Those participants who reported greater than 10 partners were excluded from my 
analysis as the validity of reports of more than 10 partners are low (Kissinger et al., 2003; 
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O'Brien et al., 2003).  Since results for those cases with multiple partners might be correlated, 
I also ran a sensitivity analysis including and excluding those with greater than 10 partners.  
Since the sensitivity analysis yielded the same conclusions as my original analysis, I only 
present results from the original analysis only reporting those with 10 or fewer partners.  
For the first two independent variables (partner relationship type and partner 
serostatus), I used multinomial logistic regression to examine HIV serostatus disclosure to 
sexual partners to determine partners to whom participants disclosed.  More specifically, I 
examined disclosure across two groups: a) participants who report one sex partner and thus 
only one opportunity to disclose, and b) participants who report more than one partner with 
more than one opportunity to disclose.  I then combined these two groups to examine overall 
disclosure across all study participants who report one or greater sexual partners.   I also ran 
separate analyses for MSW, MSM, and WSM.  These analyses demonstrate how partner 
relationship type and partner serostatus affect serostatus disclosure.  I conducted a correlated 
data analysis since results for participants with multiple partners are likely to be correlated. 
In order to assess the association between relationship type, partner serostatus type, 
serostatus disclosure, and disclosure stigma, several steps were taken to recode the data.  
First, I trichotomized the continuous relationship type variable that represents relationship 
type proportionally into three groups for participants who have: a) all primary partners, b) all 
casual partners, and c) mixed relationship type, which represents a combination of both 
primary and casual partners.  I also recoded partner serostatus type from a continuous 
variable that represents serostatus proportionally to a categorical variable with the following 
four groups among participants who report sexual partner(s) who are: a) all HIV-positive 
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partners, b) all HIV-negative partners, c) all unknown serostatus partners, and 4) mixed 
serostatus partners.    
 
4.4.3 Analysis for Aim 2 
To assess the role of moderating variables in the relationship between serostatus disclosure 
and sexual transmission risk behaviors 
I first used a contingency table analysis first to determine the rate of transmission risk 
behaviors.  In each of the four cells in table 10 below, I will examine how many times 
vaginal and anal sex occurred in the past three months with HIV-negative partners and 
unknown serostatus partners.  I also examined the number of times these sexual acts were 
protected with condoms.  This allowed me to determine if the rate of unprotected sexual 
activity is the same across partner relationship type and partner serostatus.  I conducted a 
similar analysis in each of the four cells in table 11 below for primary partners and casual 
partners.   
Table 10: Contingency Table for WSM to Examine Rate of TRB by Partner Serostatus 
TRB Partner serostatus HIV-negative HIV status unknown 
Yes   
No   
 
Table 11: Contingency Table for WSM to Examine Rate of TRB by Relationship Type 
TRB Relationship Type Primary Casual 
Yes   
No   
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I examined transmission risk behavior using logistic regression with the two 
categories listed below.  
a) Sexually active and 100% protected sexual activity 
b) Sexually active and less than 100% protected sexual activity  
 
 
I used logistic regression to examine the moderator effects in my conceptual model 
since my independent (serostatus disclosure) and moderator (partner relationship type and 
partner serostatus) variables were categorical.  When the strength of the relationship between 
two variables is dependent on a third variable, moderation is occurring.  The third variable, or 
moderator (W), interacts with X in predicting Y if the regression weight of Y on X varies as 
a function of W.  The relationship between the independent variable (serostatus disclosure) 
and outcome variable (transmission risk behavior) will be explored for each of the levels of 
each moderator variable.  The moderating variable of relationship type was categorized into 
two levels: a) all primary partners and b) all casual partners. The moderating variable of 
partner serostatus was categorized into two levels: a) all HIV-negative partners and b) all 
unknown partners.  When there is evidence of a qualitative (different direction of the effect) 
or quantitative (different strength of association) difference, I assessed the effect of the 
moderation (Frazier, Tix, & Barron, 2004).  The analysis involved the following three steps: 
1. I recoded variables so that categorical variables had dummy codes. 
2. I created an interaction term that was the product of the predictor and moderator 
variables. 
3. I ran stepwise logistic regression by entering the predictor variable, the moderator 
variables, and finally the interaction terms. 
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4.4 Power calculation 
An accepted guideline for estimating the sample size needed to have significant 
power to detect differences in multivariate logistic regression is to have approximately 20 
cases for each independent variable in the regression model (Kleinbaum, Kupper et al. 1982).  
In my dissertation, I have eight independent variables of interest. 
In logistic regression, effect sizes are stated in terms of the probability at the mean of 
the predictor variable and the probability at the mean plus one standard deviation.  Using 
PASS, a statistical and power analysis software program, I set alpha at 0.05 and my sample 
size at 490 (the pre-set participant enrollment number in the SAFETALK study).  P0 is the 
response probability at the mean of X and P1 is the response probability when X is increased 
to one standard deviation above the mean. With six independent variables, 490 cases provide 
adequate power for logistic regression (Hsieh, Bloch, & Larsen, 1998).  Table 11 below 
illustrates the calculations with 490 as my sample size with power set at .8 and power set at 
0.9. 
Table 12: Power Calculation 
Power N P0 P1 OR Squared Alpha Beta 
0.9 490 0.7 0.774 1.465 0.3 0.05 0.1 
0.8 490 0.7 0.764 1.391 0.3 0.05 0.2 
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CHAPTER FIVE: RESULTS 
 
 
In this chapter, I present the results of my dissertation research. First, I present sample 
characteristics, including frequencies of demographic characteristics and variables of interest. 
Next, I present the results of the analysis of each research question stated in Chapter Three. 
 
5.1 RESULTS FOR AIM 1 
5.1.1 Sample for Aim 1 
Baseline demographic and HIV clinical characteristics of the sample used for Aim 1 
are presented in Table 13. The sample was composed of SAFETALK participants who 
completed baseline ACASIs between June 2006 and May 2008 and met my study inclusion 
criteria (n=3694). More than half the study sample was enrolled at the UNC site (61.3%).  
Nearly two-thirds of the sample was male and the average age was 42.1 years (range = 18 to 
67).  More than half reported an annual income of $10,000 or less.  Approximately half 
reported being single and not living with a partner.  More than two-thirds of the sample was 
African American and the majority was not working.  In terms of HIV clinical 
characteristics, approximately half of the sample reported an undetectable viral load in the 
                                                 
4
 My sample excludes transgendered participants (n=4), sexually abstinent participants (n=109), and women 
who report sexual activity only with other women (n=8). 
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last six months.  Time since HIV diagnosis was varied, with half of the sample diagnosed 
between 5-15 years prior to baseline survey (mean = 9.51 years).
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Table 13: Sociodemographic and Clinical Characteristics of Sample for Aim 1 (N=369) 
Variable N % of sample 
Age (y) Mean = 42.1 SD = 8.91 
Study Site 
UNC 226 61.3 
Wake  121 32.8 
Durham 22 5.9 
Gender 
Male  245 66.4 
Female 124 33.6 
Sexual Identity 
Straight/heterosexual 206 56.3 
Gay/homosexual 124 33.9 
Bisexual 25 6.8 
Other/Not sure 11 3.0 
Annual Income 
$10,000 or less 189 54.0 
$10,001 to $40,000 129 36.9 
More than $40,000 32 9.1 
Relationship status 
Single, not living with a partner 180 49.1 
Single, living with a partner 78 21.2 
Married 52 14.2 
Separated/Divorced/Widowed/Other 57 15.5 
Race 
Black/African American 258 70.1 
White, not of Hispanic origin 77 20.9 
Other 33 9 
Education 
Less than high school 75 20.4 
High school graduate or GED 129 35.0 
Some college/AA degree/technical school training 106 28.8 
College degree or more 58 15.8 
Employment 
Working  135 36.6 
Duration of Diagnosis 
Less than one year 19 5.3 
1-5 years 80 22.1 
5-10 years 100 27.6 
10-15 years 83 22.9 
15-20 years 59 16.3 
Greater than 20 years 21 5.8 
HAART Use 
Currently on HAART 295 88.9 
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Baseline sexual partner and psychosocial characteristics of the sample used for Aim 1 
are presented in Table 14. Most participants had primary partners (61.8%).  Approximately 
one-third reported HIV-positive partners (31.3%) and less than half reported HIV-negative 
partners (41.0%).  Three-quarters of the sample resided in urban areas.  Slightly less than half 
believed that their chances of transmitting HIV with their current viral load was high (42.5%) 
and approximately half believed that the seriousness of transmission risk is about as serious 
as it used to be (53.8%). 
Table 14: Partner and Psychosocial Characteristics of Sample for Aim 1 (N=369) 
Variable N % of sample 
Disclosure Stigma Mean = 13.3 SD = 5.54 
Subjective Norms Mean = 10.4 SD = 6.12 
Relationship Type 
 Primary 220 61.8 
 Casual  88 24.7 
 Both primary and casual 48 13.5 
Partner Serostatus Type 
HIV-positive 110 31.3 
HIV-negative 144 41.0 
Unknown serostatus 60 17.1 
Multiple serostatus types 37 10.6 
Urbanicity   
Rural 94 25.8 
Urban 271 74.2 
Beliefs in Transmission Risk Likelihood with Current Viral Load 
High 154 42.5 
Medium 86 23.8 
Low 99 27.4 
No chance 23 6.3 
Beliefs in Seriousness of Transmission Risk in the Presence of HAART  
Much less/a little less serious than it used to be 76 21.2 
About as serious as it used to be 193 53.8 
A little more/much more serious than it used to be 90 25.0 
Viral load Test Result in Last 6 Months 
Undetectable 190 51.6 
Detectable 141 38.3 
Unaware 37 10.1 
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In this aim, I explored predictors of serostatus disclosure to sexual partners among 
HIV-positive patients.  The dataset consisted of 369 individuals who were sexually active 
and reported between 1-10 sexual partners in the previous three months.   
 
5.1.1 Research Question 1.1  
Research Question 1.1 was: What is the prevalence of serostatus disclosure among 
HIV-positive patients?  To answer this question, below I report disclosure patterns separately 
for three groups: 1) first among those participants who reported only one partner; 2) then 
among those who reported more than one partner; 3) combining participants who report only 
one and those who report more than one partner.  The group with more than one partner are 
reported categorized into three groups—those with disclosure to none, some, or all of their 
partners. Finally, I combined all participants with one sexual partner and those with more 
than one sexual partner.    
Figure 3 below presents disclosure patterns among study participants who report one 
sexual partner among the three risk groups: MSW (n=67), MSM (n=69), and WSM 
(n=102).5  Disclosure rates were generally high averaging 88.3% across the three sub-groups 
of participants who report only one sexual partner in the previous three months.  MSM were 
significantly less likely to disclose to their one sexual partner than MSW or WSM 
(Unadjusted OR= 0.39, 95% CI = 0.17, 0.88, p = 0.023). 
 
 
 
 
                                                 
5
 Risk groups indicate participant gender-partner gender combinations. 
 84
 
Figure 3: Among Those with One Partner, Disclosure across Three Risk Groups (N=238) 
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Figure 4 below presents disclosure patterns among study participants who report 
more than one sexual partner (2-10 partners) across the three risk groups of MSW (n=20), 
MSM (n=69), and WSM (n=14).  This figure illustrates disclosure to all, some, and no 
partners where “full disclosure” represents complete disclosure to 100% of sexual partners, 
“partial disclosure” represents disclosure proportions between 1-99%, and “no disclosure” 
represents the absence of disclosure to any sexual partner.  In general, full disclosure among 
participants who reported multiple partners was lower compared to those participants with 
only one partner, ranging from as low as 46.7% among WSM to as high as 65.0% among 
MSW.  Due to low cell frequencies, the risk groups were collapsed into two categories to 
compare MSM to heterosexual participants (MSW and WSM combined).  However, there 
were no statistically significant differences in disclosure between the groups. 
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Figure 4: Among Those with Multiple Partners, Disclosure across Three Risk Groups 
(N=103) 
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Figure 5 presents overall disclosure proportions combining those with one partner and 
those with multiple partners.  Overall, disclosure across the entire sample was high at 78.9% 
but variation among the three risk groups is evident.  Women and MSW were more likely to 
disclose to their partners than MSM (Unadjusted OR= 2.54, 95% CI 1.21, 5.34, p = 0.014 
and OR= 2.63, 95% CI = 1.14, 6.05, p = 0.023, respectively).  
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Figure 5: Among Full Sample, Disclosure across Three Risk Groups (N=341) 
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5.1.2 Research Question 1.2  
Research Question 1.2 was: To what extent is serostatus disclosure associated with 1) 
partner relationship type (main versus casual partner) and 2) partner serostatus type (HIV-
positive, HIV-negative, unknown serostatus)?  
In the full sample, most participants reported only primary partners (72.2%) with 
12.1% reporting only casual partners, and 15.7% reporting both primary and casual partners.  
Figure 6 below illustrates relationship type categories by risk group and the total for the 
entire sample.  
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Figure 6: Among Full Sample, Proportion of Participants with each of Three Types of 
Relationships across Three Risk Groups (N=341) 
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Figure 7 below illustrates partner serostatus categories by risk group and the total for 
the entire sample.  More than one-third of the sample (40.8%) reported only HIV-negative 
partners, 31.6% reported only HIV-positive partners, 10.3% reported only unknown 
serostatus partners, and 17.2% reported partners of more than one serostatus type.  No WSM 
reported having partners of multiple serostatus types. 
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Figure 7: Among Full Sample, Partner Serostatus Type across Three Risk Groups (N=341) 
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5.1.2.1 Disclosure and Relationship Type 
Looking at the association between serostatus disclosure and relationship type, for the 
242 participants with only one partner, 205 participants had one primary partner (84.7%) and 
37 had one casual partner (15.3%).  Figure 8 below illustrates disclosure patterns for these 
participants with only one sexual partner who was either a primary or a casual partner.  
Across all risk groups, primary partners were more likely to receive disclosure compared to 
casual partners.  Primary partner disclosure rates ranged from as low as 87.9% for MSM to 
98.0% for MSW.  Among those participants with casual partners, disclosure rates ranged 
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from 42.8% among WSM to 66.7% for MSW.  Overall, primary partners were more likely to 
receive disclosure than casual partners (OR= 9.25, 95% CI = 3.86, 22.18, p < 0.001). 
 
Figure 8: Among Those with One Partner, Disclosure based on Relationship Type across 
Three Risk Groups (N=242) 
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Of the 114 participants who reported multiple partners, 15 had only primary partners 
(13.2%), 51 had only casual partners (44.7%), and 48 had both casual and primary partners 
(42.1%).   Figure 9 below illustrates disclosure patterns for these participants with multiple 
sexual partners.  Full disclosure was less common to casual partners than to those with 
primary relationship types (OR= 0.21, 95% CI = 0.06, 0.69, p = 0.01) or mixed relationship 
types (OR= 0.18, 95% CI = 0.02, 1.5, p = 0.12).         
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Figure 9: Among Those with Multiple Partners, Disclosure based on Relationship Type 
(N=114) 
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Of the 356 participants in the full sample, 220 had primary partners (61.8%), 88 had 
casual partners (24.7%), and 48 had both casual and primary partners (13.5%).6  Figure 10 
presents overall disclosure based on relationship type for the full sample combining those 
with one partner and those with multiple partners.  Full disclosure was more likely to primary 
partners than to those with casual or mixed relationship types (OR= 5.28, 95% CI = 2.70, 
10.31, 0.72, p < 0.001). 
 
 
 
                                                 
6
 Sample includes those participants who answered the relationship type question and does not include the 13 
individuals who refused to answer this question.  
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Figure 10: Among Full Sample, Disclosure based on Relationship Type (N=356) 
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5.1.2.2 Disclosure and Serostatus of Partner 
Of the 242 participants reporting one sexual partner, 85 had HIV-positive partners 
(35.1%), 119 had HIV-negative partners (49.2%), and 38 had partners of unknown serostatus 
(15.7%).  Figure 11 below illustrates disclosure patterns for these participants with only one 
sexual partner who have had only one opportunity to disclose to their one sexual partner.  
Compared to HIV-positive partners, unknown serostatus partners (OR= 0.12, 95% CI = 0.02, 
0.93, p = 0.04) and HIV-negative partners (OR= 0.01, 95% CI = 0.002, 0.13, p < 0.001) were 
significantly less likely to receive disclosure. When HIV-negative and unknown serostatus 
partners were combined into an “at risk” group, they were 86% less likely to receive 
disclosure compared to HIV-positive partners (OR= 0.14, 95% CI = 0.058, 0.36, p < 0.001). 
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Figure 11: Among Those with One Partner, Disclosure by Partner Serostatus (N=242) 
1.2 9.3
41.7
11.4
98.8 90.7
58.3
88.6
0
20
40
60
80
100
HIV+ HIV- Unknown Total
Pe
rc
en
t
No Disclosure Full Disclosure
 
Participants with multiple partners were categorized based on the serostatus of their 
sexual partners into four groups (HIV-positive, HIV-negative, unknown serostatus, and 
mixed serostatus partners).  Of those with multiple partners, 25 had only HIV-positive 
partners (22.9%), 25 had only HIV-negative partners (22.9%), 22 had only partners of 
unknown serostatus (20.3%), and 37 had partners of mixed serostatus (33.9%).  Figure 12 
below illustrates disclosure patterns for these participants who report more than one sexual 
partner and have more than one opportunity to disclose their status.  Among this sub-group 
of participants with multiple partners, variation was evident across the serostatus categories 
of partners.  Participants with multiple unknown serostatus partners were less likely to 
disclose to all partners compared to partners in other serostatus groups.  Due to low cell 
frequencies, participants with multiple partners were dichotomized into 1) HIV-positive and 
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2) at-risk (HIV-negative, unknown serostatus, and mixed serostatus) partners.  However, 
there were no statistically significant differences in disclosure between the groups. 
Figure 12: Among Those with Multiple Partners, Disclosure by Partner Serostatus (N=109) 
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Of the 351 participants in the full sample, 110 had HIV-positive partners (32.2%), 
144 had HIV-negative partners (42.5%), 60 had partners of unknown serostatus (17.6%), and 
37 had partners of mixed serostatus (10.6%).7 Figure 13 below presents a combination of the 
previous two figures and illustrates overall serostatus disclosure to all partners (one or 
multiple) across the entire sample.  Those with HIV-negative, unknown serostatus, and 
mixed serostatus were slightly less likely to disclose their status to all partners compared to 
those with HIV-positive partners.  However, only disclosure to unknown status partners was 
statistically significantly different (OR= 0.038, 95% CI = 0.01, 0.12, p < 0.001).   
 
 
                                                 
7
 Sample includes those participants who answered the partner serostatus type question and does not include the 
18 individuals who refused to answer this question.   
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Figure 13: Among Full Sample, Disclosure by Partner Serostatus (N=351) 
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5.1.3 Research Question 1.3 
Research Question 1.3 was: What is the prevalence of disclosure stigma (defined as the 
experiences of or perceived consequences of other people knowing one’s HIV status) among 
HIV-positive patients? Does disclosure stigma vary by risk group? 
On the seven-item disclosure stigma scale, total scores ranged from 7 to 28 (higher 
values indicating lower disclosure stigma), and the mean score was 13.41595 (sd 5.67) for 
the full sample.  Differences in mean stigma scale scores were not statistically significant 
among the three risk groups, as presented in Table 15. 
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Table 15: Mean Stigma Scale Scores by Risk Group 
 Mean Standard Deviation N 
MSW 14.25 5.6112622 92 
MSM 12.792857 5.4038308 140 
WSM 13.372881 5.6776614 118 
Total 13.41595 5.67605 350 
 
Analysis of Variance 
Source SS MS F (Prob > F) 
Between groups 117.878208 58.9391041 1.91 (0.1493) 
Within groups 10695.8361 58.9391041  
Total 10813.7143 30.9848547  
Bartlett’s test for equal variances: X2= = 0.3381, p = 0.844 
  
The distribution of scores for each individual disclosure scale item across risk groups 
is shown in Table 16.   The only difference between groups that reaches statistical 
significance is the question related to hiding one’s illness from others (ACASI item bs5q7).  
MSW were significantly less likely to agree that they feel they need to hide the fact that they 
have HIV from others (p < 0.01). A finding important to note is that regardless of risk group, 
HIV-positive individuals experience HIV stigma related to disclosure of one’s serostatus.  
For example, 80.7% of MSW, 81.8% of MSM, and 79.3% of WSM agreed that telling 
someone they have HIV is risky.  Similarly, 86.3% of MSW, 86.0% of MSM, and 84.2% of 
WSM agreed that they are very careful who they tell that they have HIV.     
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Table 16: Individual Stigma Items by Risk Group 
ACASI item Agree a lot/ Agree a little 
In some areas of my life, no one knows I have HIV.  
MSW 76.6 
MSM 86.0 
WSM 81.8 
Telling someone I have HIV is risky.  
MSW 80.7 
MSM 81.8 
WSM 79.3 
I work hard to keep my HIV a secret.  
MSW 70.3 
MSM 69.2 
WSM 70.3 
I am very careful who I tell that I have HIV.  
MSW 86.3 
MSM 80.0 
WSM 84.2 
I feel the need to hide the fact that I have HIV.  
MSW 56.4 
MSM 72.6 
WSM 70.8 
I worry that people who know I have HIV will tell others.  
MSW 71.6 
MSM 78.3 
WSM 70.0 
I have told people close to me to keep the fact that I have HIV a secret.  
MSW 56.4 
MSM 68.1 
WSM 72.0 
 
 
5.1.4 Results of Multinomial Logistic Regression 
To test hypotheses 1.2 through 1.8, a multinomial logistic regression model was fit that 
regressed serostatus disclosure on predictor variables (see Table 17).  First, results from the 
bivariate associations of predictor and control variables with the outcome variable, 
disclosure, identified five factors that had an association with the outcome variable at a p-
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value of <0.20 in the expected direction: 1) relationship type (casual versus main), 2) partner 
serostatus type, 3) disclosure stigma scale score, 4) score on the subjective norms scale, and 
5) urbanicity.  (Bivariate results are not presented).  The following independent variables 
were not associated with serostatus disclosure in my sample: beliefs in transmission risk 
perception based on current viral load, beliefs in the seriousness of transmission risk in the 
presence of HAART, and viral load detectability.  The final multivariate model also included 
six control variables (age, relationship status, sexual partnering (heterosexual versus 
homosexual) elapsed time between date of diagnosis and baseline ACASI date, alcohol use, 
and drug use).  In the multinomial logistic regression, likelihood (or odds) of being in one 
category of the outcome versus a reference category are calculated for each group within the 
predictor variables.   
The final model yielded interesting findings.  The first section of the model reports 
results indicating the likelihood of disclosing to no partners relative to disclosing to all 
partners.  The odds of disclosing to no partners is 18% more likely for every one-point 
increase in disclosure stigma (OR = 1.1815, 95% CI = 1.0505, 1.3288, p =.005).   Among 
those with casual partners, the odds of disclosing to no partners is .27 times that of the odds 
of disclosing to all partners (OR = 0.2734, 95% CI = 0.1003, 0.7449, p = 0.011).  Participants 
were 97% less likely to disclose to unknown serostatus partners relative to HIV-positive 
partners (OR =0.0343, 95% CI = 0.0079, 0.1482, p <0.001).  Similarly, participants were 
75% less likely to disclose to HIV-negative partners (OR = 0.2549, 95% CI = 0.0626, 
1.0038, p = 0.056) compared to HIV-positive partners, although not statistically significant at 
the 0.05 level.   
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The second section of the model reports results indicating the likelihood of disclosing to 
some partners relative to disclosing to all partners.  With disclosure to some partners as the 
referent group, those who disclosed to all partners had higher subjective norms regarding 
disclosure (OR = 1.1467, 95% CI = 1.0176, 1.2923, p = 0.025).  Participants who reported 
having both casual and primary partners were 95% less likely to disclose to all of their 
partners (OR = 0.0560, 95% CI = 0.0094, 0.3567, p = 0.002).  Participants reporting mixed 
serostatus types were 97% less likely to disclose to all of their partners (OR = 0.0358, 95% 
CI = 0.0026, 0.4822, p = 0.012).  No control variable predicted disclosure in any of the 
models. 
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Table 17: Predictors of Serostatus Disclosure for Full Disclosure Model: 
Adjusted Odds Ratios with 95% Confidence Intervals 
Variables 
Disclosure to None vs.  
Disclosure to All (N=317) 
Disclosure to Some vs.  
Disclosure to All (N=293) 
OR† 95% CI OR 95% CI 
Disclosure Stigma 
   For each 1 point increase 1.1815** 1.0505, 1.3288 1.1861 .9955, 1.4132 
Subjective Norms 
   For each 1 point increase 1.0294 0.9597, 1.1043 1.1467* 1.0176, 1.2923 
Urbanicity     
   Urban 0.4871 0.1503, 1.5789 1.1222 0.2222, 5.6660 
   Rural Reference ----- Reference ----- 
Relationship Type     
   Casual Partners 0.2734* 0.1003, 0.7449 0.2358 0.0352, 1.5784 
   Both Casual and Primary 1.7091 0.1721, 16.9692 0.0560** 0.0094, 0.3567 
   Primary Partners Reference ----- Reference ----- 
Partner Serostatus Type     
   HIV-Negative 0.2549 0.0626, 1.0038 0.1702 0.0139, 2.0769 
   Unknown Serostatus 0.0343** 0.0079, 0.1482 0.1003 0.0062, 1.6268 
   Mixed Serostatus Types 0.8175 0.0662, 10.0886 0.0358* 0.0026, 0.4822 
   HIV-Positive Reference ----- Reference ----- 
† Indicates Odds Ratio 
CI = Confidence Interval 
* Indicates p < 0.05 
** Indicates p < 0.01 
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5.2 RESULTS FOR AIM 2 
 
 Of the 242 persons enrolled in the SAFETALK study who met my eligibility 
requirements for Aim 2, 157 had an at-risk partner (either HIV-negative or unknown 
serostatus).  Table 18 on the following page presents the characteristics of the sample used 
for Aim 2.  In general, the participants were similar in composition to the sample used in 
Aim 1.  Most of the sample was enrolled at the UNC Site (65.0%), of African American race 
(64.3%), male (52.9%), straight/heterosexual (69.0%), and not working (59.2%). The average 
age was 42.0 years (range = 19 to 67).  More than half of participants had an annual income 
of less than $10,000.  In terms of HIV clinical characteristics, 56.4% of the sample reported 
an undetectable viral load and more than half have been living with HIV for between 5-15 
years (mean = 9.83 years). 
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Table 18: Sociodemographic and Clinical Characteristics of Sample for Aim 2 (N=157) 
Variable N % of sample 
Age (y) Mean = 42.0 SD = 9.13 
Study Site 
UNC 102 65.0 
Wake  47 29.9 
Durham 8 5.1 
Gender 
Male  83 52.9 
Female 74 47.1 
Sexual Identity 
Straight/heterosexual 107 69.0 
Gay/homosexual 37 23.9 
Bisexual 6 3.9 
Other/Not sure 5 3.2 
Annual Income 
$10,000 or less 78 52.4 
$10,001 to $40,000 55 36.9 
More than $40,000 16 4.7 
Relationship status 
Single, not living with a partner 67 43.2 
Single, living with a partner 34 22.0 
Married 23 14.8 
Separated/Divorced/Widowed/Other 31 20.0 
Race 
Black/African American 101 64.3 
White, not of Hispanic origin 38 24.2 
Other 18 11.5 
Education 
Less than high school 32 20.4 
High school graduate or GED 46 29.3 
Some college/AA degree/technical school training 55 35.0 
College degree or more 24 15.3 
Employment 
Working  64 40.8 
Duration of Diagnosis 
Less than one year 5 3.2 
1-5 years 36 23.4 
5-10 years 40 26.0 
10-15 years 37 24.0 
15-20 years 26 16.9 
Greater than 20 years 10 6.5 
HAART Use   
Currently on HAART 132 91.0 
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5.2.1 Sexual Activity in the Sample  
 
Table 19 describes the number of participants in the sample who report one sexual 
partner of different serostatus types (HIV-negative, and unknown serostatus) in the previous 
three months across risk groups (MSW, MSM, WSM).  Three-quarters reported (n=119) 
having HIV-negative sexual partners, and the remaining quarter report unknown sexual 
partners (n=38) in the previous three months.  The association between risk group and 
partner serostatus was not statistically significant (X2=3.44, p = 0.179). 
 
Table 19: Partner Serostatus by Risk Group 
Risk Group 
Partner Serostatus 
N (%) 
HIV-Negative Unknown Serostatus Total 
MSW 32 (82.1%) 7 (17.9%) 39  
MSM 29 (65.9%) 15 (34.1%) 44  
WSM 58 (78.4%) 16 (21.6%) 74 
Total 119 (75.8%) 38 (24.2%)  157 
 
Table 20 describes the number of participants in the sample who report sexual 
partners in the previous three months across the three risk groups by relationship type.  The 
majority of participants report primary partners (80.3%). Women were more likely to report 
primary partners than males (OR = 1.18, 95% CI = 0.35, 2.01, p < 0.001).  
 
Table 20: Partner Serostatus by Relationship Type 
Risk Group 
Relationship Type 
N (%) 
Casual Primary Total 
MSW 11 (28.2%) 28 (71.8%) 39  
MSM 13 (29.5%) 31 (70.5%) 44  
WSM 7 (9.5%) 67 (90.5%) 74 
Total 31 (19.7%) 126 (80.3%) 157 
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5.2.2 Transmission Risk Behavior in the Sample 
 
RQ 2.1. What proportion of participants report transmission risk behaviors? (defined as 
unprotected acts of vaginal or anal sex with an at-risk partner, meaning HIV-negative or 
unknown serostatus partner) 
Only 16.6% of the sample reported engaging in unprotected vaginal or anal sex with 
an at-risk partner (HIV-negative or unknown serostatus).  Among MSW, 25 reported anal or 
vaginal sex with a female who was HIV-negative or of unknown serostatus.  Of these MSW, 
4 report unprotected activity (16.0%).  Among MSM, 23 reported anal sex with a male who 
was HIV-negative or of unknown serostatus.  Of these MSM, 6 report unprotected activity 
(26.1%).  Among WSM, 48 reported anal or vaginal sex with a male who was HIV-negative 
or of unknown serostatus.  Of these women, 16 report unprotected activity (33.3%). 
Prior to examining the relationship between serostatus disclosure and sexual risk 
transmission behaviors in the sample, I present contingency table analyses to determine the 
extent of transmission risk behaviors in the sample.  As shown in Table 21, the majority of 
those with HIV-negative and unknown serostatus partners engaged in safer sex behaviors 
(86.6% and 73.7%, respectively).  Those with unknown serostatus partners were more likely 
to report TRB than those with HIV-negative partners.  However, this result was not 
statistically significant (OR = 2.30, 95% CI = 0.94, 5.62, p = 0.068). 
Table 21: Contingency Table to Examine Rate of TRB by Partner Serostatus 
TRB 
Partner Serostatus 
N (%) 
Negative Unknown Total 
No 103 (86.6%) 28 (73.7%) 131 
Yes 16 (13.4%) 10 (26.3%) 26 
Total 119 38 157 
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As shown in Table 22 below, participants with primary partners were less likely to 
engage in TRB than those with casual partners, (15.9% vs. 19.3%).  However, this finding 
was not statistically significant (OR = 0.79, 95% CI = 0.28, 2.16, p = 0.641). 
Table 22: Contingency Table to Examine Rate of TRB by Relationship Type 
TRB 
Relationship Type 
N (%) 
Casual Primary Total 
No 25 (80.7%) 106 (84.1%) 131  
Yes 6 (19.3%) 20 (15.9%) 26 
Total 31 126 157 
 
5.2.3 Relationship between Serostatus Disclosure and Transmission Risk Behavior 
 
RQ 2.2. What is the association between serostatus disclosure and sexual risk transmission 
behaviors? 
Tables 23 through 26 below illustrate the relationship between serostatus disclosure 
and TRB for each of the three risk groups and then for the entire sample combining the three 
risk groups.   Ninety four percent of MSW engaged in safer sex consistently and 6% engaged 
in unsafe sex (either unprotected vaginal or anal intercourse with an HIV-negative or 
unknown serostatus partner) at least once in the previous three months.  Of the 33 MSW 
disclosers, 3 MSW engaged in TRB while 30 engaged in safer sex.   Of the 5 MSW non-
disclosers, 1 MSW engaged in TRB and 4 engaged in safer sex.  There was no statistically 
significant association between disclosure and TRB among MSW (p = 0.471).  
Table 23: Disclosure and TRB among MSW 
 Disclosure  
TRB 
 No Yes Total 
No 4 (80.0%) 30 (90.9%) 34 (89.5%) 
Yes 1 (20.0%) 3 (9.1%) 4 (10.5%) 
 Total 5 (13.2%) 33 (86.8%) 38 (100.0%) 
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Among MSM, 72.7% disclosed their HIV status to their sexual partner and 86.4% 
consistently engaged in safer sex (protected anal intercourse with an HIV-negative or 
unknown serostatus partner) in the previous three months.  Three MSM engaged in TRB and 
disclosed while 29 engaged in safer sex and disclosed.   Three MSM engaged in TRB and 
withheld disclosure while 9 engaged in safer sex and withheld disclosure.  MSM who 
disclosed were less likely to engage in TRB.  However, this finding did not reach statistical 
significance (p = 0.19).  
Table 24: Disclosure and TRB among MSM 
 Disclosure  
TRB 
 No Yes Total 
No 9 (75.0%) 29 (90.6%) 38 (86.4%) 
Yes 3 (25.0%) 3 (9.4%) 6 (13.6%) 
 Total 12 (27.3%) 32 (72.7%) 44 (100.0%) 
 
 
Among WSM, 87.5% disclosed their HIV status to their sexual partner and 77.8% 
engaged in safer sex.  Ten WSM engaged in TRB and disclosed while 53 engaged in safer 
sex and disclosed.   Six WSM engaged in TRB and withheld disclosure while 3 engaged in 
safer sex and withheld disclosure.  Women who disclosed were less likely to engage in TRB 
than those who withheld disclosure (OR = 0.09, 95% CI = 0.02, 0.44, p = 0.003).   
Table 25: Disclosure and TRB among WSM 
 Disclosure  
TRB 
 No Yes Total 
No 3 (33.3%) 53 (84.1%) 56 (77.8%) 
Yes 6 (66.7%) 10 (15.9%) 16 (22.2%) 
 Total 9 (12.5%) 63 (87.5%) 72 (100.0%) 
 
For the full sample, 83.1% disclosed their HIV status to their sexual partner; 16.9% 
withheld disclosure.  Eighty three percent engaged in safer sex and 17% engaged in unsafe 
sex (either unprotected vaginal or anal intercourse with an HIV-negative or unknown 
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serostatus partner) in the previous three months.  Sixteen participants engaged in TRB and 
disclosed while 112 participants engaged in safer sex and disclosed.  Ten participants 
engaged in TRB and failed to disclose while 16 engaged in safer sex and failed to disclose.  
Among the full sample, those who reported disclosing their status were 77% less likely to 
report engaging in TRB than those who withheld disclosure (OR = 0.23, 95% CI = 0.09, 
0.59,  p = 0.002). 
 
Table 26: Disclosure and TRB across Three Risk Groups 
 Disclosure  
TRB 
 No Yes Total 
No 16 (61.5%) 112 (87.5%) 128 (83.1%) 
Yes 10 (38.5%) 16 (12.5%) 26 (16.9%) 
 Total 26 (16.9%) 128 (83.1%) 154 (100.0%) 
 
5.2.3 Relationship between Serostatus Disclosure and Transmission Risk Behavior with 
Moderating Variables 
 
RQ 2.3. Does the relationship between disclosure and sexual transmission risk behaviors 
differ by partner characteristics that belong to (1) relationship type and (2) partner 
serostatus type?  
 
Prior to examining the statistical relationship between HIV serostatus disclosure, 
TRB, partner relationship type, and partner serostatus type, I provide data regarding the 
trends in TRB and disclosure compared across relationship type categories and partner 
serostatus type categories.  Tables 27 and 28 present serostatus disclosure and transmission 
risk behaviors by relationship type.  Most primary partners were disclosed to (90.3%) and 
most engaged in safer sex (83.9%).  Those who disclosed to primary partners were 78% less 
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likely to engage in TRB than those who withheld disclosure (OR = 0.22, 95% CI = 0.06, 
0.77, p = 0.018). 
Table 27: Disclosure and TRB among Participants with Primary Partners 
 Disclosure  
TRB 
 No Yes Total 
No 7 (58.3%) 97 (86.6%) 104 (83.9%) 
Yes 5 (41.7%) 15 (13.4%) 20 (16.1%) 
 Total 12 (9.7%) 112 (90.3%) 124 (100.0%) 
 
As evidenced in Table 28 below, just over half of casual partners received disclosure 
(53.3%) and most engaged in safer sex (80.0%).  Those who disclosed to casual partners 
were 78% less likely to engage in TRB than those who withheld disclosure (OR = 0.22, 95% 
CI = 0.06, 0.77, p = 0.018).  However, this result was not statistically significant (OR = 0.12, 
95% CI = 0.01, 1.19, p = 0.071). 
Table 28: Disclosure and TRB among Participants with Casual Partners 
  Disclosure  
TRB 
 No Yes Total 
No 9 (64.3%) 15 (93.8%) 24 (80.0%) 
Yes 5 (35.7%) 1 (6.2%) 6 (20.0%) 
 Total 14 (46.7%) 16 (53.3%) 30 (100.0%) 
  
 Table 29 presents disclosure and transmission risk behavior with HIV-negative 
partners.  Most of the sub-group disclosed to their partner (90.7%) and engaged in safer sex 
while (87.5%).  There was no statistically significant relationship between disclosure and 
TRB among those with HIV-negative partners (p = 0.177).   
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Table 29: Disclosure and TRB among Participants with HIV-Negative Partners 
  Disclosure  
TRB 
 No Yes Total 
No 8 (72.7%) 94 (87.8%) 102 (87.5%) 
Yes 3 (27.3%) 13 (12.2%) 16 (13.5%) 
 Total 11 (9.3%) 107 (90.7%) 118 (100.0%) 
 
 Table 30 presents disclosure and transmission risk behavior with partners of unknown 
serostatus.  Exactly half of the sub-group disclosed to their partner and engaged in safer sex 
while (50.0%) while 8.3% disclosed their status and engaged in unsafe sex.  Those who 
disclosed to unknown serostatus partners were less likely to engage in TRB than those who 
withheld disclosure (OR = 0.19, 95% CI = 0.04, 0.93, p = 0.041). 
Table 30: Disclosure and TRB among Participants with Unknown Partners 
  Disclosure  
TRB 
 No Yes Total 
No 8 (53.3%) 18 (85.7%) 24 (72.2%) 
Yes 7 (46.7%) 3 (14.3%) 10 (27.8%) 
 Total 15 (41.7%) 21 (58.3%) 36 (100.0%) 
 
5.2.4 Relationship between Serostatus Disclosure and Transmission Risk Behavior with 
Moderating Variables: Multivariate Model 
 
 Research Question 2.3 examined if the relationship between serostatus disclosure and 
transmission risk behavior varied by partner-specific variables: 1) relationship type (main, 
casual) and 2) partner serostatus type (HIV-negative and unknown serostatus) as well as 
interactions between relationship type and serostatus disclosure, and the interaction between 
partner serostatus type and serostatus disclosure. When the two interaction terms were 
included in the model, neither term had a statistically significant association with serostatus 
disclosure and therefore neither was retained in the final multivariate model.   From the 
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bivariate associations, the following three control variables were associated with 
transmission risk behavior at an alpha of 0.20 and included in the full model: (age, sexual 
pairing (heterosexual versus homosexual) and drug use.  As evidenced in Table 31, those 
who disclosed to their partners were 18% less likely to engage in TRB (p = 0.01).  Those 
who were in primary relationships and those with unknown serostatus partners were more 
likely to engage in TRB; however, neither of these differences was significant.  The only 
control variable that was significant was age; younger participants were less likely to engage 
in TRB (p = 0.002). 
 
 
 
 
Table 31: Predictors of Transmission Risk Behavior as assessed in 
Multivariate Logistic Regression Model: 
Adjusted Odds Ratios with 95% Confidence Intervals 
Variable Adjusted Odds Ratio 95% CI 
Serostatus Disclosure 0.1881** (0.0520, 0.6806) 
Relationship Type 2.6160 (0.5849, 11.7006) 
Partner Serostatus   
   Unknown Serostatus 1.789 (0.5509, 5.8109) 
   HIV-Negative Reference ----- 
Age 
Continuous 0.9161** (0.8670, 0.9680) 
Drug Use   
   Yes 2.3027 (0.8101, 6.5432) 
   No Reference ----- 
Sexual Pairing   
  Opposite sex partner 2.7085 (0.8224, 8.9197) 
  Same sex partner Reference ----- 
** Indicates p < 0.01 
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CHAPTER SIX: DISCUSSION 
This chapter provides an in-depth discussion of the findings presented in Chapter 
Five.  First, I summarize findings organized by specific aim, compare the results to findings 
in the literature, and offer explanations for them. Then, I present the study’s strengths and 
challenges. I conclude the chapter with the public health implications of the research and 
areas for further research consideration.  
 
6.1 DISCUSSION OF FINDINGS 
 
6.1.1 Summary of Findings for Aim 1 
The goal of the first aim was to examine predictors of serostatus disclosure among 
sexually active HIV-positive individuals.   This section discusses disclosure across different 
categories (risk group and number of partners) as well as the relationship between disclosure 
and the correlates presented in the conceptual model. 
I found an overall disclosure rate (78.9%) to sexual partners consistent with many 
previous studies (range 68-81%) (Mohammed & Kissinger, 2006; Niccolai et al., 1999; 
Niccolai et al., 2006; Petrak et al., 2001; Raj, Cheng, Levison, Meli, & Samet, 2006) but 
higher than some key studies (range 29-57%) (N. Crepaz & G. Marks, 2003; D'Angelo et al., 
2001; R. Klitzman et al., 2007; O'Brien et al., 2003; Simon Rosser et al., 2008).  This result 
may have occurred for several reasons.  First, the majority of published literature on 
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disclosure to sexual partners includes only gay or bisexual men, excluding heterosexual men 
and women.  This difference from our more diverse study population may partially explain 
the higher levels of overall disclosure in the sample.  Second, many previous studies 
examined disclosure in the context of one specific sexual event or to the most recent sexual 
partner (N. Crepaz & G. Marks, 2003; Holtgrave, Crosby, & Shouse, 2006; Niccolai et al., 
1999; Poppen, Reisen, Zea, Bianchi, & Echeverry, 2005), using a dichotomous outcome 
variable (Niccolai et al., 2006).  This study presents a novel way to examine disclosure to all 
partners in the previous three months by using a three-category outcome variable that 
captured disclosure to none, some, or all partners.  Third, this study examined disclosure 
across both seroconcordant and serodiscordant partners, while several studies only explored 
at-risk partners (HIV-negative and unknown serostatus) which may explain the lower 
disclosure rates (Ciccarone et al., 2003; N Crepaz & G Marks, 2003).   
 
6.1.2 Discussion of Findings for Aim 1 
While serostatus disclosure was high in the sample reported here, variation among the 
three risk groups is evident.  MSM had the lowest disclosure to all partners (70%) where 
MSW and WSM had similarly high full disclosure (85.0% and 85.2%, respectively).  These 
findings support previous work that found differences in disclosure based on sexual 
orientation and partner pairing, in which gay and bisexual men were more likely to withhold 
disclosure (Ciccarone et al., 2003; N Crepaz & G Marks, 2003; Mayfield Arnold, Rice, 
Flannery, & Rotheram-Borus, 2008; Semple, Patterson, & Grant, 2004; J. M. Serovich & K. 
E. Mosack, 2003).  Of the published research on serostatus disclosure and men, few include 
heterosexual men, and those that do often collapse heterosexual participants to include both 
  
 
 
 
113
men and women (Sullivan, 2005).  As such, more research is needed to provide a better 
picture of factors that facilitate or impede disclosure among heterosexual men.  Among 
women, reported rates of disclosure to sexual partners in the literature have ranged between 
56-87% (Armistead et al., 2001) (J. M. Simoni et al., 1995; R. Sowell, Seals, Phillips, & 
Julious, 2003; R. L. Sowell et al., 1997).   A 2009 study among HIV-positive women found 
disclosure to spouse or romantic partner to be 88.9% (Rice, Comulada, Green, Arnold, & 
Rotheram-Borus, 2009) which is consistent with the findings in this study regarding 
disclosure to main partners among women.   
When examining disclosure in the sample by the number of sexual partners reported, 
a different and important pattern emerged in these data.  The majority of participants (88.3%) 
with one partner disclosed their status.  Of those reporting more than one partner, however, 
full disclosure was to just over half of partners (56.3%).  These findings are consistent with 
previous research that found the likelihood of disclosure decreased as the number of partners 
increased (DeRosa & Marks, 1998; Mohammed & Kissinger, 2006; Reece, 2003; Wolitski, 
Parsons, & Gomez, 2004).  This finding suggests that at least part of the reason that the 
prevalence of serostatus disclosure is higher among HIV-positive women than men is 
because more women reported only one sexual partner.   
It is important to note methodologic differences in the measures used for those 
participants with one partner versus those with greater than one partner. For example, those 
with one partner can only fall into the “full disclosure” or “no disclosure” categories and not 
the “partial disclosure” category since there is only one partner involved.  However, for those 
with more than partner, all three disclosure categories are possible.  There are clear trade-offs 
in different disclosure measurements and the decision to create a three-category variable for 
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disclosure is not perfect.  While it presents a challenge when comparing participants with one 
partner to participants with multiple partners, it is possible that it may have over-simplified 
comparisons, particularly among those participants who disclosed to some, but not all, of 
their partners.  
 
6.1.2.1 Disclosure and Hypothesized Correlates in the Final Model 
 
Disclosure and Partner Characteristics 
Among those with one partner, most participants reported a primary partner (84.7%) 
compared to a casual partner (15.3%).  The vast majority of primary partners received 
disclosure (93.6%) compared to casual partners (59.4%).  Among those with multiple 
partners, 66.7% of primary partners received full disclosure compared to 47.9% of casual 
partners.   Among the full sample, almost all (92.1%) of primary partners received disclosure 
compared to 53.6% of casual partners and 61.9% of mixed relationship types (casual and 
primary combined).  
 Published studies on the effect of relationship type on disclosure have differed in the 
manner in which they have defined or categorized “relationship type.  For example, such 
designations in the context of a sexual relationship have been defined as “the degree of 
intimacy” or “level of involvement”, “depth of a relationship”, or “whether the relationship is 
exclusive”.  A 16-study review of evaluations among HIV-positive men found full disclosure 
to main partners ranged from 67-88% (Sullivan, 2005), which is lower than the findings of 
this study.   This difference may have resulted from the fact that the review only included 
men and this study sample included both men and women.  For example, the vast majority of 
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women in this study reported only one partner (86.5%) compared to men (57.5%).  Similarly, 
most women with one partner said that individual was a main partner (81.2%) who received 
disclosure (94.9%) compared to men who had one partner (51.5%) who received disclosure 
(89.7%).  
We also found slightly higher disclosure rates to casual partners than what is 
published in the literature, where full disclosure ranges from 24-42% (Klitzman et al., 2007; 
O’Brien et al., 2003; Parsons et al., 2005; Simon Rosser et al., 2008).  However, it is critical 
to point out that approximately half of casual partners and some main partners did not receive 
serostatus disclosure and may be at risk for HIV acquisition. Such lack of knowledge of their 
partner’s serostatus may deny these partners the opportunity to make an informed decision 
about accepted levels of risk. 
Among those with one partner, virtually all HIV-positive partners received disclosure 
(98.8%) compared to HIV-negative and unknown serostatus partners (90.7% and 58.3%, 
respectively). A similar trend was found among those with multiple partners, with 
seroconcordant partners most likely to receive disclosure (87.5%) compared to mixed 
serostatus, HIV-negative, and unknown serostatus partners (60.0%, 56.0%, and 9.5%, 
respectively).  Among the full sample, 96.3% of HIV-positive partners were disclosed to 
compared to HIV-negative, mixed serostatus, and unknown partners (84.6%, 60.0%, and 
40.3%, respectively). 
Research findings often demonstrate higher disclosure to seroconcordant partners 
(DeRosa & Marks, 1998; Lightfoot et al., 2005; Marks & Crepaz, 2001; Niccolai et al., 2006; 
Parsons, Missildine, Van Ora, Purcell, & Gomez, 2004; Somlai, Kalichman, & Bagnall, 
2001) and the results in this study are consistent with previous studies.  It is not surprising to 
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find that differences in disclosure rates with HIV-positive, HIV-negative, and unknown 
serostatus partners occur, which may be a reflection of differences in perceptions of the risk 
of rejection (Sullivan, 2005; Zea et al., 2003) .  In addition, the findings in the literature that 
disclosure is more prevalent to HIV-negative partners than to those of unknown status may 
suggest that in instances where partner status is not discussed (i.e., unknown status) partners 
are at risk for transmission (Sullivan, 2005).   
 
Disclosure and Stigma 
Similar to other studies among PLWHA in the United States, the results of this study 
demonstrate considerable levels of stigma associated with disclosure concerns (Berger et al., 
2001; Clark et al., 2003; Dowshen, Binns, & Garofalo, 2009; Smith et al., 2008).  In 
particular, the greater the disclosure stigma perceived by participants the less likely they were 
to disclose their serostatus to sexual partners.  Although some literature cites differences 
between genders in the daily experiences of living with HIV, such as physical harm 
following disclosure (Hader, Smith, Moore, & Holmberg, 2001; Zierler et al., 2000), I did 
not find differences in stigma across gender lines or between risk groups.   
 The findings in this study lend support to the consequences theory described in 
Chapter Two in which disclosure decisions are influenced by the consequences an individual 
expects as a result of disclosure (Serovich, 2001).  In other words, stresses accumulate as 
one’s HIV progresses, resulting in the need for an individual to evaluate the negative and 
positive consequences of disclosure, and stigma can be a stressor for PLWHA. 
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Disclosure and Subjective Norms 
This study goes beyond prior studies of factors affecting HIV serostatus disclosure in 
that it examines whether subjective norms are associated with serostatus disclosure.  I found 
that disclosure is more likely when people feel that their friends, family members, and 
partners approve of this behavior.  This important finding sheds some light into 
understanding how the influence of different referent groups acts as a social force to affect 
disclosure behavior which has potential implications for interventions to enhance disclosure.  
This study, to my knowledge, is the only study to show that subjective norms are correlated 
with serostatus disclosure among PLWHA.  However, a meta-analysis using 96 datasets 
demonstrated that subjective norms were correlated with condom use (Albarracin, Johnson, 
Fishbein, & Muellerleile, 2001).   A better understanding of the influence of different 
referent groups on disclosure decisions could be incorporated into interventions delivered to 
HIV-positive persons and build upon previous research which has found norms to be 
associated with safer sex behaviors.  Understanding how and why friends, family members, 
and sexual partners’ beliefs about disclosure influence actual disclosure decisions has 
implications for increasing the rate of partner disclosure among PLWHA. 
 An interesting finding in the multinomial logistic regression model was that 
subjective norms were not associated with disclosure in the first section of the model that 
compares disclosure to none versus disclosure to all.  However, subjective norms were 
associated with disclosure in the second section of the model that compares disclosure to 
some versus disclosure to all.  It is important to note that the sample sizes for these two 
sections of the model were different in that the first section includes those with one or more 
partners and the second section only includes those with more than one partner.  The 
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mechanisms of being influenced by subjective norms regarding serostatus disclosure are 
different for those who report more than one partner.    
 
Disclosure and Transmission Risk Beliefs  
 While literature suggests that the use of highly active antiretroviral treatment 
(HAART) may lead to an increase in disclosure to partners, this study was unique in that I 
examined HAART-related beliefs not actual HAART use.  Neither the perception that 
transmission risk is serious given the availability of HAART nor the beliefs regarding one’s 
chances of transmitting HIV given one’s current viral load was associated with serostatus 
disclosure.  The few research studies on transmission risk beliefs with HAART and risk 
perceptions given different viral loads have used unprotected sexual activity as the primary 
outcome variable, not serostatus disclosure (Crepaz & Marks, 2004; Kalichman et al., 2006; 
Vanable, Ostrow, & McKirnan, 2003).  These studies found HIV-positive patients’ beliefs 
about HAART and viral load were associated with unprotected sexual activity.   
Traditional health behavior theories tend to focus on constructs that emphasize an 
individual’s attitudes, beliefs, and behaviors to predict or explain events, often 
conceptualized as a way to keep oneself healthy and avoid disease or illness.  Since the two 
HIV transmission risk belief variables utilized in this study pertain to reducing or eliminating 
an individual’s chances of exposing another individual to HIV, it may be more difficult to 
link directly constructs from the Health Belief Model to these concepts.  A possible 
explanation for the lack of association between HAART-related beliefs and disclosure may 
lie in the limited number of questions to examine the association that may not have fully 
recognized the complex interactions at play between medication beliefs, actual adherence, 
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and disclosure patterns.  While it is reasonable to assume that beliefs precede behavior, it is 
also plausible that the lack of association was a result of the people making a connection 
between beliefs and risk behavior (i.e., unprotected sexual activity) and not disclosure 
behavior.  Perhaps people do not take HAART-related beliefs into account when making 
decisions about disclosure to sexual partners. 
To date, only one qualitative study specifically examined HAART-associated beliefs 
among PLWHA as they relate specifically to serostatus disclosure and the sample only 
included MSM (Klitzman et al., 2004).  This limitation of previous research warrants 
additional research into a better understanding of not only actual HAART use but the beliefs 
about how these medications and corresponding viral loads influence actual disclosure 
behaviors, particularly since HAART is offering PLWHA to live longer, healthier lives.  
Future studies must also broaden the study population to include women and heterosexual 
men.  
 
Disclosure and Viral Load Detectability  
Viral load detectability was not associated with disclosure in this study.  The finding 
of a lack of association between these two variables may have resulted from people who use 
safer sex as a substitute for the need to disclose.  This “uninformed protection” may 
contribute to an individual’s belief that disclosure is not necessary as long as condoms are 
used for sexual activity with an at-risk partner.  Therefore, viral load detectability would not 
predict disclosure but it may predict safer sex.  It is also possible that while viral load 
detectability influences individuals, it may do so in different ways that therefore obscures any 
association.   For example, I hypothesized that those HIV-positive patients who report 
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undetectable viral load test results are less likely to disclose than those who report detectable 
viral load test results.   It is reasonable to expect those with undetectable viral loads to 
believe that they don’t have to disclose because they are not putting a partner at risk due to 
their undetectable viral load.  Similarly, it is possible that those with undetectable viral loads 
may be more conscientious in general about their health, medication adherence, and 
responsibility to partners and are therefore more likely to disclose.  Such relationships may 
vary from person to person and this lack of consistency may contribute to the absence of an 
association.  Another possible explanation is that people do not take their viral load 
detectability into account when making decisions about whether or not to disclose to a sexual 
partner. 
It is possible that viral load detectability may involve a more complex relationship 
with serostatus disclosure. I was not able to evaluate such relationships in this study.  I had 
only one item with self-reported viral load detectability (detectable, undetectable, and 
unaware).  Examining actual viral load detectability via chart abstractions in conjunction 
with perceived viral load detectability may yield different results and warrant further 
exploration, particularly for those individuals who perceive an undetectable viral load but 
actually have a detectable viral load. 
 
Disclosure and Urbanicity  
 Contrary to the original hypothesis presented in Chapter Three, greater urbanicity was 
not associated with more serostatus disclosure to partners.  This finding may have been an 
artifact of the way in which urbanicity was categorized.  Due to low frequencies in several 
RUCA codes, I chose to aggregate them into two groups: rural and urban.  I did not have a 
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broad range of codes in the sample, so if a relationship exists between urbanicity and 
disclosure, I would not be able to detect it given the distribution of the sample.  Researchers 
have used a variety of definitions for classifying rural and urban communities, and one 
difficulty in studying rural populations is a lack of agreement in the literature about how to 
define urban and rural.  Given the lack of consensus, it is difficult to compare the results 
presented here with the few published studies on urbanicity/rurality and disclosure among 
PLWHA.  In addition, more research is needed to explore how urban/rural differences 
manifest themselves in the daily living experiences of PLWHA.   
 If anything, people in urban areas were less likely to disclose than those in rural areas, 
though this association was not statistically significant.  Although we should interpret this 
finding with caution, one may speculate that perhaps people in urban areas are more likely to 
have partners who they meet in clubs or bars for a one-time sexual encounter and are then 
less likely to receive disclosure from their HIV-positive partners.  It is possible that people in 
rural areas are more likely to have primary partners only and therefore are less likely to 
withhold disclosure.  Therefore, it is not so much where you live, but rather who your partner 
is that influences disclosure patterns. 
 
6.1.3 Summary of Findings for Aim 2 
The goal of the second aim was to examine the relationship between serostatus 
disclosure and transmission risk behaviors among sexually active HIV-positive individuals.   
This section discusses transmission risk behavior for the sample and reviews the 
hypothesized partner characteristics as moderating variables presented in the conceptual 
model. 
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Reported transmission risk behavior was low as only 17% of the sample reported 
engaging in unprotected vaginal or anal sex with an at-risk partner (HIV-negative or 
unknown serostatus).  The majority of those with HIV-negative and unknown serostatus 
partners engaged in safer sex behaviors (87.5% and 72.2%, respectively).  Participants with 
casual partners were less likely to engage in TRB than those with primary partners.  Overall, 
an important finding in this study was that serostatus disclosure was correlated with 
transmission risk behavior; specifically, those who disclosed their status were less likely to 
engage in TRB than those who withheld disclosure.   
Given the high levels of safer sex behavior in the sample, there was limited power to 
detect differences between those who engaged in TRB and those who did not across 
disclosers and non-disclosers.  I also had an insufficient sample size to fully explore the 
moderating effects of partner serostatus and relationship type on serostatus disclosure as 
predictors of TRB with adequate statistical power.  These finding are discussed in the 
following section.   
 
6.1.4 Discussion of Findings for Aim 2 
Many HIV researchers have speculated that there is an association between serostatus 
disclosure to sexual partners and transmission risk behaviors.  However, the relationship 
between HIV disclosure and sexual risk behavior is complex, and there has been 
inconsistency in research findings about this relationship.   
Only 16.6% of the sample reported engaging in unprotected vaginal or anal sex with 
an at-risk partner (HIV-negative or unknown serostatus).  When examining serostatus 
disclosure as a predictor of transmission risk behavior regardless of partner serostatus or 
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relationship type, the following pattern emerged where participants fell into one of four 
categories:  
1) 72.7% engaged in informed protection (safer sex with disclosure)  
2) 10.4% engaged in uninformed protection (safer sex without disclosure) 
3) 10.4% engaged in informed exposure (unsafe sex with disclosure)  
4) 6.5% engaged in uninformed exposure (unsafe sex without disclosure)    
 
This distribution is markedly different from a key study of HIV-positive patients 
(Marks & Crepaz, 2001) regarding the relationship between disclosure and sexual practices 
which found the following:  
1) 40% engaged in informed protection (safer sex with disclosure)  
2) 35% engaged in uninformed protection (safer sex without disclosure) 
3) 12% engaged in informed exposure (unsafe sex with disclosure)  
4) 13% engaged in uninformed exposure (unsafe sex without disclosure)    
 
The findings in the study presented here are consistent with that of Marks and Crepaz 
with the highest percentage falling into the “preferred category” of safer sex with disclosure 
(“informed protection”).  However, in the study reported here, not only did the highest 
percentage fall into the “preferred category,” but also this group was the vast majority 
whereas in Marks and Crepaz’s study, this group made up less than 50% of the total.   The 
study reported here had only 17% of the sample engaging in TRB which is fairly consistent 
to 25% found by Marks and Crepaz.   
The study presented here differs from Marks and Crepaz’s study in several ways.  
Although both studies were cross-sectional assessments, I assessed disclosure and TRB 
among MSM, MSW, and WSM at three clinics in North Carolina from data collected from 
2005-2007.  Marks and Crepaz only sampled MSM at a clinic in Los Angeles with data 
collected between 1995 and 1997.  Given some earlier findings presented here, MSM are 
more likely to engage in TRB than heterosexual men and women and less likely to disclose.  
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It is possible that PLWHA are becoming more safety conscious over time which may explain 
the higher figures of both disclosure and safer sex found in my study compared to Marks and 
Crepaz’s study with data collection from the mid 1990s.  In addition, I assessed the number 
of unprotected sex acts relative to the total number of sex acts in the previous three months to 
determine any transmission risk behaviors.  Marks and Crepaz assessed protected and 
unprotected sex acts in the most recent sexual encounter, which may have higher recall than a 
three-month period as was the case in my sample.  Finally, this sample did not assess the 
timing of disclosure relative to sexual acts while Marks and Crepaz determined if participants 
disclosed to partners prior to sexual activity.  It is possible that participants in my sample 
engaged in TRB either before or after disclosure.  These differences may explain why these 
two studies found different relationships between serostatus disclosure and transmission risk 
behaviors.  
The type of relationship a person has with their sexual partner may influence the 
association between disclosure and safer sex behavior.  When examining the main effect, 
those who disclosed to primary partners were less likely to engage in TRB than those who 
withheld disclosure.  Similarly, those who disclosed to casual partners were less likely to 
engage in TRB than those who withheld disclosure.  These findings are consistent with the 
results of three recent studies.  A large study with a national probability sample of more than 
2,000 PLWHA that found that gay or bisexual men were more likely to report TRB without 
disclosure with non-exclusive partners than primary partners (Ciccarone et al., 2003).  
However, this relationship was not found among women and heterosexual men.  Another 
study with a national probability sample found that compared to primary relationships, 
occasional and one-time sexual encounters were more likely to involve sex without 
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disclosure (Duru et al., 2006).  A more recent study had similar findings where unprotected 
sex with serodiscordant partners was more likely among those with casual partners than main 
partners.  However, this study only included MSM (Schwarcz et al., 2007).    
 Perceived partner serostatus also appears to influence the relationship between 
disclosure and safer sex behavior.  In the main effects model, those who disclosed to 
unknown serostatus partners were less likely to engage in TRB than those who withheld 
disclosure.  This finding is consistent with the literature which shows that unprotected sex 
without disclosure with serodiscordant partners is more likely to involve “mutual non-
disclosure” where the partner was of unknown serostatus (Ciccarone et al., 2003; Duru et al., 
2006).   
 When examining relationship type and partner serostatus type as moderators of the 
relationship between serostatus disclosure and transmission risk behavior, none of the 
interaction effects met criteria for significance and they were therefore dropped from the 
final models.  The main reason why I may not have found evidence of moderation in this 
study is that I may not have had adequate power to detect differences due to unequal sample 
sizes across groups as the majority of participants disclosed and engaged in safer sex.  
Finding no evidence of moderation highlights the need to address disclosure and TRB for all 
sub-groups of PLWHA, regardless of partner serostatus or relationship type.  
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6.2 LIMITATIONS AND STRENGTHS 
The research findings reported here, building on previous studies of serostatus 
disclosure and transmission risk behavior among PLWHA, sought to understand why some 
HIV-positive individuals disclose and practice safer sex behaviors or both while others fail to 
carry out these behaviors.  The findings discussed above may help identify key behavior 
change targets for future public health efforts in the area of Prevention with Positives. The 
study has both strengths and limitations, discussed below. 
The sample for this study was unique in that it included individuals from several 
counties across the state of North Carolina, who ranged in age from 18-70 years, were 
racially diverse, and fell into three different risk groups.  The heterogeneous nature of the 
study sample with regard to race, gender, and mode of HIV acquisition represents a greater 
reflection of the changing epidemiology of HIV in the United States compared with previous 
studies that have more homogenous populations.  In addition, the majority of studies on 
serostatus disclosure and transmission risk behaviors have been conducted in large urban 
areas, particularly in New York, San Francisco, and Los Angeles.  This study is unique in 
that it is was conducted in the South, a region of the country that is experiencing a significant 
growth in HIV/AIDS cases that is likely to continue in the near future.   
Another strength of this study is that the sample includes women, thus allowing us to 
examine variables associated with serostatus disclosure and transmission risk behaviors 
among this sub-population.  In general, HIV-positive women in the United States have been 
an understudied group, especially in disclosure and safer sex behavior research.   Another 
strength is the measure used to assess serostatus disclosure to partners.  By asking the 
participant if a partner “knew you were positive because you told him/her that you were 
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positive” I was able to determine active disclosure rather than a passive or implied 
disclosure, such as leaving a pill bottle in clear view.  Similarly, using a three-category 
variable to assess disclosure improves upon dichotomous measures frequently used in 
previous studies, where non-disclosure to one partner is categorized the same as those who 
report nondisclosure to all partners. 
All data were self-reported using baseline ACASI data from the parent study 
(SAFETALK).  As such, it is possible that some HIV-positive persons were reluctant to share 
information about withholding disclosure or unprotected sexual behavior and provided 
socially desirable responses to ACASI items regarding disclosure and sexual beavior.  
However, several studies have demonstrated that ACASI methods produce a more accurate 
reporting of self-reported sensitive behaviors compared to other data collection method (Des 
Jarlais et al., 1999; Hewett, Mensch, & Erulkar, 2004; Morrison-Beedy, Carey, & Tu, 2006; 
Newman et al., 2002).   
The cross-sectional nature of the study allows for the identification of possible 
associations between independent variables of interest and outcome variables (serostatus 
disclosure in Aim 1 and transmission risk behavior in Aim 2.)  However, it limits our ability 
to draw conclusions regarding causality.  The directionality of the relationships between 
variables is unclear.  For example, it is not possible to determine whether previous negative 
experiences with disclosure to a sexual partner lead to stigma or if past experiences of stigma 
decrease the likelihood of disclosure.  In addition, because those participants who were not 
sexually active are not included in the study sample, I am unable to determine if my 
independent variables in my conceptual model contributed to sexual abstinence.  Future 
studies could examine serostatus disclosure to partners as more of a process, whereby data 
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are collected longitudinally to collect partner-by-partner information not only on serostatus 
disclosure but also on sexual transmission risk behavior.   
All study participants were individuals who were diagnosed with HIV and were 
patients at an HIV clinic receiving clinical care by infectious disease providers.  Therefore, 
the findings cannot be generalized beyond this group to either HIV-positive individuals not 
receiving medical care or HIV-positive individuals who are unaware of their status.  Patterns 
of disclosure and sexual transmission risk behavior may be different among those who are 
not receiving medical care for their HIV and those represented in the SAFETALK study.    
As all study participants were from North Carolina, generalizations outside of the region 
cannot be made.  The ACASI instrument did not assess the timing of disclosure relative to 
the timing of sexual activity.  It is possible that some people had unprotected sex before or 
after disclosure occurred.   
For Aim 1, I chose to create a three-category outcome variable for serostatus 
disclosure and grouped individuals by whether they disclosed to all, some, or none of their 
partners.  Many previous studies only looked at disclosure with the last sexual encounter 
which only allows for a dichotomous outcome of disclosure.  This strategy has the 
disadvantage of only examining disclosure to the most recent partner and fails to capture data 
for those who report more than one sexual partner.  By including participants who reported 
between 1-10 partners in the previous three months in my study, I was able to provide a more 
thorough picture of serostatus disclosure based on the number of sexual partners as not all 
participants had only one partner.  However, a disadvantage of my chosen approach was that 
those who reported only one partner can only be categorized as disclosing to “all” or “none” 
of their partners and cannot fall into the “some” category.  In addition, individuals with more 
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than partner who were categorized in the “some” category disclosed to more than one but 
less than all of their partners, which captures a large range of partner disclosure.  As such, the 
results of the final multinomial logistic regression model must take this into consideration.   
For Aim 2, there was limited power to detect differences between those who engaged 
in TRB and those who did not across disclosers and non-disclosers given the high levels of 
safer sex behavior in the sample.  I also had an insufficient sample size to fully explore the 
moderating effects of partner serostatus and relationship type on serostatus disclosure as 
predictors of TRB with adequate statistical power.  This issue was partially due to the fact 
that Aim 2 only included participants who reported one partner.  By excluding those with 
greater than one partner for Aim 2, the sample may have lacked variability in the proposed 
moderators, specifically partner relationship type and partner serostatus.  
 
 
6.3 IMPLICATIONS OF RESEARCH 
 Findings of this research have multiple methodological, theoretical and practice 
implications.  The findings for Aim 1 are consistent with Serovich’s consequence theory of 
serostatus disclosure.  Serovich argues that better research into understanding disclosure 
patterns specifically to sexual partners is needed because they are a unique sub-group of 
individuals who are disclosed to, different from family members, friends, or health care 
providers.  Serovich states that feeling of an obligation or duty to inform may be more 
predictive of disclosure to sexual partners that to other subgroups.  Many public health 
officials argue that disclosure is a necessity with all sexual partners in all cases, (Marks & 
Crepaz, 2001) particularly since 23 states have laws that make it a criminal offense for HIV-
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positive persons to engage in various types of sexual activity without disclosure to 
prospective sexual partners (Galletly & Pinkerton, 2006).   Perhaps part of the explanation 
for the high disclosure figures found in this study can be linked to the idea that PLWHA feel 
not only the moral responsibility to disclose to a sexual partner out of concern for a partner 
and his/her health, but also the legal obligation to disclose one’s status.  
 The influence of stigma on disclosure decisions is critical for prevention interventions 
that aim to enhance serostatus disclosure to sexual partners.  While withholding disclosure to 
sexual partners is a product of multiple factors, the decision likely involves a cognitive 
appraisal of the potential positive and negative consequences based on perceived social 
attitudes towards PLWHA.  Future interventions might examine how people gauge 
discrimination to decide on the safety of disclosure as well as provide a supportive 
environment for discussing the ways in which stigma affects disclosure decisions.  Findings 
presented here also suggest that HIV education among the general public must continue to 
decrease the discrimination, prejudice, and stigma experienced by PLWHA. 
Despite an abundance of literature on the topic, there remains much to be learned not 
only regarding factors that affect disclosure but also the patterns of disclosure and risk 
behavior among PLWHA.   The findings of this study regarding these patterns enrich the 
literature on this relationship.  The particular nature of the relationship between serostatus 
disclosure and TRB is not clear, partially because of inconsistency of results found in the 
literature.  As discussed in Chapter Two, considerable debate has centered on whether 
disclosure increases or decreases the occurrence of unsafe or safe sex with an at-risk partner. 
Varied findings from the aforementioned studies suggest that future researchers should not 
assume that disclosure will lead to safer sex behaviors.  As evidenced in results presented 
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here, an individual’s disclosing of his/her status to a sexual partner does not ensure that the 
couple abstain from any unsafe sexual practices.  Disclosure does not necessarily indicate 
that sexual partners will use this information to protect themselves from infection (Serovich 
& Mosack, 2003).  Research supports this notion as several studies have found no association 
between disclosure and transmission risk behaviors (Hart, 2005; Kalichman, 2002; Marks, 
2001; Stein, 1998; Wolitski, 1998).  Conversely, as found here, it should not be assumed that 
nondisclosure will automatically lead to unprotected sexual activity as some individuals may 
feel that safer sex obviates the need for disclosure.  For example, HIV-positive individuals 
may consciously choose not to disclose as a way to protect their privacy and escape the 
possible negative consequences of disclosure, such as stigma.  Yet, these individuals will 
engage in protected sexual activity despite nondisclosure, perhaps as a result of personal 
responsibility to protect their partner (Kalichman, 2005).  However, practicing safer sex 
without disclosure is not an ideal behavior, as safer sex may not be practiced on a consistent 
basis with these partners.  
There are methodological limitations in many of the studies of serostatus disclosure 
including the study described here.  For example, failure to assess the specific timing of 
disclosure in relation to sexual activity and lack of assessment of partnership-specific 
characteristics regarding disclosure and sexual activity prohibit the ability to make definitive 
interpretations about the relationship between serostatus disclosure and safer sex.  In 
addition, the lack of a strong correlation in many studies between disclosure and safer sex 
may be due to the high frequency of uninformed protection (safer sex without disclosure) and 
informed exposure (unsafe sex with disclosure) likely to exist for many PLWHA.  However, 
this was not the case in this study as the majority of the sample disclosed and engaged in 
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safer sex with at-risk partners.  In terms of uninformed exposure (unsafe sex without 
disclosure), instances of this behavior were relatively small in this study.  However, even a 
small number of such cases can contribute to new cases of HIV infection (Marks & Crepaz, 
2001; Simoni & Pantalone, 2005). 
 
6.4 CONCLUSIONS AND AREAS FOR FUTURE RESEARCH 
Future research should include a larger sample from a broader geographic area to 
provide more insight into the correlates of serostatus disclosure to partners and transmission 
risk behaviors.  Clarifying the relationship between serostatus disclosure and transmission 
risk behavior remains a critical public health priority as researchers need to better understand 
the strategies people employ to decide whether or not to disclose and how the dyad 
ultimately decides to engage in protected or unprotected sexual activity.  Future research may 
consider examining stigma and substance abuse as moderators of the relationship between 
serostatus disclosure and transmission risk behavior.  Perhaps alcohol and other substance 
use alter the decision-making process to disclose and engage in protected sex with an at-risk 
partner.  A key issue involves the potential shift of responsibility from HIV-positive partner 
to at-risk partner after disclosure to determine the level of risk one is comfortable taking.    
As a whole, the results presented here raise vital questions regarding the 
encouragement of disclosure to partners as a larger part of Prevention with Positives 
programming.  I argue that programs should stress the need to protect the health of all 
partners who may be serodiscordant (including unknown status partners) regardless of 
disclosure.  Future studies need to examine the dyadic relationship both quantitatively and 
qualitatively and include at-risk persons in the study sample.  Qualitative research could help 
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to answer the unanswered questions left in this study, such as the situations that determine 
whether disclosure and sexual risk behavior occur or not and why.  In addition to individual-
level and intrapersonal-level determinants, future research must examine contextual factors 
that affect transmission risk behaviors among PLWHA (Aidala et al., 2006).   
Although actual measurement of disclosure can vary from study to study, the majority 
of research identifies disclosure dichotomously with a simple yes/no question.  However, this 
style of measurement does not capture the timing of disclosure in relation to sexual activity 
with a particular partner (Niccolai et al., 2006).  Future research should elucidate the timing 
of disclosure relative to risk behavior by determining if disclosure occurred before or after 
having had sexual activity with a partner as standard measures of disclosure found in the 
literature do not capture this timing element.  It is important to recall that disclosure is 
inherently an activity within the context of a social relationship between two individuals 
(Rice et al., 2009).  That said, disclosure is also undeniably complicated by fears of 
discrimination, rejection, and violence (Gaskins, 2006; Sowell, 2003; Simbayi, 2007).   This 
reality cannot be ignored and stigma associated with disclosure concerns needs to continue to 
be studied across various sub-groups of PLWHA.   
While the majority of the sample did not engage in transmission risk behaviors, the 
fact that unprotected sex with at-risk partners was found provides a rationale for continuing 
Prevention with Positives programs in HIV clinical care settings.  Establishing and 
maintaining ongoing relationships between health care providers and HIV-positive patients 
about their experiences with disclosure and risk behavior has the potential to make 
Prevention with Positives a meaningful and necessary component of HIV care in the clinical 
setting.  
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APPENDIX 1:  
 
SAFETALK BASELINE ACASI SURVEY 
 
 
SAFETALK SURVEY 
REVISED Patient Assessment (English) 
The date is recorded as [DATE] and the time is recorded as [STTIME].  If these are incorrect, please exit and correct system 
clock. 
BAQ1. Patient ID Number: __ __ __ __ __ 
BAQ2. Site ID: __ __ 
If Q2 is not equal to PAID2 then Site ID does not correspond with first two digits of Patient ID.  Please correct."  skip to BAQ1. 
 BAQ3.  Visit Number:  __ 
BAQ4.  RA Initials:  __ 
The ID is recorded as [Response to BAQ1].  Site is recorded as [Response to BAQ2] and visit is recorded as [Response to 
BAQ3].  If these are incorrect, please go back and correct. 
 
HISTORY QS.  
Ever on ART  
BAQ5.  Have you ever taken HIV medications to treat your HIV-infection? 
1 Yes 
0 No 
7 Don’t Know 
8 Refuse to Answer 
 
If BAQ5 is equal to 0, then skip to BS1Q1. 
 
Currently on ART 
BAQ6.  Are you currently taking HIV medications to treat your HIV-infection? 
1 Yes 
0 No 
7 Don’t Know 
8 Refuse to Answer 
If BAQ6 is equal to zero, skip to BS1Q1. 
                                                                            
 
[INTER: Enter HIV medicines into column headings on next page using Card A and prior interview.    
[INTER: Proceed to BAQ7 on GRID on next page] 
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Thank you for agreeing to participate in our study today.  The purpose of this study is to help us 
develop programs for people living with HIV to help them stay healthy. The information we gather 
will help us learn how different health programs affect what people living with HIV think and 
believe about their health.   
This survey contains questions about sensitive topics such as drug and alcohol use, and sexual 
behavior.  Everything you say will be kept private and confidential. We do not share your 
individual answers with any doctors or nurses in the clinic.  We will combine what you tell us with 
everyone else’s answers to the same questions and remove all names for reports.  
Because many men and women are participating, some questions in this interview may not apply 
to you; however, we have to ask the same questions of all participants.  All the information you 
can provide is important and will be helpful, but we don’t want you to feel uncomfortable.  Feel 
free to skip any questions that you do not feel comfortable answering, or when the question 
doesn’t apply to you, if that’s the case.  When you answer, please answer as honestly as 
possible.  There are no right or wrong answers.   We want to get a true picture of what you and 
everyone else who answers these questions thinks or feels.  We appreciate your helping us 
today, as well as your important contribution to HIV prevention research.  This interview will take 
about 45-50 minutes to complete.  Do you have any questions for me before we get started? 
 
[Tutorial here—optional] 
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1.  HIV History and Current Medical Status 
 We will start by asking you some questions about your health and medical care. 
 
GLOBAL HEALTH 
BS1Q1.  In general, would you say your health is: (Select one)  
1 Poor 
2 Fair 
3 Good 
4 Very Good 
5 Excellent 
8 Refuse to Answer  
  
CLINICAL QUESTIONS.   
BS1Q2.  We are doing this study with people who are living with HIV. It is helpful for us to know how long 
you have been personally dealing with HIV.  What month and year did you first learn that you were HIV-
positive? [The HIV antibody test was first given in 1985.]  
 __ __ / __ __ __ __ mm / yyyy 
BS1Q2a.  Have you had a viral load test in the past 6 months?  
1 Yes 
0 No->SKIP TO BS1Q3 
7 Don’t Know->SKIP TO BS1Q3 
8 Refuse to Answer->SKIP TO BS1Q3 
   
BS1Q2b.  At that time, were you undetectable?  
1 Yes 
0 No 
7 Don’t Know 
8 Refuse to Answer 
                                                             
BS1Q3.  Do you have an HIV case manager at this clinic or at any other location (someone who helps with 
getting medical and social support services)?  
1 Yes 
0 No 
7 Don’t Know 
8 Refuse to Answer 
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Patient/Provider Communication  
BS1Q4.  During your office visits, how much do you and your healthcare provider usually talk about HIV 
prevention issues like safer sex and drug use?  Would you say that you talk about HIV prevention issues: 
 
1 A lot 
2 Somewhat 
3 A little 
4 You do not really talk about them at all 
8 Refuse to Answer  
 
 
II. Beliefs/Attitudes toward Safer Sex and Nutrition 
Now, we will ask some questions about what YOU believe about your health.  Some of the 
questions are about eating habits and some are about safer sex.  Each of the following questions 
is asking about your habits in the last month (30 days).  For each one, pick the response that 
matches best for you.  
 
BS2Q1.  In the last month (30 days), about how many servings of fresh fruits or vegetables did you eat 
each day? 
1 5 or more servings 
2 3-4 servings 
                                                                                          3              2 or less servings  
 
BS2Q2.  In the last month (30 days), how many non-diet sodas or glasses of sweetened tea did you drink 
each day? 
1 3 or more a day 
2 1-2 a day 
3 Less than 1 a day 
 
BS2Q3.  In the last month (30 days), how much margarine, butter, or meat fat did you use to season 
vegetables or put on potatoes, bread, corn or other foods each day? 
1 A fair amount  
2 Some 
3 Very little 
 
BS2Q4.  In the last month (30 days), how many times a week did you eat fast food? 
1 4 or more times a week 
2 1-3 times a week 
3 Less than once a week 
 
BS2Q5.  In the last month (30 days) how many times a week did you eat chicken, or fish, or beans (like 
pinto or black beans)?   
1 3 or more times a week 
2 1-2 times a week 
3 Less than once a week 
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BS2Q6.  In the last month (30 days), how many times a week did you eat snack chips or crackers (not the 
low-fat)? 
1 4 or more times a week 
2 1-3 times a week 
3 Less than once a week 
 
BS2Q7.  In the last month (30 days), how many times a week did you eat desserts OR other sweets? 
1 4 or more times a week 
2 1-3 times a week 
3 Less than once a week 
 
Now, the next question is about what you believe your chances are of getting or giving a sexually 
transmitted disease or STD.   
 
Likelihood of infecting others 
STEP (Thomas/Earp)   
BS2Q8.  If you had sex with someone just one time, it would be pretty hard to catch a STD from that 
person.  Do you: 
1 Agree A Lot 
2 Agree A Little 
3 Disagree A Little 
4 Disagree A Lot 
 
The next questions are about the chances of passing HIV to others.  The first few questions are 
about the possibility of giving HIV to someone who is HIV negative.  After that, we’ll ask you 
about transmitting to people who are HIV positive.   After hearing each statement, pick the 
answer that best matches what you believe. 
 
Seriousness of transmission risk 
Elford (revised)          
BS2Q9.  New HIV medications make giving someone HIV:   
1 Much less serious than it used to be 
2 A little less serious than it used to be 
3 About as serious as it used to be 
4 A little more serious than it used to be  
5 Much more serious than it used to be 
      7 Don’t Know 
8 Refused to Answer 
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Belief about condom efficacy  
(spns) 
 
BS2Q10.  Using condoms correctly is:  
1 A completely effective way to keep you from giving 
HIV to someone else 
2 A very effective way to keep you from giving HIV to 
someone else 
3 A somewhat effective way to keep you from giving 
HIV to someone else 
4 Not a very effective way to keep you from giving HIV 
to someone else 
5 Not at all an effective way to keep you from giving 
HIV to someone else 
 
7 Don’t Know 
8 Refused to Answer 
 
Worry 
BS2Q11.  How worried are you that you gave HIV to someone else in the last six months?  Would you say 
that you are:                                                   
 
 1 Very worried that you gave HIV to someone else 
 2 Somewhat worried that you gave HIV to someone 
else 
 3 A little bit worried that you gave HIV to someone 
else 
 4 Not worried at all that you gave HIV to someone else 
 
 7 Don’t Know 
 8 Refuse to Answer 
 
 
TRANSMISSION RISK—Perceived Risk with Different Viral Loads 
Kalichman “In the Mix”  
The next three questions ask you about your likelihood of giving HIV to someone.  (Have 
narrator’s inflection change when saying the level of viral load) 
 
BS2Q12.  Imagine you had unprotected sex one time today with an HIV negative partner.  What’s the 
chance that you would give HIV to that partner given your current viral load? 
1 High 
2 Medium 
3 Low 
      4 No chance 
7 Don’t Know 
8 Refused to Answer 
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BS2Q13.  Now imagine that your viral load is undetectable.   Now, what’s the chance you would give HIV to 
a HIV negative partner if you had unprotected sex one time today? 
1 High 
2 Medium 
3 Low 
      4 No chance 
7 Don’t Know 
8 Refused to Answer 
         
BS2Q14.  Now imagine the other extreme.  Imagine your viral load is high (over 100,000).  What’s the 
chance you would give HIV to a HIV negative partner if you had unprotected sex one time today? 
1 High 
2 Medium 
3 Low 
      4 No chance 
7 Don’t Know 
8 Refused to Answer 
 
Transmission Risk—Perceived Risk of reinfection  
(Colfax, 2004) 
 
Now let’s talk about reinfection.  Reinfection is when a person who has one strain of HIV 
becomes infected with a different strain of the virus.  Some people call this superinfection. 
BS2Q15.  Have you ever heard of HIV reinfection or superinfection? 
1 Yes 
0 No 
8 Refused to Answer 
 
For the next two questions, give the answer that comes closest to how you feel.  What we’d like 
is your first reaction, your “gut reaction.” 
 
BS2Q16.  Given your current sexual behaviors, how likely do you think you are to be reinfected with 
another strain of HIV in the next year? 
 
1 Very likely 
2 Somewhat likely 
3 A little likely 
4 Not at all likely 
 
7 Don’t Know 
8 Refused to Answer 
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BS2Q17.  Getting reinfected with HIV could really harm my health.  Do you? 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
8 Refused to Answer 
 
 
ATTITUDES TOWARD CONDOMS 
STEP (THOMAS/EARP)  
Now I am going to read you some things people think about sex and sexually transmitted 
diseases (STDs).  For each one, tell me whether you agree or disagree with it by clicking on the 
answer that best fits with what you believe.   
 
BS2Q18.  Just about any kind of sex feels better when you don’t use a condom.  Do you: 
1 Agree A Lot 
2 Agree A Little 
3 Disagree A Little 
4 Disagree A Lot 
8 Refuse to Answer 
 
BS2Q19.  Having to stop sex to put on a condom takes the fun out of it.  Do you: 
1 Agree A Lot 
2 Agree A Little 
3 Disagree A Little 
4 Disagree A Lot 
8 Refuse to Answer 
 
BS2Q20.  Using a condom during sex is like telling others that you might have an STD or HIV. Do you: 
1 Agree A Lot 
2 Agree A Little 
3 Disagree A Little 
4 Disagree A Lot 
8 Refuse to Answer 
 
Golin (de novo)         
BS2Q21.  Using a condom during sex feels uncomfortable.  Do you: 
1 Agree A Lot 
2 Agree A Little 
3 Disagree A Little 
4 Disagree A Lot 
      8 Refuse to Answer 
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Golin (de novo)  
BS2Q22.  Using a condom during sex is embarrassing.  Do you: 
1 Agree A Lot 
2 Agree A Little 
3 Disagree A Little 
4 Disagree A Lot 
      8 Refuse to Answer 
Satisfaction with Sex Life 
BS2Q23.  Think about your sex life.  In the past 6 months, would you say you have been: 
1 Very satisfied with your sex life 
2 Somewhat satisfied with your sex life 
3 Not very satisfied with your sex life 
4 Not satisfied at all with your sex life 
7 Don’t Know 
8 Refused to Answer 
9 Not Applicable  
  
    
III. MOTIVATION and INTENTIONS TO AVOID UNSAFE SEX 
Roffman’s “The Sex Check” study (modified) 
 
The next questions are about how you feel about having sex in the next 3 months with a main 
partner.  By sex, we mean anal (in the butt) or vaginal sex.  A main partner would be someone 
you have lived with or seen a lot, and to whom you have felt a special emotional commitment.  
 
BS3Q1.  In the next three months, how motivated or unmotivated do you feel about having safer sex.  Do 
you feel: 
1 Not at all motivated  
2 Somewhat motivated  
3 Very motivated  
4 Totally motivated  
8 Refused to Answer 
9              Not Applicable  
 
Golin (de novo adapted from PACT adherence motivation question) 
BS3Q2.  In the next three months, how important or unimportant will it be to you to use a condom every 
single time you have sex?  Would you say that for you it is:  
1 Not at all important to use a condom every single 
time 
2 Somewhat important to use a condom every single 
time 
3 Very important to use a condom every single time 
4 Extremely important to use a condom every single 
time  
8 Refused to Answer 
9              Not Applicable  
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BS3Q3.  In the next three months, how important or unimportant is it to you to tell any new partner that you 
have HIV?  Would you say it is:  
1 Not at all important 
2 Somewhat important 
3 Very important 
4 Extremely important  
8 Refused to Answer  
9              Not Applicable  
 
 
The next questions are about how you feel about having sex in the next 3 months with a casual 
partner.  (by sex, we mean anal or vaginal sex)   A “casual partner” would be anyone you don’t 
consider a main partner? 
 
BS3Q4.  In the next three months, how motivated or unmotivated do you feel about having safer sex with a 
casual partner.  Do you feel: 
1 Not at all motivated  
2 Somewhat motivated  
3 Very motivated  
4 Totally motivated  
      8 Refused to Answer 
9              Not Applicable  
 
Golin (de novo adapted from PACT adherence motivation question) 
BS3Q5.  In the next three months, how important or unimportant will it be to you to use a condom every 
single time you have sex?  Would you say that for you it is:  
1 Not at all important to use a condom every single 
time 
2 Somewhat important to use a condom every single 
time 
3 Very important to use a condom every single time 
4 Extremely important to use a condom every single 
time  
      8 Refused to Answer 
9              Not Applicable  
 
BS3Q6.  In the next three months, how important or unimportant is it to you to tell any new partner that you 
have HIV?  Would you say it is:  
1 Not at all important 
2 Somewhat important 
3 Very important 
4 Extremely important  
      8 Refused to Answer 
9              Not Applicable  
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Roger Roffman’s Intentions Scale (“The Sex Check” Study) 
 
We know that many people do not practice safer sex every time they have sex. (Pause) 
For the next few questions, please think about what you would be likely to do and who you would 
be likely to have sex with. 
 
If you were going to have sex in the next 3 months, how likely or unlikely is it that every time you 
have sex, you… 
 
BS3Q7.  will keep condoms nearby? 
1 Very unlikely 
2 Somewhat unlikely 
3 Somewhat likely 
4 Very likely 
8 Refused to Answer 
 
BS3Q8.   will be sure you know your partner’s HIV status, (meaning knowing whether your partner is HIV 
positive or negative) before having sex with him or her?   
1 Very unlikely 
2 Somewhat unlikely 
3 Somewhat likely 
4 Very likely 
8 Refused to Answer 
 
BS3Q9.  will tell your partner that you need to use a condom? 
1 Very unlikely 
2 Somewhat unlikely 
3 Somewhat likely 
4 Very likely 
8 Refused to Answer 
 
Think about what you would be likely to do and who you would be likely to have sex with. 
 
If you were going to have sex in the next 3 months, how likely or unlikely is it that every time you 
have sex, you… 
 
BS3Q10.  will actually use a condom? 
1 Very unlikely 
2 Somewhat unlikely 
3 Somewhat likely 
4 Very likely 
8 Refused to Answer 
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BS3Q11.  will discuss safer sex with your partner? 
1 Very unlikely 
2 Somewhat unlikely 
3 Somewhat likely 
4 Very likely 
8 Refused to Answer 
 
Think about what you would be likely to do and who you would be likely to have sex with. 
 
If you were going to have sex in the next 3 months, how likely or unlikely is it that every time you 
have sex, you… 
 
BS3Q12.  will use alcohol before sex? 
1 Very unlikely 
2 Somewhat unlikely 
3 Somewhat likely 
4 Very likely 
8 Refused to Answer 
 
BS3Q13. will use drugs before sex? 
1 Very unlikely 
2 Somewhat unlikely 
3 Somewhat likely 
4 Very likely 
8 Refused to Answer 
 
BS3Q14. will use a condom even if your partner does NOT want to? 
1 Very unlikely 
2 Somewhat unlikely 
3 Somewhat likely 
4 Very likely 
8 Refused to Answer 
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IV. Stress and Coping 
A. Stressful Life Events 
The following questions ask you about important things that may have happened to you in the 
past. 
 
BS4Q1.  Have you ever been molested, sexually attacked, raped, sexually abused, or forced to have sex? 
1 Yes 
0 No 
8 Refused to Answer 
 
BS4Q1a.  [If yes to BS4Q1] 
What age were you when you were first molested, sexually attacked, raped, sexually abused, or 
forced to have sex? (select one) 
1 age 12 years or younger 
2 13-18 years old 
3 Over 18 years old 
8 Refused to Answer 
 
  
BS4Q2.  Have you ever been a victim of a violent crime (like assault or physical abuse) other than sexual 
abuse? 
1 Yes 
0 No 
8 Refused to Answer 
 
BS4Q3.  Have you ever traded sex for money, drugs, food or shelter? 
1 Yes 
0 No 
8 Refused to Answer 
 
BS4Q4.  Have you ever been in prison or in jail?    
1 Yes 
0 No 
8 Refused to Answer 
 
 
B. SETH KALICHMAN-REVISED ACASI FOR STRESSORS 
People react to stress in many different ways. In a minute, I will read you a list of possible 
stressful events.  Thinking about your life, tell me how much stress each of these events has 
caused YOU in the past 6 months.  For each event I read to you, if you have not experienced it at 
all in the last 6 months, please check “did not happen in the last six months”.  Otherwise, please 
check the box that shows how much stress this event has caused you in the last 6 months. 
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BS4Q5.  Started disability 
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months  
    
BS4Q6.  Experienced the serious illness or the death of a close friend or family member  
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
  
BS4Q7.  Experienced discrimination of some type 
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
  
BS4Q8.  Found out you had a change in your viral load 
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
  
BS4Q9.  Found out you had a change in your T cell or CD4 count 
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
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BS4Q10.  Started a new medication 
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
  
BS4Q11.  Got a serious illness 
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
  
BS4Q12.  Was hospitalized  
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
    
BS4Q13.  Fired or laid off from a job 
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
  
BS4Q14.  Put in prison or jail  
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9                  Did not happen in last 6 months 
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BS4Q15.  Told your HIV status to someone new 
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
  
BS4Q16.  An important relationship ended with a separation, divorce, or break-up  
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
 
BS4Q17.  A close friend, or family member or sex partner told you they had HIV  
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9                  Did not happen in last 6 months                           
BS4Q18.  Knowing you infected another person with HIV 
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
  
 
BS4Q19.  Evicted or asked to leave your housing  
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
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BSQ420.  Had problems with your health insurance 
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
 
BS4Q21.  Experienced violence or abuse, either physical or sexual           
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
 
BS4Q22.  Traded sex for money, drugs, food or shelter  
0 No stress 
1 A little stress 
2 Some stress 
3 A lot of stress 
8 Refused to Answer 
9 Did not happen in last 6 months 
 
BS4Q23.  Are there any other events that I didn’t list that caused you stress in the last 6 months? 
1 Yes 
0 No 
7 Don’t Know 
8 Refused to Answer 
 
If BS4Q23 is equal to 0, then skip to BS4Q25. 
BS4Q24.  What were they?  Please type in your answer(s). 
 __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ 
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KALICHMAN-REVISED ACASI FOR STRESSORS (BASED ON PICKING TOP STRESSOR) 
 
BS4Q25.  The stressors from the previous screen that you said caused you the most stress are listed 
below.  Please indicate which ONE STRESSOR caused you the GREATEST amount of stress in the last 6 
months.  (Choose one) 
JG: program ACASI so only those that got the highest rating by them on the previous screens actually get 
listed here on this screen 
1  I went on disability 
2 I experienced a serious illness or the death of a 
close friend or family member 
3 I experienced discrimination of some type 
4 I experienced a change in my viral load 
5 I experienced a change in my T cell or CD4 count 
6 I started a new medication 
7 I got a serious illness 
8 I was hospitalized 
9 My appearance changed 
10 I was fired or laid off from a job 
11 I was put in prison or jail       
12 I told my HIV status to someone new 
14 An important relationship ended with a separation, 
divorce, or break-up  
15 A close friend, family member, or sex partners told 
me they had HIV 
16 I infected another person with HIV  
17 I was evicted or asked to leave my housing  
18 I had problems with my health insurance  
19 I experienced violence or abuse, physical or sexual 
20 I traded sex for money, drugs, food or shelter    
21 If they checked other above and typed it in, then 
shouldn’t it be programmed to automatically show that 
22 Other: 
____________________________________________  then 
this one, 22 would be if they at this point, decide there is 
something else that is more stressful.  Although do we really 
need to give them this option twice??? 
98 Refused to Answer 
 
If BS4Q25 is equal to 1, then skip to instruction before BS4Q26 (had to change all the numbering here). 
If BS4Q25 is equal to 2, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 3, then skip to instruction before BS4Q26. 
If  BS4Q25 is equal to 4, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 5, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 6, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 7, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 8, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 9, then skip to instruction before BS4Q26. 
 152 
If BS4Q25 is equal to 10, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 11, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 12, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 13, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 14, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 15, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 16, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 17, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 18, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 19, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 20, then skip to instruction before BS4Q26. 
If BS4Q25 is equal to 21, then skip to instruction before BS4Q26. 
 
BS4Q25a.  Please type in what other stressor you found to be the MOST stressful. 
__ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __   __ __ __ __ __ __ __ __ __ __ _ __  
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Coping: Combination of Kalichman and Folkman’s short version of Ways of Coping 
People tend to deal with stress in different ways.  Please think about [Response to BS4Q25], the situation 
that you indicated on the previous screen that was the most stressful for you.  Please check how much you 
used each of the following ways to help you deal with [Response to BS4Q25a]. 
 
BS4Q26.   I tried to keep my feelings to myself.  
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
 
BS4Q27.  I talked to someone to find out more information. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
   
BS4Q28.  I knew what had to be done, and I worked harder at it. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
   
BS4Q29.  I prayed.  
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
                                                                                                8              Refused to Answer  
 
Please check how much you used each of the following ways to help you deal with [Response to 
BS4Q25]. 
 
BS4Q30.  I went on as if nothing had happened. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
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BS4Q31.  I made a plan of action and followed it. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
 
BS4Q32.  I asked a friend or relative for advice. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
   
BS4Q33.  I tried to forget the whole thing. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
 
Please check how much you used each of the following ways to help you deal with [Response to 
BS4Q25a]. 
 
BS4Q34.  I tried to make myself feel better by sleeping, or eating, or drinking, or smoking, or using drugs, 
etc. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
   
BS4Q35.  I concentrated on what I had to do next. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
  
BS4Q36.  I talked to someone about how I was feeling. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
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BS4Q37.  I criticized or lectured myself. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
 
Please check how much you used each of the following ways to help you deal with [Response to 
BS4Q25a]. 
 
BS4Q38.  I let my feelings out somehow.  
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
 
BS4Q39.  I found new faith. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
   
BS4Q40.  I rediscovered what is important in life. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
  
BS4Q41.  I avoided being with people in general. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
 
Please check how much you used each of the following ways to help you deal with [Response to 
BS4Q25a]. 
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BS4Q42.  I kept others from knowing how bad things were. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
   
BS4Q43.  I made a promise to myself that things would be different next time. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
  
BS4Q44.  I wished that the situation would go away or somehow be over with. 
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
                                                                                 8              Refused to Answer  
 
BS4Q45.  I stood my ground and fought for what I wanted.  
1 Not used at all 
2 Used a little 
3 Used some of the time 
4 Used a lot 
8 Refused to Answer 
 
 
V. Stigma 
Berger et al, 2001 
Next are some things people living with HIV may have experienced in the past or may be 
experiencing right now.  We realize the next few questions may make you feel uncomfortable. 
(PAUSE)  For each one you see on the screen, please pick how much you agree or disagree 
with it by clicking on the answer that best fits you. 
 
BS5Q1.  In some areas of my life, no one knows that I have HIV. 
 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
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BS5Q2.  Telling someone I have HIV is risky. 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
 
 
BS5Q3.  I work hard to keep my HIV a secret. 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
 
 
BS5Q4.  People I care about stopped calling after finding out I had HIV. 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
 
BS5Q5.  I am very careful who I tell that I have HIV. 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
 
 
BS5Q6.  Some people I know have become more distant from me after finding out I have HIV. 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
 
BS5Q7.  I feel the need to hide the fact that I have HIV. 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
 158 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
 
 
BS5Q8.  I have been hurt by how people reacted after finding out I have HIV. 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
 
BS5Q9.  I worry that people who know I have HIV will tell others. 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
 
BS5Q10.  Some people avoid touching me after they find out I have HIV. 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
 
 
BS5Q11.  People physically backed away from me when they found out I had HIV. 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
 
 
BS5Q12. I have stopped socializing with some people because of their reactions to my having HIV. 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
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BS5Q13.  I lost friends by telling them I have HIV. 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
 
BS5Q14.  I have told people close to me to keep the fact that I have HIV a secret. 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
 
BS5Q15.  People seemed afraid of me once they found out I had HIV. 
1 Agree a lot 
2 Agree a little 
3 Disagree a little 
4 Disagree a lot 
7 Don’t Know 
8 Refused to Answer 
 
VI. Discrimination 
BS6Q1.  Thinking of your experiences with receiving health care in the past 12 months, have you ever felt 
you were discriminated against for any reason? 
1 Yes 
2 No->SKIP TO BS7Q1 
8 Refuse to Answer>SKIP TO BS7Q1 
9 Not Applicable>SKIP TO BS7Q1 
BS6Q2.  What do you think was the biggest reason that you were discriminated against? (Choose one) 
01 Age 
02 Race or ethnic group 
03 Language/accent 
04 HIV status   
05 Body weight 
06 Insurance type 
07 Income level 
08 Health or disability   
09 Religion 
10 Sexual orientation 
11 Gender/sex 
12 Some other reason (specify): ________________ 
97 Don’t Know 
98 Refuse to Answer 
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VII. Sexual Behavior Self Efficacy 
PARSONS ET. AL, 1998  
Here are some questions about your sexual activity.  When we say “partner”, we mean a 
boyfriend, girlfriend, spouse, or person who you have sexual activity with.  This can include 
kissing, petting, oral sex, and intercourse.  For the next questions, please tell me on a scale of 1 
to 10, how confident you feel that you could do each of the following today if you decided to do it 
with zero (00) being “not at all confident” and 10 being “completely confident”.   
 
BS7Q1.   How confident are you that you can talk with your partner(s) about sex? 
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
09 
10 Completely confident 
98 Refused to Answer 
 
BS7Q2.   How confident are you that you can use a condom correctly?   
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
09 
10 Completely confident 
98 Refused to Answer 
 
 
 
BS7Q3.   What if you DID want to have vaginal or anal sex but you didn’t have any condoms?  How 
confident are you that you could switch to other sexual activities instead?  
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
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06 
07 
08 
09 
10 Completely confident 
98 Refused to Answer 
 
BS7Q4.   How confident are you that you can convince your partner(s) to use condoms every single time 
you have sex?  
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
09 
10 Completely confident 
98 Refused to Answer 
    
BS7Q5.  How confident are you that you could say “No” to having sex with your partner? 
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
09 
10 Completely confident 
98 Refused to Answer 
 
BS7Q6.  If a partner tells you that they would not use condoms, how confident are you that you could 
refuse to have sex with them?  
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
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09 
10 Completely confident 
98 Refused to Answer 
 
BS7Q7.   How confident are you that you can talk about using condoms with EVERY future partner? 
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
09 
10 Completely confident 
98 Refused to Answer 
 
Now, please rate how confident you are that you can use condoms in each of the following 
situations today, if you decided to do it: 
 
BS7Q8.   How confident are you that you can use condoms if you are feeling depressed?    
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
09 
10 Completely confident 
98 Refused to Answer 
 
BS7Q9.  How confident are you that you can use condoms when you’ve been drinking or using drugs 
before sex?   
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
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09 
10 Completely confident 
98 Refused to Answer 
  
 
BS7Q10.  How confident are you that you can use condoms if condoms are NOT readily available and you 
(or your partner) have to go and get them?   
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
09 
10 Completely confident 
98 Refused to Answer 
 
BS7Q11.  How confident are you that you can use condoms if you are feeling good?   
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
09 
10 Completely confident 
98 Refused to Answer 
 
BS7Q12.  How confident are you that you can use condoms if you are in love with your partner?   
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
09 
10 Completely confident 
98 Refused to Answer 
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BS7Q13.  How confident are you that you can use condoms with a new partner?   
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
09 
10 Completely confident 
98 Refused to Answer 
  
BS7Q14.  How confident are you that you can use condoms if you won’t see this partner again?    
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
09 
10 Completely confident 
98 Refused to Answer 
 
BS7Q15.  How confident are you that you can use condoms with a partner who you have not used 
condoms with before?  
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
09 
10 Completely confident 
98 Refused to Answer 
.  
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BS7Q16.  How confident are you that you can use a condom when your partner doesn’t want to use a 
condom?                           
00 Not at all confident 
01 
02 
03 
04 
05 Somewhat confident 
06 
07 
08 
09 
10 Completely confident 
98 Refused to Answer 
 
 
VIII. Risky Sexual Behavior 
SEXUAL RISK ASSESSMENT FOR MEN- Sexual Behavior with Women 
GENDER 
BS8Q1. Are you:  (Select one)   
1 Male 
2 Female 
3 Transgender (Male to Female) 
4 Transgender (Female to Male) 
8 Refused to Answer 
 
If BS8Q1 is equal to 1, then skip to M1. 
If BS8Q1 is equal to 2, then skip to W1. 
If BS8Q1 is equal to 3, then continue to BS8Q2. 
If BS8Q1 is equal to 4, then skip to BS8Q2. 
 
BS8Q2. Do you have a penis? 
1 Yes 
0 No 
 
If BS8Q2 is equal to 1, then skip to M1. 
If BS8Q2 is equal to 0, then skip to W1. 
The next questions are about the sexual relationships you might have had in the last 3 months.  
Again, please remember that all your answers are strictly confidential.  Your answers are 
protected by law and cannot be shared with any outside organization or agency not involved with 
this study. 
The following questions ask about your sexual behavior with partners who are HIV-positive and 
HIV-negative, as well as partners whose HIV status you are not sure of.  Again, these questions 
are about the last 3 months. 
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M1. Have you had any female sex partners in the last 3 months? By female sex partners, we mean 
women with whom you had vaginal, anal or oral sex, with or without ejaculation. 
  1 Yes 
 0 No 
 8 Refuse to 
Answer 
If M1 is equal to 0, then skip to instruction before M15. 
M1a. How many female sexual partners have you had in the last 3 months? 
 __ __ __ 
 998 Refuse to 
Answer 
If M1a is greater than 1, then skip to instruction before M2. 
M1b. What was this partner's HIV status?  (Choose one) 0 Positive 
 1 Negative 
 88 Not Sure 
 998 Refuse to 
Answer 
M1c. Were you in a primary relationship with this sex partner?  By primary we mean 
someone you have lived with or seen a lot, and to whom you have felt a special 
emotional commitment.  
  1 Yes 
 0 No 
 8 Refuse to 
Answer 
M1d. Did this partner know that you were HIV-positive because you told her that you were 
positive?  (Choose one) 
 0 No 
 1 Yes 
 88 Not Sure 
 998 Refuse to 
Answer 
If M1b is equal to 0, then skip to instruction before M6. 
If M1b is equal to 1, then skip to instruction before M9. 
If M1b is equal to 88, then skip to instruction before M12. 
The next questions ask about the HIV-status of the sexual partners we asked about in the last 
question.  When we say HIV status, we mean whether you know, for certain, whether your 
partners are either HIV positive, HIV negative, or not sure.  First, we will ask you about your HIV-
positive sexual partner(s).  Then we will ask you about your HIV-negative sexual partner(s). 
Lastly, we will ask you about sex partner(s) whose HIV status you are not sure of.  For these next 
questions, please keep in mind that the number of HIV-positive sexual partners, HIV-negative 
sexual partners, and partners whose HIV status you are not sure of MUST EQUAL the total 
number of partners that you entered in the last question. If you want to, write your number of 
partners down on the sheet of scratch paper provided to help you answer the next questions. 
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M2. In the last three months... How many of your [Response to M1a] female sex partners were HIV-
positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M2 is greater than M1a then The number of your HIV-positive sex partners cannot be greater than your 
total number of sex partners."  skip to M2. 
If M2 is equal to 0 or M2 is equal to "Refuse to Answer", then skip to instruction before M3. 
M2a. Of this/these [Response to M2] partner(s), how many knew that you were HIV-positive 
because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M2a is greater than M2 then the number of partners you told cannot be greater than your number of 
partners."  Skip to M2a. 
M3. In the last three months... How many of your [Response to M1a] female sex partners were HIV-
negative? 
 __ __ __ 
 998 Refuse to 
Answer 
If M3 is greater than M1a then The number of your HIV-negative sex partners cannot be greater than your 
total number of sex partners."  skip to M3. 
If M3 is equal to 0 or M3 is equal to "Refuse to Answer", then skip to instruction before M4. 
M3a. Of this/these [Response to M3] partner(s), how many knew that you were HIV-positive 
because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M3a is greater than M3 then The number of partners you told cannot be greater than your number of 
partners."  skip to M3a. 
M4. In the last three months... How many of your [Response to M1a] female sex partners' HIV status 
were you unsure of? 
 __ __ __ 
 998 Refuse to 
Answer 
If M4 is greater than M1a then The number of your sex partners whose status you were not sure of cannot 
be greater than your total number of sex partners."  skip to M4. 
If M2 + M3 + M4 is not equal to M1a and M2 is not equal to "Refuse to Answer" and M3 is not equal to 
"Refuse to Answer" and M4 is not equal to "Refuse to Answer" then The number of HIV+, HIV-, and 
unknown HIV status partners must equal your total number of partners.  We will now ask you about these 
partners again."  skip to M2. 
If M4 is equal to 0 or M4 is equal to "Refuse to Answer", then skip to instruction before M5. 
M4a. Of this/these [Response to M4] partner(s), how many knew that you were HIV-positive 
because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M4a is greater than M4 then The number of partners you told cannot be greater than your number of 
partners."  skip to M4a. 
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M5. Were you in a primary relationship with at least one female sex partner during the last 3 months? 
This would be someone you have lived with or seen a lot, and to whom you have felt a special 
emotional commitment. 
 1 Yes 
 0 No 
 8 Refuse to 
Answer 
If M5 is equal to 0, then skip to instruction before M6. 
M5a. How many primary partners have you had in the last 3 months?  (Choose one) 
 0 1 
 1 More than 
1 
 8 Refuse to 
Answer 
If M5a is equal to 1, then skip to instruction before M5d. 
M5b. What is your primary partner's HIV status?  (Choose one) 00 Positive 
 01 Negative 
 88 Not Sure 
 98 Refuse to 
Answer 
M5c. Did your primary partner know that you were HIV-positive because you told her that 
you were positive? 
 1 Yes 
 0 No 
 8 Refuse to 
Answer 
If M5a is equal to 0, then skip to instruction before M6. 
M5d. How many primary partners have you had in the last 3 months?__ __ __ 
 998 Refuse to 
Answer 
If M5d is greater than M1a then The number of your primary partners cannot be greater than your total 
number of sex partners."  skip to M5d. 
M5e. How many of your [Response to M5d] primary partners were HIV-positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M5e is greater than M5d then The number of HIV-positive primary partners cannot be greater than the 
number of primary partners"  skip to M5e. 
If M5e is greater than M2 then The number of HIV-positive primary partners cannot be greater than the 
number of your HIV-positive partners"  skip to M5e. 
If M5e is equal to 0 or M5e is equal to "Refuse to Answer", then skip to instruction before M5f. 
M5e1. Of this/these [Response to M5e] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M5e1 is greater than M5e then the number of partners you told cannot be greater than your number of 
partners."  Skip to M5e. 
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M5f. How many of your [Response to M5d] primary partners were HIV-negative? 
 __ __ __ 
 998 Refuse to 
Answer 
If M5f is greater than M5d then the number of HIV-negative primary partners cannot be greater than the 
number of primary partners."  Skip to M5f. 
If M5f is greater than M3 then the number of HIV-negative primary partners cannot be greater than the 
number of your HIV-negative partners"  Skip to M5f. 
If M5f is equal to 0 or M5f is equal to "Refuse to Answer", then skip to instruction before M5g. 
M5f1. Of this/these [Response to M5f] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M5f1 is greater than M5f then the number of partners you told cannot be greater than your number of 
partners."  Skip to M5f. 
M5g. How many of your [Response to M5d] primary partners' HIV status were you unsure 
of? 
 __ __ __ 
 998 Refuse to 
Answer 
If M5g is greater than M5d then the number of primary partners whose HIV status you are unsure of cannot 
be greater than the number of primary partners."  Skip to M5g. 
If M5g is greater than M4 then the number of primary partners whose HIV status you are unsure of cannot 
be greater than the number of your unknown HIV-status partners."  Skip to M5g. 
If M5g is equal to 0 or M5g is equal to "Refuse to Answer", then skip to instruction before M6. 
M5g1. Of this/these [Response to M5g] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M5g1 is greater than M5g then The number of partners you told cannot be greater than your number of 
partners."  skip to M5g. 
If M5e + M5f + M5g is not equal to M5d then The sum of the number of HIV-positive, HIV-negative, and 
unknown HIV status primary partners must equal your total number of primary partners"  skip to M5e. 
If M1a is equal to 1 and M1b is not equal to 0 or M1a is greater than 1 and M2 is equal to 0, then skip to 
instruction before M9. 
 
 
HIV-POSITIVE PARTNERS (the yellow sheet) 
The next group of questions asks about the sexual contacts you have had in the last 3 months 
with your HIV-positive female partner(s). 
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Some of the next questions are about sexual behaviors where you or your partner may or may 
not have used a male or a female condom. When we ask about sex with a condom, we mean 
that a condom was put on or inserted before penetration and used throughout sex.  For example, 
when we ask how many times a condom was used during intercourse, do not include times when 
penetration occurred without a condom, then a condom was put on and sex continued.  Include 
those occasions when we ask you about intercourse without condoms. 
M6. In the last 3 months: 
How many times did you ejaculate or cum in this/these HIV-positive partner(s)' mouth(s) without 
a condom? 
 __ __ __ 
 998 Refuse to 
Answer 
M7. How many times did you have vaginal sex with this/these HIV-positive partner(s)? This would be 
with or without a condom and whether or not you ejaculated. 
 __ __ __ 
 998 Refuse to 
Answer 
If M7 is equal to 0 or M7 is equal to "Refuse to Answer", then skip to instruction before M8. 
M7a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If M7a is greater than M7 then the number of times you used a condom cannot be greater than the number 
of times having sex."  Skip to M7. 
M8. How many times did you have anal sex with your HIV-positive partner(s)? This would be with or 
without a condom and whether or not you ejaculated. 
 __ __ __ 
 998 Refuse to 
Answer 
If M8 is equal to 0 or M8 is equal to "Refuse to Answer", then skip to instruction before M9. 
M8a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If M8a is greater than M8 then the number of times you used a condom cannot be greater than the number 
of times having sex."  Skip to M8. 
If M1a is equal to 1 and M1b is not equal to 1 or M1a is greater than 1 and M3 is equal to 0, then skip to 
instruction before M12. 
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HIV-NEGATIVE PARTNERS (the green sheet) 
The next group of questions asks about the sexual contacts you have had in the last 3 months 
with your HIV-negative female partner(s). 
Some of the next questions are about sexual behaviors where you or your partner may or may 
not have used a male or a female condom. When we ask about sex with a condom, we mean 
that a condom was put on or inserted before penetration and used throughout sex.  For example, 
when we ask how many times a condom was used during intercourse, do not include times when 
penetration occurred without a condom, then a condom was put on and sex continued.  Include 
those occasions when we ask you about intercourse without condoms. 
M9. In the last 3 months: 
How many times did you ejaculate or cum in this/these HIV-negative partner(s)' mouth(s) without 
a condom? 
 __ __ __ 
 998 Refuse to 
Answer 
M10. How many times did you have vaginal sex with this/these HIV-negative partner(s)? This would 
be with or without a condom and whether or not you ejaculated. 
 __ __ __ 
 998 Refuse to 
Answer 
If M10 is equal to 0 or M10 is equal to "Refuse to Answer", then skip to instruction before M11. 
M10a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If M10a is greater than M10 then The number of times you used a condom cannot be greater than the 
number of times having sex."  skip to M10. 
M11. How many times did you have anal sex with your HIV-negative partner(s)? This would be with or 
without a condom and whether or not you ejaculated. 
 __ __ __ 
 998 Refuse to 
Answer 
If M11 is equal to 0 or M11 is equal to "Refuse to Answer", then skip to instruction before M12. 
M11a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If M11a is greater than M11 then the number of times you used a condom cannot be greater than the 
number of times having sex."  Skip to M11. 
If M1a is equal to 1 and M1b is not equal to 88 or M1a is greater than 1 and M4 is equal to 0, then skip to 
instruction before M15. 
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PARTNERS OF UNCERTAIN HIV-STATUS (the blue sheet) 
The next group of questions asks about the sexual contacts you have had in the last 3 months 
with your female partner(s) whose HIV status you were not sure of. 
Some of the next questions are about sexual behaviors where you or your partner may or may 
not have used a male or a female condom. When we ask about sex with a condom, we mean 
that a condom was put on or inserted before penetration and used throughout sex.  For example, 
when we ask how many times a condom was used during intercourse, do not include times when 
penetration occurred without a condom, then a condom was put on and sex continued. Include 
those occasions when we ask you about intercourse without condoms. 
M12. In the last 3 months: 
How many times did you ejaculate or cum in this/these partner(s)' mouth(s) without a condom? 
 __ __ __ 
 998 Refuse to 
Answer 
M13. How many times did you have vaginal sex with this/these partner(s) whose status you were not 
sure of? This would be with or without a condom and whether or not you ejaculated. __ __ __ 
 998 Refuse to 
Answer 
If M13 is equal to 0 or M13 is equal to "Refuse to Answer", then skip to instruction before M14. 
M13a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If M13a is greater than M13 then The number of times you used a condom cannot be greater than the 
number of times having sex."  skip to M13. 
M14. How many times did you have anal sex with your partner(s) whose status you were not sure of? 
This would be with or without a condom and whether or not you ejaculated.__ __ __ 
 998 Refuse to 
Answer 
If M14 is equal to 0 or M14 is equal to "Refuse to Answer", then skip to instruction before M15. 
M14a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If M14a is greater than M14 then the number of times you used a condom cannot be greater than the 
number of times having sex."  Skip to M14. 
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SEXUAL RISK ASSESSMENT FOR MEN- Sexual Behavior with Men 
The following questions ask about your sexual behavior with partners who are HIV-positive and 
HIV-negative, as well as partners whose HIV status you were not sure of.  Again, these questions 
refer to the last 3 months. 
M15. Have you had any male sex partners in the last 3 months? By male sex partners, we mean men 
with whom you had anal or oral sex, with or without ejaculation. 
 1 Yes 
 0 No 
 8 Refuse to 
Answer 
If M15 is equal to 0, then skip to instruction before SUQ1. 
M15a. How many male sexual partners have you had in the last 3 months? 
 __ __ __ 
 998 Refuse to 
Answer 
If M15a is greater than 1, then skip to instruction before M16. 
M15b. What is this partner's HIV status?  (Choose one) 0 Positive 
 1 Negative 
 88 Not Sure 
 998 Refuse to 
Answer 
M15c. Were you in a primary relationship with this sex partner?  This would be someone you 
have lived with or seen a lot, and to whom you have felt a special emotional 
commitment.  
  1 Yes 
 0 No 
 8 Refuse to 
Answer 
M15d. Did this partner know that you were HIV-positive because you told him that you were 
positive?  (Choose one) 
 0 No 
 1 Yes 
 88 Not Sure 
 998 Refuse to 
Answer 
If M15b is equal to 0, then skip to instruction before M20a. 
If M15b is equal to 1, then skip to instruction before M23a. 
If M15b is equal to 88, then skip to instruction before M26a. 
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The next questions ask about the HIV-status of the sexual partners we asked about in the last 
question.  When we say HIV status, we mean whether you know, for certain, whether your 
partners are either HIV positive, HIV negative, or not sure.  First, we will ask you about your HIV-
positive sexual partner(s).  Then we will ask you about your HIV-negative sexual partner(s). 
Lastly, we will ask you about sex partner(s) whose HIV status you are not sure of.  For these next 
questions, please keep in mind that the number of HIV-positive sexual partners, HIV-negative 
sexual partners, and partners whose HIV status you are not sure of MUST EQUAL the total 
number of partners that you entered in the last question. If you want to, write your number of 
partners down on the sheet of scratch paper provided to help you answer the next questions. 
 
M16. In the last three months... How many of your [Response to M15a] male sex partners were HIV-
positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M16 is greater than M15a then the number of your HIV-positive sex partners cannot be greater than your 
total number of sex partners."  Skip to M16. 
If M16 is equal to 0 or M16 is equal to "Refuse to Answer", then skip to instruction before M17. 
M16a. Of this/these [Response to M16] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M16a is greater than M16 then the number of partners you told cannot be greater than your number of 
partners."  Skip to M16. 
M17. In the last three months... How many of your [Response to M15a] male sex partners were HIV-
negative? 
 __ __ __ 
 998 Refuse to 
Answer 
If M17 is greater than M15a then the number of your HIV-negative sex partners cannot be greater than 
your total number of sex partners." Skip to M17. 
If M17 is equal to 0 or M17 is equal to "Refuse to Answer", then skip to instruction before M18. 
M17a. Of this/these [Response to M17] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M17a is greater than M17 then the number of partners you told cannot be greater than your number of 
partners."  Skip to M17. 
M18. In the last three months... How many of your [Response to M15a] male partners' HIV status were 
you unsure of? 
 __ __ __ 
 998 Refuse to 
Answer 
If M18 is greater than M15a then the number of your partners whose HIV status you were not sure of 
cannot be greater than your total number of sex partners."  Skip to M18. 
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If M16 + M17 + M18 is not equal to M15a and M16 is not equal to "Refuse to Answer" and M17 is not equal 
to "Refuse to Answer" and M18 is not equal to "Refuse to Answer" then The number of HIV+, HIV-, and 
unknown HIV status partners must equal your total number of partners.  We will now ask you about these 
partners again." skip to M16. 
If M18 is equal to 0 or M18 is equal to "Refuse to Answer", then skip to M19. 
M18a. Of this/these [Response to M18] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M18a is greater than M18 then the number of partners you told cannot be greater than your number of 
partners."  Skip to instruction before M18a. 
M19. Were you in a primary relationship with at least one male sex partner during the last 3 months? 
This would be someone you have lived with or seen a lot, and to whom you have felt a special 
emotional commitment. 
  1 Yes 
 0 No 
 8 Refuse to 
Answer 
If M19 is equal to 0, then skip to instruction before M20a. 
M19a. How many primary partners have you had in the last 3 months?  (Choose one) 
 0 1 
 1 More than 
1 
 8 Refuse to 
Answer 
If M19a is equal to 1, then skip to instruction before M19d. 
M19b. What is your primary partner's HIV status?  (Choose one) 00 Positive 
 01 Negative 
 88 Not Sure 
 98 Refuse to 
Answer 
M19c. Did your primary partner know that you were HIV-positive because you told him that 
you were positive? 
 1 Yes 
 0 No 
 8 Refuse to 
Answer 
If M19a is equal to 0, then skip to instruction before M20a. 
M19d. How many primary partners have you had in the last 3 months?__ __ __ 
 998 Refuse to 
Answer 
If M19d is greater than M15a then the number of your primary partners cannot be greater than your total 
number of sex partners"  Skip to M19d. 
M19e. How many of your [Response to M19d] primary partners were HIV-positive? 
 __ __ __ 
 998 Refuse to 
Answer 
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If M19e is greater than M19d then the number of HIV-positive primary partners cannot be greater than the 
number of primary partners."  Skip to M19e. 
If M19e is greater than M16 then the number of HIV-positive primary partners cannot be greater than the 
number of your HIV-positive partners."  Skip to M19e. 
If M19e is equal to 0 or M19e is equal to "Refuse to Answer", then skip to instruction before M19f. 
M19e1. Of this/these [Response to M19e] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M19e1 is greater than M19e then the number of partners you told cannot be greater than your number of 
partners."  Skip to M19e. 
M19f. How many of your [Response to M19d] primary partners were HIV-negative? 
 __ __ __ 
 998 Refuse to 
Answer 
If M19f is greater than M19d then the number of HIV-negative primary partners cannot be greater than the 
number of primary partners." Skip to M19f. 
If M19f is greater than M17 then the number of HIV-negative primary partners cannot be greater than the 
number of your HIV-negative partners."  Skip to M19f. 
If M19f is equal to 0 or M19f is equal to "Refuse to Answer", then skip to instruction before M19g. 
M19f1. Of this/these [Response to M19f] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M19f1 is greater than M19f then the number of partners you told cannot be greater than your number of 
partners."  Skip to Mf. 
M19g. How many of your [Response to M19d] primary partners' HIV status were you unsure 
of? 
 __ __ __ 
 998 Refuse to 
Answer 
If M19g is greater than M19d then the number of primary partners whose HIV status you were unsure of 
cannot be greater than the number of primary partners."   Skip to M19g. 
If M19g is greater than M18 then the number of primary partners whose HIV status you are unsure of 
cannot be greater than the number of your unknown HIV-status partners." Skip to M19g. 
If M19g is equal to 0 or M19g is equal to "Refuse to Answer", then skip to instruction before M20a. 
M19g1. Of this/these [Response to M19g] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If M19g1 is greater than M19g then the number of partners you told cannot be greater than your number of 
partners." Skip to M19g. 
If M19e + M19f + M19g is not equal to M19d then The sum of the number of HIV-positive, HIV- negative 
and unknown HIV status primary partners must equal your total number of primary partners"  skip to M19e. 
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If M15a is equal to 1 and M15b is not equal to 0 or M15a is greater than 1 and M16 is equal to 0, then skip 
to instruction before M23a. 
 
 
HIV-POSITIVE PARTNERS (the yellow sheet) 
The next group of questions asks about the sexual contacts you have had in the last 3 months 
with your HIV-positive male partner(s). 
Some of the next questions are about sexual behaviors where you or your partner may or may 
not have used a male or a female condom. When we ask about sex with a condom, we mean 
that a condom was put on or inserted before penetration and used throughout sex.  For example, 
when we ask how many times a condom was used during intercourse, do not include times when 
penetration occurred without a condom, then a condom was put on and sex continued. Include 
those occasions when we ask you about intercourse without condoms. 
M20a. In the last 3 months: 
How many times did you have oral sex without a condom when your HIV-positive 
partner(s) ejaculated or came in your mouth? 
 __ __ __ 
 998 Refuse to 
Answer 
M20b. In the last 3 months: 
How many times did you ejaculate or cum in this/these HIV-positive partner(s)' 
mouth(s) without a condom? 
 __ __ __ 
 998 Refuse to 
Answer 
M21. How many times did you have anal sex with this/these HIV-positive partner(s) when his/their 
penis was in your rectum? This would be with or without a condom and whether or not he/they 
ejaculated. 
 __ __ __ 
 998 Refuse to 
Answer 
If M21 is equal to 0, then skip to instruction before M22. 
M21a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If M21a is greater than M21 then the number of times you used a condom cannot be greater than the 
number of times having sex."  Skip to M21. 
M22. How many times did you have anal sex with your HIV-positive partner(s) when your penis was in 
his/their rectum? This would be with or without a condom and whether or not you ejaculated. 
 __ __ __ 
 998 Refuse to 
Answer 
If M22 is equal to 0, then skip to instruction before M23a. 
M22a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If M22a is greater than M22 then the number of times you used a condom cannot be greater than the 
number of times having sex."  Skip to M22. 
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If M15a is equal to 1 and M15b is not equal to 1 or M15a is greater than 1 and M17 is equal to 0, then skip 
to instruction before M26a. 
 179 
HIV-NEGATIVE PARTNERS (the green sheet) 
The next group of questions asks about the sexual contacts you have had in the last 3 months 
with your HIV-negative male partner(s). 
Some of the next questions are about sexual behaviors where you or your partner may or may 
not have used a male or a female condom. When we ask about sex with a condom, we mean 
that a condom was put on or inserted before penetration and used throughout sex. For example, 
when we ask how many times a condom was used during intercourse, do not include times when 
penetration occurred without a condom, then a condom was put on and sex continued. Include 
those occasions when we ask you about intercourse without condoms. 
M23a. In the last 3 months: 
How many times did you have oral sex without a condom when your HIV-negative 
partner(s) ejaculated or came in your mouth? 
 __ __ __ 
 998 Refuse to 
Answer 
M23b. In the last 3 months: 
How many times did you ejaculate or cum in this/these HIV-negative partner(s)' 
mouth(s) without a condom? 
 __ __ __ 
 998 Refuse to 
Answer 
M24. How many times did you have anal sex with this/these HIV-negative partner(s) when his/their 
penis was in your rectum? This would be with or without a condom and whether or not he/they 
ejaculated. 
 __ __ __ 
 998 Refuse to 
Answer 
If M24 is equal to 0, then skip to instruction before M25. 
M24a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If M24a is greater than M24 then the number of times you used a condom cannot be greater than the 
number of times having sex."  Skip to M24. 
M25. How many times did you have anal sex with your HIV-negative partner(s) when your penis was 
in his/their rectum? This would be with or without a condom and whether or not you ejaculated. 
  __ __ __ 
 998 Refuse to 
Answer 
If M25 is equal to 0, then skip to instruction before M26a. 
M25a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If M25a is greater than M25 then the number of times you used a condom cannot be greater than the 
number of times having sex."  Skip to M25. 
If M15a is equal to 1 and M15b is not equal to 88 or M15a is greater than 1 and M18 is equal to 0, then skip 
to instruction before SUQ1. 
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PARTNERS OF UNCERTAIN HIV-STATUS (the blue sheet) 
The next group of questions asks about the sexual contacts you have had in the last 3 months 
with your male partner(s) whose HIV status you were not sure of. 
Some of the next questions are about sexual behaviors where you or your partner may or may 
not have used a male or a female condom. When we ask about sex with a condom, we mean 
that a condom was put on or inserted before penetration and used throughout sex. For example, 
when we ask how many times a condom was used during intercourse, do not include times when 
penetration occurred without a condom, then a condom was put on and continued. Include those 
occasions when we ask you about intercourse without condoms. 
M26a. In the last 3 months: 
How many times did you have oral sex without a condom when your partner(s) whose 
HIV status you were not sure of ejaculated or came in your mouth? 
 __ __ __ 
 998 Refuse to 
Answer 
M26b. How many times did you ejaculate or cum in this/these partner(s)' mouth(s) without a 
condom? 
 __ __ __ 
 998 Refuse to 
Answer 
M27. How many times did you have anal sex with your partner(s) whose HIV status was unknown 
when his/their penis was in your rectum? This would be with or without a condom and whether 
or not he/they ejaculated. 
 __ __ __ 
 998 Refuse to 
Answer 
If M27 is equal to 0, then skip to instruction before M28. 
M27a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If M27a is greater than M27 then the number of times you used a condom cannot be greater than the 
number of times having sex."  Skip to M27. 
M28. How many times did you have anal sex with your partner(s) whose HIV status was unknown 
when your penis was in his/their rectum? This would be with or without a condom and whether 
or not you ejaculated. 
 __ __ __ 
 998 Refuse to 
Answer 
If M28 is equal to 0, then skip to instruction before SUQ1. 
M28a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If M28a is greater than M28 then the number of times you used a condom cannot be greater than the 
number of times having sex."  Skip to M28. 
Skip to instruction before SUQ1. 
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SEXUAL RISK ASSESSMENT FOR WOMEN- Sexual Behavior with Men 
These next questions are about the sexual relationships you might have had in the last 3 months.  
Again, please remember that all data are strictly confidential and your responses are protected 
by law and cannot be disclosed to any outside organization or agency not involved with this 
study. 
The following questions ask about your sexual behavior with partners who are HIV-positive and 
HIV-negative, as well as partners whose HIV status you were not sure of.  Again, these questions 
refer to the last 3 months. 
W1. Have you had any male sex partners in the last 3 months? By male sex partner, we mean men 
with whom you had vaginal, anal or oral sex, with or without ejaculation. 
 1 Yes 
 0 No 
 8 Refuse to 
Answer 
If W1 is equal to 0, then skip to instruction before SUQ1. 
W1a. How many male sexual partners have you had in the last 3 months? 
 __ __ __ 
 998 Refuse to 
Answer 
If W1a is greater than 1, then skip to instruction before W2. 
W1b. What is this partner's HIV status?  (Choose one) 0 Positive 
 1 Negative 
 88 Not Sure 
 998 Refuse to 
Answer 
W1c. Were you in a primary relationship with this sex partner?  This would be someone you 
have lived with or seen a lot, and to whom you have felt a special emotional 
commitment.  
  1 Yes 
 0 No 
 8 Refuse to 
Answer 
W1d. Did this partner know that you were HIV-positive because you told him that you were 
positive?  (Choose one) 
 0 No 
 1 Yes 
 88 Not Sure 
 998 Refuse to 
Answer 
If W1b is equal to 0, then skip to instruction before W6. 
If W1b is equal to 1, then skip to instruction before W9. 
If W1b is equal to 88, then skip to instruction before W12. 
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The next questions ask about the HIV-status of the sexual partners we asked about in the last 
question.  When we say HIV status, we mean whether you know, for certain, whether your 
partners are either HIV positive, HIV negative, or not sure.  First, we will ask you about your HIV-
positive sexual partner(s).  Then we will ask you about your HIV-negative sexual partner(s). 
Lastly, we will ask you about sex partner(s) whose HIV status you are not sure of.  For these next 
questions, please keep in mind that the number of HIV-positive sexual partners, HIV-negative 
sexual partners, and partners whose HIV status you are not sure of MUST EQUAL the total 
number of partners that you entered in the last question. If you want to, write your number of 
partners down on the sheet of scratch paper provided to help you answer the next questions. 
 
W2. In the last three months... How many of your [Response to W1a] male sex partners were HIV-
positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If W2 is greater than W1a then the number of your HIV-positive sex partners cannot be greater than your 
total number of sex partners."  Skip to W2. 
If W2 is equal to 0 or W2 is equal to "Refuse to Answer", then skip to instruction before W3. 
W2a. Of this/these [Response to W2] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If W2a is greater than W2 then the number of partners you told cannot be greater than your number of 
partners."  Skip to W2. 
W3. In the last three months... How many of your [Response to W1a] male sex partners were HIV-
negative? 
 __ __ __ 
 998 Refuse to 
Answer 
If W3 is greater than W1a then the number of your HIV-negative sex partners cannot be greater than your 
total number of sex partners."  Skip to W3. 
If W3 is equal to 0 or W3 is equal to "Refuse to Answer", then skip to instruction before W4. 
W3a. Of this/these [Response to W3] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If W3a is greater than W3 then the number of partners you told cannot be greater than your number of 
partners."  Skip to W3. 
W4. In the last three months... How many of your [Response to W1a] male partners' HIV status were 
you unsure of? 
 __ __ __ 
 998 Refuse to 
Answer 
If W4 is greater than W1a then the number of your partners whose HIV status you are not sure of cannot be 
greater than your total number of sex partners."  Skip to W4. 
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If W2 + W3 + W4 is not equal to W1a and W2 is not equal to "Refuse to Answer" and W3 is not equal to 
"Refuse to Answer" and W4 is not equal to "Refuse to Answer" then The number of HIV+, HIV-, and 
unknown HIV status partners must equal your total number of partners.  We will now ask you about these 
partners again."  Skip to W2. 
If W4 is equal to 0 or W4 is equal to "Refuse to Answer", then skip to W5. 
W4a. Of this/these [Response to W4] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If W4a is greater than W4 then the number of partners you told cannot be greater than your number of 
partners."  Skip to instruction before W4a. 
W5. Were you in a primary relationship with at least one male sex partner during the last 3 months? 
This would be someone you have lived with or seen a lot, and to whom you have felt a special 
emotional commitment. 
 1 Yes 
 0 No 
 8 Refuse to 
Answer 
If W5 is equal to 0, then skip to instruction before W6. 
W5a. How many primary partners have you had in the last 3 months?  (Choose one) 
 0 1 
 1 More than 
1 
 8 Refuse to 
Answer 
If W5a is equal to 1, then skip to instruction before W5d. 
W5b. What is your primary partner's HIV status?  (Choose one) 00 Positive 
 01 Negative 
 88 Not Sure 
 98 Refuse to 
Answer 
W5c. Did your primary partner know that you were HIV-positive because you told him that 
you were positive? 
 1 Yes 
 0 No 
 8 Refuse to 
Answer 
If W5a is equal to 0, then skip to instruction before W6. 
W5d. How many primary partners have you had in the last 3 months?__ __ __ 
 998 Refuse to 
Answer 
If W5d is greater than W1a then the number of your primary partners cannot be greater than your total 
number of sex partners."  Skip to W5d. 
W5e. How many of your [Response to W5d] primary partners were HIV-positive? 
 __ __ __ 
 998 Refuse to 
Answer 
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If W5e is greater than W5d then the number of HIV-positive primary partners cannot be greater than the 
number of primary partners."  Skip to W5e. 
If W5e is greater than W2 then the number of HIV-positive primary partners cannot be greater than the 
number of your HIV-positive partners."  Skip to W5e. 
If W5e is equal to 0 or W5e is equal to "Refuse to Answer", then skip to instruction before W5f. 
W5e1. Of this/these [Response to W5e] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If W5e1 is greater than W5e then the number of partners you told cannot be greater than your number of 
partners."  Skip to W5e. 
W5f. How many of your [Response to W5d] primary partners were HIV-negative? 
 __ __ __ 
 998 Refuse to 
Answer 
If W5f is greater than W5d then the number of HIV-negative primary partners cannot be greater than the 
number of primary partners."  Skip to W5f. 
If W5f is greater than W3 then the number of HIV-negative primary partners cannot be greater than the 
number of your HIV-negative partners."  Skip to W5f. 
If W5f is equal to 0 or W5f is equal to "Refuse to Answer", then skip to instruction before W5g. 
W5f1. Of this/these [Response to W5f] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If W5f1 is greater than W5f then the number of partners you told cannot be greater than your number of 
partners."  Skip to W5f. 
W5g. How many of your [Response to W5d] primary partners' HIV status were you unsure 
of? 
 __ __ __ 
 998 Refuse to 
Answer 
If W5g is greater than W5d then the number of primary partners whose HIV status you were unsure of 
cannot be greater than the number of primary partners."  Skip to W5g. 
If W5g is greater than W4 then The number of primary partners whose HIV status you are unsure of cannot 
be greater than the number of your unknown HIV-status partners."  Skip to W5g. 
If W5g is equal to 0 or W5g is equal to "Refuse to Answer", then skip to instruction before W6. 
W5g1. Of this/these [Response to W5g] partner(s), how many knew that you were HIV-
positive because you told them that you were positive? 
 __ __ __ 
 998 Refuse to 
Answer 
If W5g1 is greater than W5g then the number of partners you told cannot be greater than your number of 
partners."   Skip to W5g. 
If W5e + W5f + W5g is not equal to W5d then The sum of the number of HIV-positive, HIV-negative, and 
unknown HIV status primary partners must equal your total number of primary partners."  Skip to W5e. 
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If W1a is equal to 1 and W1b is not equal to 0 or W1a is greater than 1 and W2 is equal to 0, then skip to 
instruction before W9. 
 
 
HIV-POSITIVE PARTNERS (the yellow sheet) 
The next group of questions asks about the sexual contacts you have had in the last 3 months 
with your HIV-positive male partner(s). 
Some of the next questions are about sexual behaviors where you or your partner may or may 
not have used a male or a female condom. When we ask about sex with a condom, we mean 
that a condom was put on or inserted before penetration and used throughout sex. For example, 
when we ask how many times a condom was used during intercourse, do not include times when 
penetration occurred without a condom, then a condom was put on and sex continued. Include 
those occasions when we ask you about intercourse without condoms. 
W6. In the last 3 months: 
How many times did you have oral sex without a condom when your HIV-positive partner(s) 
ejaculated or came in your mouth? 
 __ __ __ 
 998 Refuse to 
Answer 
W7. How many times did you have vaginal sex with your HIV-positive partner(s)? This would be with 
or without a condom and whether or not he/they ejaculated. 
 __ __ __ 
 998 Refuse to 
Answer 
If W7 is equal to 0 or W7 is equal to "Refuse to Answer", then skip to instruction before W8. 
W7a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If W7a is greater than W7 then the number of times using a condom cannot be greater than the number of 
times having sex."  Skip to W7. 
W8. How many times did you have anal sex with your HIV-positive partner(s)? This would be with or 
without a condom and whether or not he/they ejaculated. 
 __ __ __ 
 998 Refuse to 
Answer 
If W8 is equal to 0 or W8 is equal to "Refuse to Answer", then skip to instruction before W9. 
W8a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If W8a is greater than W8 then the number of times using a condom cannot be greater than the number of 
times having sex."  Skip to W8. 
If W1a is equal to 1 and W1b is not equal to 1 or W1a is greater than 1 and W3 is equal to 0, then skip to 
instruction before W12. 
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HIV-NEGATIVE PARTNERS (the green sheet) 
The next group of questions asks about the sexual contacts you have had in the last 3 months 
with your HIV-negative male partner(s). 
Some of the next questions are about sexual behaviors where you or your partner may or may 
not have used a male or a female condom. When we ask about sex with a condom, we mean 
that a condom was put on or inserted before penetration and used throughout sex. For example, 
when we ask how many times a condom was used during intercourse, do not include times when 
penetration occurred without a condom, then a condom was put on and sex continued. Include 
those occasions when we ask you about intercourse without condoms. 
W9. In the last 3 months: 
How many times did you have oral sex without a condom when your HIV-negative partner(s) 
ejaculated or came in your mouth? 
 __ __ __ 
 998 Refuse to 
Answer 
W10. How many times did you have vaginal sex with your HIV-negative partner(s)? This would be with 
or without a condom and whether or not he/they ejaculated. 
 __ __ __ 
 998 Refuse to 
Answer 
If W10 is equal to 0 or W10 is equal to "Refuse to Answer", then skip to instruction before W11. 
W10a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If W10a is greater than W10 then the number of times using a condom cannot be greater than the number 
of times having sex."  Skip to W10. 
W11. How many times did you have anal sex with your HIV-negative partner(s)? This would be with or 
without a condom and whether or not he/they ejaculated. 
 __ __ __ 
 998 Refuse to 
Answer 
If W11 is equal to 0 or W11 is equal to "Refuse to Answer", then skip to instruction before W12. 
W11a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If W11a is greater than W11 then the number of times using a condom cannot be greater than the number 
of times having sex."  Skip to W11. 
If W1a is equal to 1 and W1b is not equal to 88 or W1a is greater than 1 and W4 is equal to 0, then skip to 
instruction before SUQ1. 
 
WW1. Have you had any female sex partners in the last 3 months? By female sex partner, we mean 
women with whom you had oral sex. 
0=No, 1=yes, 8=RTA.    If NO or RTA, skip to S9Q1.   If YES, go to WW2. 
[like M15] 
 
WW2. How many female sexual partners have you had in the last 3 months?   
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0-996=range, 998=RTA.  If 0 or RTA, skip to S9Q1.  If answer is 1 or greater, then go to WW3.  
                                                                                                                                                                                                                       
WW3. In the last 3 months, how many times did you have oral sex without a barrier, such as a female 
condom or dental dam? 
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PARTNERS OF UNCERTAIN HIV-STATUS (the green sheet) 
The next group of questions asks about the sexual contacts you have had in the last 3 months 
with your male partner(s) whose HIV status you were not sure of. 
Some of the next questions are about sexual behaviors where you or your partner may or may 
not have used a male or a female condom. When we ask about sex with a condom, we mean 
that a condom was put on or inserted before penetration and used throughout sex. For example, 
when we ask how many times a condom was used during intercourse, do not include times when 
penetration occurred without a condom, then a condom was put on and sex continued. Include 
those occasions when we ask you about intercourse without condoms. 
W12. In the last 3 months: 
How many times did you have oral sex without a condom when your partner(s) whose HIV status 
you were not sure of ejaculated or came in your mouth? 
 __ __ __ 
 998 Refuse to 
Answer 
W13. How many times did you have vaginal sex with this/these partner(s) with uncertain HIV status? 
This would be with or without a condom and whether or not he/they ejaculated.__ __ __ 
 998 Refuse to 
Answer 
If W13 is equal to 0 or W13 is equal to "Refuse to Answer", then skip to instruction before W14. 
W13a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If W13a is greater than W13 then the number of times using a condom cannot be greater than the number 
of times having sex."  Skip to W13. 
W14. How many times did you have anal sex with partner(s) whose HIV status you were not sure of 
when his/their penis was in your rectum? This would be with or without a condom and whether 
or not he/they ejaculated. __ __ __ 
 998 Refuse to 
Answer 
If W14 is equal to 0 or W14 is equal to "Refuse to Answer", then skip to instruction before SUQ1. 
W14a. How many of these times was a condom used? __ __ __ 
 998 Refuse to 
Answer 
If W14a is greater than W14 then the number of times using a condom cannot be greater than the number 
of times having sex."   
Skip to W14a. 
 
WW1. Have you had any female sex partners in the last 3 months? By female sex partner, we mean 
women with whom you had oral sex. 
0=No, 1=yes, 8=RTA.    If NO or RTA, skip to S9Q1.   If YES, go to WW2. 
[like M15] 
 
WW2. How many female sexual partners have you had in the last 3 months?   
0-996=range, 998=RTA.  If 0 or RTA, skip to S9Q1.  If answer is 1 or greater, then go to WW3.  
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WW3. In the last 3 months, how many times did you have oral sex without a barrier, such as a female 
condom or dental dam? 
 
 
IX. Healthy Habits: Substance Use and Physical Activity 
The following questions ask about some personal habits.  Some questions are about your 
alcohol and drug use and others are about your physical activity.  All of the questions ask about 
your behavior over the last three months.  Please answer the questions as honestly as possible.  
Remember, nothing you tell us as part of this survey will ever been seen by anyone not part of 
this study nor will it ever be reported in any way that connects your name with what you answer. 
 
BS9Q1.  Pick the answer that best tells how often you drank alcohol in the last 3 months.  By alcohol we 
mean wine, beer, or any kind of liquor. In the last 3 months, did you drink alcohol:  (Choose one)  
1 Every day 
2 2 to 6 times a week 
3 Once a week 
4 1 to 3 times a month 
5 Less than once a month 
6 Never->SKIP TO BS9Q3 
8 Refuse to Answer->SKIP TO BS9Q3 
 
BS9Q2.  If you are a male, how often did you drink five or more drinks of alcohol in a single day in the last 
three months?  If you are a female, how often did you drink four or more drinks of alcohol in a single day in 
the last three months? (Choose one) 
1 Every day 
2 2 to 6 times a week 
3 Once a week 
4 1 to 3 times a month 
5 Less than once a month 
6 Never 
8 Refuse to Answer 
 
BS9Q3.  From the list below, pick up to 3 forms of physical activity that you have done the most in the past 
three months.   
01 Jogging or running 
02 Brisk walking 
03 Biking 
04 Yoga or Pilates 
05 Basketball 
06 Swimming 
07 Aerobics 
08 Dancing 
09 Rowing 
10 Yard work 
11 Soccer 
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      12 Weight lifting 
      13 Other: ___________________________________ 
      14 Have not exercised->SKIP TO BS9Q4 
98 Refuse to Answer-.SKIP TO BS9Q4 
 
For up to three items selected above 
BS9Q3a.  In the last 30 days how many days did you do <above type of physical activity>? 
 
__ days (acceptable range 0 -30 days)   
 
 
98  Refused to Answer 
 
 
 
BS9Q4.  Please check the box next to all those drugs that you sniffed, snorted, smoked, swallowed, or 
injected  in the last 3 months.  (Select all that apply)  
  191
a __ Marijuana or hashish 
8 Refused to Answer 
 
b __ Crack, freebase cocaine, or rock cocaine 
8 Refused to Answer 
 
c __ Powder cocaine (by itself) 
8 Refused to Answer 
 
d __ Heroin (by itself) 
8 Refused to Answer 
 
e __ Methamphetamine like Speed or Crystal 
Meth 
8 Refused to Answer 
 
f __ PCP or Angel Dust 
8 Refused to Answer 
 
g __ Opiates like Vicodin, Oxycontin, Dilaudid, 
Percocet, or Darvocet not prescribed by your 
doctor 
8 Refused to Answer 
 
h __ Street Methadone 
8 Refused to Answer 
 
i __ Tranquilizers or Barbiturates like Valium, 
Xanax, Librium, or Seconal 
8 Refused to Answer 
 
j __ Club drugs like Ecstasy, Roophies 
(Rohypnol), Special K/Vitamin K (Ketamine), or 
GHB 
8 Refused to Answer 
 
k __ Hallucinogens like LSD, Mushrooms, 
Peyote, or Mescaline 
8 Refused to Answer 
 
l __ Inhalants like glue, poppers, nitrous oxide 
(NO2) 
8 Refused to Answer 
 
m __ Viagra 
8 Refused to Answer 
 
n __ None->SKIP TO BS10Q1 
8 Refused to Answer 
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o __ Other: ___________________________ 
8 Refused to Answer 
 
  
For each item answered “yes” 
BS9Q4a.  In the last 30 days how many days did you use <substance>? 
    
__  __ days  (acceptable range 0 -30 days)  If 0 ⇒ Skip to Question SUQ3b 
 
98 Refused to Answer 
 
    
BS9Q4b.  How about in the 30 days before that?  How many days did you use <substance>? 
__  __ days  (acceptable range 0 -30 days) 
 
98 Refused to Answer 
 
 
BS9Q4c.  In the last 30 days about how many times per day did you use <substance>? 
   __  __ times per day 
 
   98 Refused to Answer 
  193
X. Emotional Well-Being (SF-36) 
 
You are getting there.  Just three more short sections and you’ll be done.   
 
The next questions will ask you about how you have been feeling and how things have been 
during the past 30 days.  As you read each statement, please give me the one answer that fits 
best with the way you have been feeling.  Your choices are: All of the time, Most of the time, 
Some of the time, A little of the time, or None of the time? 
 
BS10Q1. How much of the time during the past 30 days have you been a very nervous person? 
1 All of the time 
2 Most of the time 
3 Some of the time 
4 A little of the time 
5 None of the time 
8 Refused to Answer 
 
 
BS10Q2. did you have a lot of energy? 
1 All of the time 
2 Most of the time 
3 Some of the time 
4 A little of the time 
5 None of the time 
8 Refused to Answer 
 
 
BS10Q3.  How much of the time during the past 30 days have you felt depressed? 
1 All of the time 
2 Most of the time 
3 Some of the time 
4 A little of the time 
5 None of the time 
8 Refused to Answer 
 
 
BS10Q4.  felt so down in the dumps that nothing could cheer you up? 
1 All of the time 
2 Most of the time 
3 Some of the time 
4 A little of the time 
5 None of the time 
8 Refused to Answer 
 
 
BS10Q5.  How much of the time during the past 30 days have you been a happy person? 
1 All of the time 
2 Most of the time 
3 Some of the time 
4 A little of the time 
5 None of the time 
8 Refused to Answer 
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BS10Q6.  felt downhearted and blue? 
1 All of the time 
2 Most of the time 
3 Some of the time 
4 A little of the time 
5 None of the time 
8 Refused to Answer 
 
 
 
BS10Q7.  How much of the time during the past 30 days have you felt calm and peaceful? 
1 All of the time 
2 Most of the time 
3 Some of the time 
4 A little of the time 
5 None of the time 
8 Refused to Answer 
 
 
XI. SUBJECTIVE NORMS 
The next section will ask about what three different groups of people think about whether or not 
people living with HIV should use condoms and tell their HIV status to partners. We will ask you 
about three different groups of people—your friends, your close family members, and your sex 
partners.  
BS11Q1R.  
 
First we’ll ask about your friends. 
 
How much do you agree or disagree with this statement [slight pause]: 
 
Most of your friends think that people living with HIV should always wear a condom when having vaginal or 
anal sex.   
       
1 Agree A Lot 
2 Agree A Little 
3 Disagree A Little 
4 Disagree A Lot 
      8 Refuse to Answer 
 
BS11Q2R 
 
How much do you agree or disagree that: 
 
Most of your friends think that people living with HIV should always tell their sex partner their HIV status 
before having vaginal or anal sex with them.   
 
      1 Agree A Lot 
2 Agree A Little 
3 Disagree A Little 
4 Disagree A Lot 
      8 Refuse to Answer 
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BS11Q3R.   
 
How about your family members? 
 
How much do you agree or disagree that: 
 
Most of your close family members think that people living with HIV should always wear a condom when 
having vaginal or anal sex.   
 
      1 Agree A Lot 
2 Agree A Little 
3 Disagree A Little 
4 Disagree A Lot 
      8 Refuse to Answer 
 
BS11Q4R  
How much do you agree or disagree that: 
 
Most of your close family members think that people living with HIV should always tell their sex partner their 
HIV status before having vaginal or anal sex with them. 
      1 Agree A Lot 
2 Agree A Little 
3 Disagree A Little 
4 Disagree A Lot 
      8 Refuse to Answer 
 
BS11Q5R 
How about your sex partners? 
 
How much do you agree or disagree that: 
 
Most of your sex partner(s) think that people living with HIV should always wear a condom when having 
vaginal or anal sex. 
      1 Agree A Lot 
2 Agree A Little 
3 Disagree A Little 
4 Disagree A Lot 
      8 Refuse to Answer 
 
BS11Q6R  
How much do you agree or disagree that: 
 
Most of your sex partner(s) think that people living with HIV should always tell their sex partner their HIV 
status before having vaginal or anal sex with them. 
      1 Agree A Lot 
2 Agree A Little 
3 Disagree A Little 
4 Disagree A Lot 
      8 Refuse to Answer 
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F1S11Q7.  In general, how important or unimportant is it to you what other people think you should do?  Is 
it: 
1 Not at all important 
2 Somewhat important 
3 Very important 
4 Extremely important 
8 Refused to Answer 
 
 
XII. Demographics 
We are just about at the end of our questions.  The last few questions will help us better 
understand some of the other information you’ve already told us.   
AGE 
BS12Q1.  How old are you? __ __ __ 
 
998  Refuse to Answer 
 
ETHNICITY 
BS12Q2.  What is your primary race or ethnic identification?  (Choose one) 
1 Black/African American 
2 Hispanic/Latino 
3 White, not of Hispanic origin 
4 Asian/Pacific Islander 
5 American Indian/Alaskan Native 
6 Another Race/Ethnicity 
7 Mixed Race 
8 Refused to Answer 
  
 
EMPLOYMENT STATUS 
BS12Q3a.  At this time, are you: 
1 Working full-time->SKIP TO BS12Q5 
2 Working part-time-> SKIP TO BS12Q5 
3 Not working 
8 Refused to Answer-> SKIP TO BS12Q5 
 
BS12Q3b.  Are you: 
1 Retired 
2 Laid off from a job temporarily 
3 Unemployed with disability 
4 Unemployed but don’t have disability 
5 Working in the home without pay 
8 Refused to Answer 
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HEALTH INSURANCE 
BS12Q4.  What kind of health insurance do you have now? (Check all that apply) 
__ Medicaid 
__ Medicare 
__ Veteran’s Administration 
__ Private insurance or HMO (Blue Cross and Blue 
Shield, Kaiser, etc.) 
__ None 
__ Other 
__ Refused to Answer 
 
LIVING ARRANGEMENT 
BS12Q5a.  Who do you live with now?  (Check all those that apply) 
1 Alone 
2 Spouse or partner 
3 Children 
4 Parent(s) 
5 Sibling(s) 
6 Other adult relatives (grandparents, cousins) 
7 Friends or roommates 
8 Refused to Answer 
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BS12Q5b.  Where do you live at this point in time? (Choose one) 
1 In a house or apartment that you rent 
2 In a house or apartment that you own 
3 In a family member’s house or apartment 
4 In another person’s house or apartment (who is 
not a family member) 
5 Halfway house or treatment center 
6 Homeless shelter 
7 Motel, hotel, or boarding house 
8 Other: ______________________ 
98 Refused to Answer 
 
BS12Q5c.  How long have you lived there?  Is it: 
1 More than 2 years-> SKIP TO BS12Q7 
2 More than 1 year but less than 2 years SKIP to 
BS12Q7 
3 More than 6 months but less than 1 year 
4 A few months, but not more than 6 
5 Less than 1 month 
8 Refused to Answer 
 
BS12Q5d.  In the past year, how many times have you moved from one place to another place?   
1 Moved 1 time 
2 Moved 2 times 
3 Moved 3-4 times 
4 Moved 5 or more times 
8 Refused to Answer 
 
RELATIONSHIP STATUS 
BS12Q6.  How would you describe your relationship status at this point in time?  
1 Single, not living with a partner 
2 Single, living with a partner  
3 Married             
4 Separated 
5 Divorced 
6 Widowed 
7 Other: _____________________________ 
8 Refused to Answer 
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SEXUAL IDENTITY 
BS12Q7. Do you now identify as:   (Choose one) 
1 Straight/Heterosexual 
2 Gay/Homosexual 
3 Bisexual 
4 Other 
5 Not sure 
8 Refused to Answer 
   
EDUCATION 
BS12Q8.  What is the highest level of education you have completed?   (Choose one) 
1 No formal education 
2 Did not graduate from high school 
3 High school graduate or GED 
4 Some college/AA degree/technical school training 
5 College graduate (BA/BS) 
6 Some graduate school 
7 Master’s degree 
8 Doctorate/Medical degree/Law degree 
98 Refused to Answer 
INCOME 
BS12Q9a.  During the last 12 months, what was your total income from all sources?  (Choose one) 
1 $10,000 or less 
2 $10,001 to $20,000 
3 $20,001 to $40,000 
4 $40,001 to $60,000 
5 $60,001 to $80,000 
6 Over $80,000 
8 Refused to Answer 
 
INCOME SOURCE 
BS12Q9b.  During the last 12 months, where did you mainly get your income?  (Check all the MAIN 
sources of your income that apply) 
__ A job 
__ Unemployment 
__ Welfare, food stamps, AFDC 
__ VA Benefits 
__ Disability or SSI 
__ Spouse or sexual partner 
__ Other family 
__ Friends 
__ Alimony or child support 
__ Sex work 
__ Selling drugs 
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__ Hustling (petty theft, shoplifting, panhandling, 
scams, etc.) 
__ Other: __________________________________ 
__ Refuse to Answer 
 
 
Thank you so much for your time! 
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